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SUMMARY 
Chapters 1 to 5 provide an introduction, an overview of the 
blood coagulation mechanism, and reviews of tissue thromboplastin, 
partial thromboplastin and freeze-drying. Chapter 6 describes 
materials and methods. In Chapter 7 the structure of the 
thromboplastin reagent is examined and changes to this structure and 
to the lipid moiety of the reagent on prolonged storage at 4°C are 
demonstrated. In Chapter 8 the clotting activities, ultrastructure 
and biochemical composition of several partial thromboplastin 
reagents are compared. The liposomal nature of the reagents is 
demonstrated and correlations are established between clotting 
activity and electrophoretic mobility, liposome size and lipid 
composition. Liposomes of varying composition are prepared. By 
adjusting the relative concentration of phosphatidyl serine it is 
possible not only to regulate procoagulant activity and sensitivity 
to heparin but also to produce a liposome that accelerates the APTT 
of plasmas containing a lupus-like inhibitor while having no effect 
on APTT prolonged by other types of inhibitor, factor deficiencies 
or oral anticoagulants. In Chapter 9 the freeze-drying of tissue 
thromboplastin reagents is examined. A freeze-drying sequence is 
described that achieves a residual moisture of 1.8%, a value that is 
shown to be acceptable for long-term storage. 
Modifications to the freeze-drying machinery are evaluated. It 
is shown that traditional views on ratio of shelf area to condenser 
surface area may be incorrect. The freeze-drying machinery is found 
to be free of any intrinsic variation. A description is given of 
i n- 
the freeze-drying of three International Reference Preparations of 
thromboplastin and consideration is given to their long-term 
stability. Finally, a comparison is made of rubber-stoppered glass 
vials with fusion-sealed vampoules. The latter prove to be more 
reliable for storage of reagents at high temperature. Chapter 10 
contains a summary and conclusions. 
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SOME HEALTH AND SAFETY CONSIDERATIONS 
Two main classes of hazards encountered during the course of 
this work were 1) biological and 2) fire. The biological hazards 
stemmed from handling blood and plasma, both human and non-human, 
and from human brains which were received unfixed from post mortem 
rooms. To reduce the possibility of dangers from these materials, 
they were processed in a room set aside for the purpose, with 
appropriate extraction systems, by trained staff wearing suitable 
disposable clothing. Testing of brain extracts for bacteriological 
contamination and testing of brain extracts and plasma for 
hepatitis, and HIV when a test became available, was routinely 
undertaken. 
Fire hazards were due to the need for organic solvents for 
lipid extraction and chromatography. Solvents were stored in locked 
steel cupboards in a secure outbuilding designed to house 
inflammable substances. Only the absolute minimum volumes of 
solvents were taken to the laboratory, on a daily basis, and were 
stored in metal boxes during this time. A further possible fire 
hazard was the hydrogen gas required for the flame ioniser detector 
in the gas chromatograph. The gas was piped to the laboratory from 
a gas cylinder store, situated in a secure outbuilding. Testing for 
leaks was a matter of daily routine. Smoking and naked lights were 
not permitted in the laboratory. 
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ABBREVIATIONS USED IN THE THESIS 
BCR Bureau Communautaire de Reference 
EEC European Economic Community 
WHO World Health Organisation 
ICSH International Committee for Standards in Haematology 
BCT British Comparative Thromboplastin 
MCR Manchester Comparative Reagent 
ISI International Sensitivity Index 
INR International Normalised Ratio 
ICC International Calibration Constant 
ICR International Calibrated Ratio 
PL phospholipid 
PA phosphatidic acid 
PS phosphatidyl serine 
PE phosphatidyl ethanolamine 
PC phosphatidyl choline 
PG phosphatidyl glycerol 
PI phosphatidyl inositol 
SPH sphingomyelin 
lyso-PC lysophosphatidyl choline 
di-PG di-phosphatidyl glycerol (or cardiolipin) 
chol cholesterol 
FFA free fatty acid(s) 
16: 0 palmitic acid - 16 is the number of carbon atoms, 0 
means that there are no double bonds in the molecule 
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18: 306,9,12 linolenic acid - 18 carbons are to be found in the 
molecule and 3 double bonds. The u" shows that these 
occur at bonds 6,9 and 12, counting from the methyl 
end of the molecule 
USFAR unsaturated to saturated fatty acid ratio 
mda malondialdehyde 
v/v volume to volume ratio 
TLC thin-layer chromatography 
Rf relative to front. A term used in TLC to describe 
mobility of separated spots. Rf is the ratio of 
distance from origin to spot/distance from origin to 
solvent front. 
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CHAPTER 1 AIM OF THE STUDY 
The aim of the investigations presented in this thesis is to 
elucidate current understanding of tissue thrcmboplastin and partial 
thromboplastin reagents and to improve the preservation of 
standardised tissue thromboplastin reagents by freeze-drying. 
The present author previously described the successful 
freeze-drying of tissue thromboplastin reagents derived from human 
brain (Stevenson 1978). The lipid class composition of human brain 
thromboplastin reagent was determined and an effort was made to 
determine the changes undergone by the material during storage, in 
the liquid form at 4°C, and in the lyophilised state at a variety 
of elevated storage temperatures. Some progress was made in the 
area of measurement of lipid class composition in these reagents and 
in the use of protective antioxidant compounds. 
This thesis attempts to expand on the work on tissue 
thromboplastin, by examining further the lipid class composition, 
including fatty acid distribution and presenting evidence of the 
structure of tissue thromboplastin reagents, both fresh and aged. 
Consideration is also given to the technique of freeze-drying of 
thrcmboplastin and data is presented to show how changing conditions 
within the freeze-drying machinery affects the final product. 
Attention is also given to the freeze-drying containers employed for 
tissue thromboplastin reagents and it is shown that fusion-sealed 
glass vampoules provide more reliable vessels for long-term storage 
of the reagent at elevated temperatures than rubber-stoppered 
1 
vials. There is now a recognised system for standardisation of the 
prothrombin time based on the use of international reference 
preparations for thromboplastin which has a place in its hierarchy 
for three thromboplastin reagents which have been prepared at the UK 
Reference Laboratory for Anticoagulant Reagents and Control. 
Unfortunately, no equivalent system yet exists for partial 
thromboplastin reagents. One reason for this may be the general 
lack of understanding of the lipid reagent, or cephalin, central to 
the partial thrombplastin time test system. 
Some fundamental questions are addressed, therefore, in this 
work and it is shown that currently available, widely used partial 
thromboplastin reagents are comprised of liposomes of varying lipid 
composition and structure, and that these properties influence the 
clotting activity of the test systems in which they are used. To 
test this further, a series of liposomes is prepared which 
demonstrate the central importance of phosphatidyl serine in the 
regulation of the procoagulant activity of partial thromboplastin 
time systems, their sensitivity to heparin and to the detection of 
the lupus anticoagulant. These observations may be valuable in 
formulating a lipid reagent that might serve as a reference 
preparation. 
In order to put these experimental data in their context, the 
introductory chapters offer a view of the haemostatic system, and 
reviews of the biology of tissue thromboplastin and its role as a 
laboratory reagent. A review of the events leading to the current 
2 
understanding of the partial thromboplastin is then presented, with 
consideration of the laboratory use of partial thromboplastin 
reagents. A section is then devoted to freeze-drying, a technique 
which is incompletely understood, despite its common use. A chapter 
confined to details of the methods and materials employed opens the 
experimental section. 
3 
CHAPTER 2 THE MECHANISM OF BLOOD COAGULATION 
In the first part of this chapter a limited view of the blood 
coagulation mechanism is presented and is confined to areas relevant 
to the subject matter of this thesis. These include the initiation 
of the sequence by tissue thromboplastin, the form of phospholipids 
and biological membranes and their role at several stages of the 
process. The second part of the chapter describes some 
anticoagulant mechanisms and examines the effect of dicoumarol on 
the biosynthesis of clotting factors, the roles of protein C and 
protein S, and the action of heparin. 
2.1 THE HAEMOSTATIC MECHANISM - THE ROLES OF TISSUE THROMBOPLASTIN 
AND PHOSPHOLIPIDS 
Traditional Theories of Blood Coagulation 
Traditionally, the blood coagulation mechanism was considered 
to be a "cascade" (MacFarlane 1964) or "waterfall" (Davie and 
Ratnoff 1964) of plasma proenzymes to their active enzyme forms, 
leading ultimately to the formation of fibrin. This cascade was 
depicted as having an "intrinsic" pathway and an "extrinsic" pathway 
resulting in the activation of factor X. In the former, no agent 
external to the blood was considered necessary while the latter 
depended upon an ill-defined interaction of tissue thromboplastin 
with factor VII to activate factor X. Fig 2.1 shows the classical 
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Fig 2.1 A scheme of blood coagulation. 
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While the current view of the haemostatic mechanism inevitably 
requires some modification to this scheme, the most important 
premise of the classical system is unaltered i. e. the idea of the 
activation of proenzymes to active enzymes by limited proteolysis. 
This elegant control mechanism is at the heart of the system. 
Prothrombin, for example, may be activated by a single 
proteolytic cleavage. Prothrombin is a single chain glycoprotein 
with a molecular weight of 60,000 daltons, to be found in plasma at 
a concentration of 100 Pg cm 
3. This first cleavage produces 
meizothrombin, which is a two-chain molecule, because the two parts 
of the originial molecule resulting from the cleavage remain 
attached via a disulphide linkage. This molecule has the capacity 
to split small peptides in the same way as thrombin, but before it 
can carry out the role of thrombin in coagulation, a second cleavage 
is required. This cleavage separates thrombin from a large 
activation peptide known as fragment 1,2 (Owen et al 1974, Esmon and 
Jackson 1974, Esmon et al 1974). The action of thrombin on clotting 
factors V, VIII, XIII and fibrinogen, on platelets, on protein C, 
and on endothelial cells cannot be mimicked by meizothrombin, 
(Nesheim and Mann 1979, Suzuki et al 1982) showing that not only is 
an active site required for enzymatic activity, but also a correct 
arrangement of binding sites. This is an important means of 
regulation of the reaction sequence. 
6 
Pathways involving Tissue Thromboplastin 
Tissue thromboplastin is discussed at length in Chapter 3. 
Many years of research have gone into the current understanding of 
how this protein, also known as tissue factor, interacts with the 
blood coagulation sequence. Hjort (1957) suggested that a product 
of the reaction of factor VII, tissue factor and calcium was 
responsible for extrinsic activation of factor X while Hougie (1959) 
believed factor VII had enzymatic properties and that factor X was 
its natural substrate. Recently, Bom and Bertina (1985) showed that 
factor Ma in the absence of any co-factors can activate factor X. 
Addition of calcium ions stimulated the reaction rate eight-fold, 
and phospholipids, in the form of a liposome comprising phosphatidyl 
choline (PC) and phosphatidyl serine (PS) in 1: 1 ratio, resulted in 
a further 250-fold stimulation. They attributed this increase to an 
accumulation of enzyme and substrate in the phospholipid membrane. 
The addition of tissue factor to this system resulted in a 20,000 
-fold stimulation in the rate of factor X activation. 
Factor X is a two chain proenzyme to be found in the 
circulation at a concentration of 10 'pg cm 
3. Its molecular 
weight is 56,000 daltons. Factor VII is a single chain molecule 
with a molecular weight of 50,000 daltons and is present in plasma 
at a concentration of 0.5 pg cm 
3. These two factors, together 
with factor IX and protein C show marked homology in structure 
(Furie and Furie 1988). 
7 
It has been shown by several groups that there is little 
difference in the affinity of tissue factor for binding to factor 
VII or factor VIIa (Bach et al 1986, Zur et al 1982, Broze 1982). 
Zur and his colleagues calculated that the proenzyme factor VII had 
about 0.8% of the activity of the two chain factor VIIa. This was 
confirmed by Jesty and Morrison (1983). The initial event in the 
extrinsic factor X activation is probably the formation of a complex 
of factor VII and tissue factor. This catalyses the activation of 
factor X to factor Xa which can then cleave factor VII to factor 
VIIa. Nemerson and Gentry (1986) proposed an ordered addition model 
for the assembly of the catalytic complex in which factor VIIa 
undergoes two separate conformational changes. The first of these 
was due to binding of tissue factor and the second due to the 
binding of factor X to the factor VIIa-tissue factor complex. This 
second change induced a 100-fold increase in the affinity of factor 
VIIa for tissue factor and prevented the dissociation of factor VIIa 
from the complex. 
In 1977, Osterud and Rapaport showed that the factor 
VIIa-tissue factor complex was able to activate factor IX. Until 
this time it was believed that factor IX could be activated only by 
factor XIa, via the intrinsic pathway. Jesty and Morrison (1983) 
and Sanders et al (1985) observed a lag in the activation of factor 
IX by factor VII-tissue factor, confirming that factor IXa is also 
an activator of the proenzyme factor VII. 
It may be seen, therefore, that the tissue factor-factor VII 
complex can contribute to the activation of factor X in two ways, 
S 
either directly, or via factor IX and factor IXa. Van Dieijen et al 
(1981) and Mertens et al (1985) showed that the latter reaction 
depends on the availability of factor VIIIa. Factor IX shares many 
common features with factors X and VII, and protein C. It has a 
molecular weight of 56 000 daltons and is to be found in plasma at a 
concentration of 5 }lg cm 
3. 
A number of workers have concerned themselves with discovering 
the relative contribution of the two possible pathways of factor X 
activation. It is well known that patients with severe deficiencies 
of factors XI or XII have only a very mild bleeding tendency when 
compared to patients with severe factor VIII or IX deficiencies. 
This could indicate that coagulation in the normal physiology 
depends very little both on the intrinsic pathway (the pathway that 
proceeds via factor XI - IX - X) and on the direct factor X 
activation pathway described above (the VII -X pathway). Bertina 
et al (1981) have described a patient with an abnormal factor X 
molecule (factor X Utrecht) which can be activated by the factor IXa 
- VIII complex, but not by the factor VII-tissue factor complex. 
The patient had a prolonged prothrombin time and a normal partial 
thromboplastin time and had never suffered a bleeding diathesis. A 
similar abnormality has been observed by Girolami et al (1985) in a 
patient also free from bleeding symptoms. 
A different line of evidence comes from transfusion 
experiments in normal and haemophilic (factor VIII deficient) dogs. 
Mertens et al (1985) found that the infusion of purified factor VIIa 
in haemophilic dogs did not result in increased fibrinopeptide A 
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levels, while similar infusion in normal dogs resulted in an 
approximately 100-fold increase in plasma fibrinopeptide A. These 
experiments offer strong evidence that the direct activation of 
factor X by the factor VII-tissue factor complex is of only minor 
importance. 
Hemker (1988) discussed the kinetic efficiency of these 
various pathways. He points out that several mechanisms exist to 
remove thrombin from the coagulation sequence e. g. antithrombins 
will inactivate it while diffusion will transport it away from the 
site of tissue damage. It is essential, therefore, that a minimum 
concentration of thrombin must be produced for successful 
propagation of the clotting sequence. A three-step enzyme cascade 
will eventually provide sufficient thrombin (Henker and Hemker 1969) 
but if thromboplastin is in short supply a four-step cascade will be 
more efficient. This is provided by the activation of factor IX by 
VIIa-tissue thromboplastin complex, (Josso and Prou-Wartelle 1956, 
Marlar and Griffin 1981, Osterud and Rapaport 1977) which in turn 
activates factor X and so on. It may be significant that 
haemophiliacs tend to bleed in thromboplastin-poor organs such as 
skin, joints and muscle while bleeding in thromboplastin-rich 
organs, such as brain and lung is much rarer (van Trotsenburg 1975, 
Drake et al 1989). Because the activation of factor IX is slower 
than that of factor X, the reinforcement loop, provided by factor IX 
activation, does not contribute significantly to the reaction 
velocity in the prothrombin time test. For this reason, 
haemophiliacs have a normal prothrombin time (Hemker 1988). 
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He also points out that the classical description of the 
coagulation mechanism is based on some unrealistic premises e. g. the 
clotting of blood in the absence of thromboplastin, initiated by 
glass, kaolin, ellagic acid etc. In this system the contact factors 
interact after absorption to a "foreign" surface and this 
interaction results in the formation of factor XIa, which can 
activate factor IX. 
The extrinsic pathway was envisaged as the activation of 
factor X by factor VII acting in concert with tissue thromboplastin, 
which was held to be external to the circulation. As Hemker (1988) 
reminds us, foreign surfaces are rarely encountered unless 
artificial organs and extracorporeal circulation are employed and an 
excess of thromboplastin will be equally rare unless massive damage 
occurs to brain, lung or placenta. The most likely physiological 
activator of clotting, therefore, is a small amount of tissue 
thromboplastin. 
When tissue thromboplastin is exposed to the blood it will 
bind factor VII and subsequently activate trace amounts of factors X 
and IX at about similar rates. The formed factor Xa will rapidly 
activate factors VII, VIII and prothrombin. Factor X activation 
will continue by the catalytic action of both the factor VIIa-tissue 
factor complex and the factor IXa-VIIIa ccmplex. The rate of the 
first reaction will be efficiently suppressed by the inhibition of 
the factor VIIa-tissue factor pathway by factor Xa, while the rate 
of the second reaction is controlled by the availability of VIIIa 
and will continue until the factor VIIIa has been inactivated, for 
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Fig 2.2 An alternative scheme of blood coagulation. 
(from Bertina et al. 1988) 
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instance by the proteolytic action of the activated protein 
C-protein S complex (Clouse and Comp 1986). The scheme, as 
described by Bertina et al (1988) is shown in figure 2.2. 
Lipids and Biological Membranes 
Gorter and Grendel (1925) proposed a model of the biological 
membrane based on a lipid bilayer. Their suggestion provided the 
basis for modern theories. The "fluid mosaic" model described by 
Singer and Nicolson (1972) is now well accepted, providing a working 
model which accommodates a wide variety of plasma membrane 
phenomena. The model retains the lipid bilayer concept, both 
surfaces being depicted as largely naked lipid. Proteins are 
visualised as being embedded in the bilayer, going part of the way 
through, in the case of so-called extrinsic proteins, or all the way 
through in the case of intrinsic or integral proteins. The tissue 
factor protein is an example of this latter group (see Chapter 3). 
It is the amphipathic nature of the membrane lipids that 
governs their arrangement in cells or in model biomembrane systems 
i. e. they possess a highly polar group at one end, attached to a 
hydrophobic tail. The majority of the membrane lipids are in the 
form of glycero-phospholipids which have a glycerol molecule as 
their common structural feature. Fatty acids are esterified to the 
hydroxyl groups at positions 1 and 2 while the hydroxyl group at 
position 3 is esterified to phosphate. The simplest of the 
phospholipids is therefore 1,2-diacyl-sn-glycero-3-phosphate which 
is usually known as phosphatidic acid and abbreviated to PA. This 
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molecule will carry a strong negative charge at physiological pH. 
The phosphate group is esterified to either ethanolamine, choline or 
serine to give, respectively, 1,2-diacyl-sn-glycero-3-phosphoryl 
ethanolamine, -choline or -serine. These are known as phosphatidyl 
ethanolamine (PE), -choline (PC) or -serine (PS). PS will be 
negatively charged at physiological pH due to its possession of a 
carboxyl group. The NH2 group will be protonated but will be 
compensated for by the negative charge on the phosphate moiety. PC 
and PE each have an NH2 and a phosphate group and will therefore 
be zwitterionic and neutral at physiological pH. 
1,2-diacyl-sn-glycero-3-phospho-inositol, known as phosphatidyl 
inositol (PI), and two phosphorylated derivatives, phosphatidyl 
inositol-4-phosphate (PIP) and -4,5-bisphosphate (PIP 2) comprise 
approximately 2 or 3 percent of the total phospholipid in plasma 
membranes. These are highly negatively charged molecules, as are 
phosphatidyl glycerol (PG) and diphosphatidyl glycerol (di-PG) or 
cardiolipin. 
Another major phospholipid component of plasma membranes is 
sphingomyelin (SPH). In this molecule, the polar headgroup is 
phosphocholine, as in PC, but the hydrophobic region is formed by 
the aliphatic tail of sphingosine plus a long chain fatty acid, 
which is connected to the NH2 group of the sphingosine by an amide 
bond. 
Cullis and de Kruiyff (1979) have offered an explanation of 
how the chemical structure of individual phospholipids determines 
the structure assumed when the molecule is hydrated. The average 
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diameter of the polar headgroup of a lysophospholipid is larger than 
that of a single fatty acyl chain (a lysophospholipid is a 
phospholipid which contains only one fatty acid). The molecule 
therefore will have a cone shape, with the polar group at the 
non-pointed end. As a result, lysophospholipids will form micellar 
structures. PC and SPH, on the other hand, have a cylindrical shape 
which will form bilayers, irrespective of temperature, pH, ionic 
strength or the presence of calcium ions. Providing the buffer is 
not acidic and is calcium-free, bilayers will also be formed by PS, 
PI, PG, PA and di-PG. At acidic pH or in the presence of calcium 
ions, however, the bilayers may assume the hexagonal (HII) phase 
consisting of a hexagonally packed cylinder with the polar headgroup 
on the inside. PE, when it contains unsaturated fatty acids may 
also tend to form hexagonal phase, due to the relatively small size 
of the head group giving a cone shape to the molecule when attached 
to the relatively large diameter unsaturated fatty acids. 
Cullis and Verklej (1979) have shown that in the absence of 
calcium, PS stabilizes the bilayer structure. The addition of 
calcium induces phase separation of PS, allowing PE to form the 
hexagonal phase. At the same time extensive fusion between bilayers 
occurs. This process is similar to the process thought to occur 
during the secretory event described by Satir (1975) e. g. in 
activated platelets, where an influx of calcium is required to 
trigger the release of granules into the extra-cellular environment. 
In those membrane phenomena which are impossible to explain in 
terms of a strict, unchanging bilayer model, it may be that 
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transient formation of non-bilayer phases is recognised as a lesion 
by the immune system and that the anti-phospholipid antibodies 
reported in systemic lupus erythematosis result from this phase 
change (Rauch et al 1986). The form of hydrated phospholipids and 
its significance in the APTT test is discussed further in Chapter 
8.14. 
The fatty acyl constituents of phospholipids, therefore, are 
highly significant in determining the physical character of the 
molecule and, thereby, fundamental membrane characteristics, for 
example fluidity (Cullis et al 1985). The great variety to be found 
in the fatty acid constituents, e. g. in chain length and degree of 
unsaturation, means that over twenty molecular species may occur 
within each phospholipid class. An alternative to fatty acids in 
the hydrophobic moiety of a glycerophospholipid may be offered by 
fatty aldehydes, which attach by a vinyl ether linkage to the 1 
position of the glycerol backbone to form a plasmalogen. The 
composition of phospholipids in human and rabbit brains is broadly 
very similar with the notable exception of the ethanolamine 
containing portion. In the human some 36% of the total phospholipid 
is in the form of diacyl phosphatidyl ethanolamine, while in the 
rabbit about 13% of the total is diacyl PE and 23% is plasmalogen 
(White 1973). 
Implicit in the fluid mosaic model is the idea of an extreme 
degree of fluidity. The term fluidity embraces several distinct 
features of the lipid bilayer - one type of fluidity involves motion 
of the hydrocarbon chain relative to the head group. In the gel 
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conformation the hydrocarbon chains show little mobility. This 
state is referred to as ordered or crystalline and the abbreviation 
L"ß is used to indicate a lamellar arrangement in gel conformation. 
In the liquid crystalline, or random, conformation the hydrocarbon 
chains are highly mobile and the term La is used to indicate a 
lamellar arrangement in this state. Raising the temperature can 
form La from Lß and the temperature at which this conformational 
change takes place is known as the transition temperature (Tc). The 
Tc will depend upon the nature of the head group and on the length 
and degree of unsaturation of the hydrocarbon chains. Phase 
transition from L6 to La is accompanied by an increase in bilayer 
thickness and in area per lipid molecule (Chapman et al 1967, 
Phillips and Chapman 1968) as well as an approximately ten-fold 
increase in lateral diffusion of phospholipids. 
Van Deenen et al (1962) and Demel et al (1976) showed that 
cholesterol has a condensing effect on phospholipids in bilayers, 
decreasing the average area per molecule. When cholesterol is 
introduced into the bilayer, the steroid rings interact with, and 
partly immobilize, those regions of the hydrocarbon chains closest 
to the polar head group, while leaving the rest of the chain 
flexible. As a result, cholesterol abolishes temperature-induced 
phase transition and imparts an intermediate fluid condition to the 
interior of the bilayer. 
A further sense of the term fluidity refers to the lateral 
diffusion of lipid molecules within one half of the bilayer. At 
body temperature, natural lipid molecules may exchange places with 
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their neighbours more than a million times per second (Zwaal and 
Hemker 1982). Exchange across the bilayer, known as flip-flop 
translocation, on the other hand, occurs infrequently unless bilayer 
integrity is disturbed. Van Meer and Op den Kamp (1982) and 
Middelkoop et al (1986) have shown that species of PC containing one 
or two unsaturated fatty acids experience transbilayer movements at 
higher rates than saturated species e. g. 1,2-dipalmitoyl-PC showed a 
flip-flop half time of about 26 hours compared to approximately 14 
hours for 1,2-dioleoyl-PC. 
Overall unsaturation, however, was not the determining factor, 
since the rate for 1-palmitoyl, 2-linoleoyl-PC was about five times 
as fast as that of 1,2-dioleoyl-PC i. e. 2.9 hours compared to 14.4 
hours. 1-palmitoyl, 2-arachidonyl-PC was three times slower than 
1-palmitoyl, 2-linoleoyl-PC, again demonstrating that degree of 
unsaturation is not strictly proportional to rate of flip-flop. 
These experiments were carried out in the presence of lipid transfer 
proteins and it may be that lipid mobility is, at least partially, 
under protein control. 
Flip-flop can occur at significant rates when irregularities 
occur in the bilayer structure. In liposomes, flip-flop can be 
induced by triggering the formation of non-bilayer arrangements or 
by insertion of proteins that span the bilayer e. g. glycophorin (van 
Deenen 1981, Cullis and De Kruiyff 1979). Flip-flop in erythrocyte 
membranes has been shown to occur when the organisation of 
cytoskeletal proteins is disturbed (Haest et al 1978, Dressler et al 
1984). Seigneuret and Devaux (1984) and Tilley et al (1986) have 
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shown that flip-flop of aminophospholipids from the external to the 
internal leaflet of erythrocyte membranes is an ATP-dependent 
process. 
The Role of Phospholipids in the Activation of Factor X and 
Prothrombin 
The prothrcmbinase complex, the tenase complex, and the 
extrinsic factor X activator complex are envisaged in the classical 
scheme of haemostasis as being comprised of an activating enzyme 
(Xa, IXa and VIIa respectively) a protein co-factor (Va, VIIIa and 
tissue factor apoprotein respectively), calcium ions, and a 
negatively charged phospholipid surface. Four of these proteins, 
factors VII, IX, X and prothrombin, known as the vitamin K-dependent 
proteins, contain two unusual amino acids. The first of these is 
y -carboxyglutamic acid (see Fig 2.3) which occurs as a result of a 
postribosomal carboxylation of a number of glutamic acid residues of 
the proteins (Suttie and Jackson 1977, Davie et al 1979). It is 
thought that the y-carboxyglutamic acid residues are essential for 
the calcium-dependent binding of vitamin K-dependent coagulation 
factors to negatively charged phospholipid surfaces. The binding 
parameters appear to be a function of pH, ionic strength, calcium 
concentration, type and mole fraction of acidic phospholipid in the 
membrane and the physical properties of the phospholipid preparation 
i. e. whether they are in the form of monolayers or vesicles. 
Nelsestuen et al (1978) compared the dissociation constants for 
protein-membrane complexes of various vitamin K-dependent factors 
with phospholipid vesicles of 20 mol% PS/80 mol% PC. The affinity 
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of the factors for this membrane decreased in the order Factor 
X-prothrombin-protein S-Factor IX-Factor VII-protein C and was not 
changed if the factors were activated. Nelsestuen and Broderius 
(1977) reported that PS- and PA-containing membranes have 
approximately the same affinity for coagulation factors while 
PG-containing membranes were less effective. This latter 
observation was confirmed by van Dieijen et al (1981) and is tested 
in the present study (see Chapter 8). Prothrombin contains 10 
y-carboxyglutamic acid residues (Magnusson et al 1975) and factor X 
contains 12-14 (DiScipio and Davie 1979). Resnick and Nelsestuen 
(1980) proposed that prothrombin-membrane binding can be explained 
by a model in which calcium forms ionic bridges between the two 
carboxyl groups of Y-carboxyglutamic acid in the protein and two 
negative charges of the phospholipid molecule in the membrane. 
The second modified amino acid to be found in the vitamin 
K-dependent factors is ß -hydroxyaspartic acid (see Fig 2.3) 
(Drakenberg et al 1983, McMullen et al 1983). The function of this 
amino acid has not yet been elucidated. 
The protein co-factors of the prothrombin- and factor 
X-activating complexes also bind with high affinity to phospholipid 
membranes. Factors V and VIII do not contain y-carboxyglutamic acid 
residues so an alternative to the calcium-dependent binding, 
described above, must be involved. The binding of factors V and Va 
requires acidic phospholipids (Bloom et al 1979, Pusey et al 1982). 
These groups compared the binding of factor V and Va. Pusey et -al 
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Fig 2.3 r-carboxyglutamic acid (A) and ý -hydroxyaspartic acid (F) 
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similar while Higgins and Mann (1983) were of the opinion that 
factor V binds with four to six-fold higher affinity than factor 
Va. Pusey et al (1982) and van de Waart et al (1983) suggested that 
factor Va-phospholipid interaction is primarily the result of ionic 
forces. Mann's group, however, held that ionic strength hardly 
affects the dissociation constant of the factor Va-phospholipid 
complex. 
Isolated factor Va consists of two polypeptide chains of 
95,000 daltons and 75,000 daltons which are noncovalently associated 
in the presence of calcium ions (Esmon 1979, Hibbard and Mann 
1980). The heavy chain does not bind to phospholipid (van de Waart 
et al 1983, Higgins and Mann 1983) while the light chain, which is 
positively charged at physiological pH, has a high affinity for 
negatively charged membrane surfaces (van de Waart et al 1983, 
Higgins and Mann 1983, Pusey and Nelsestuen 1984). The binding 
parameters for the light chain are similar to those for the entire 
molecule, which suggests that the light chain of factor Va contains 
the peptide domain responsible for the binding of factor Va to 
membrane surfaces. 
Andersson and Brown (1981) and Lajmanovich et al (1981) showed 
that when Factor VIII-von Willebrand complex was incubated with 
phospholipid vesicles containing PS, the coagulant activity (factor 
VIII: C) dissociated from the von Willebrand factor activity (factor 
VIIIR: WF) and bound to the phospholipid surface. Andersson et al 
(1981) suggested that factor VIII-phospholipid binding depends 
mainly on hydrophobic interactions. Factors V and VIII each have a 
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molecular weight, in the native state, of 330,000 daltons. Factor V 
is present in plasma at a concentration of 10 »g cm -3 while factor 
VIII concentration is only 0.1 fag cm 
3. 
It is now accepted that phospholipids function in the 
activation of vitamin K-dependent factors by providing a surface 
onto which the factors can bind. Jobin and Esnouf (1967) and Hemker 
et al (1967) proposed that the effect of phospholipids on 
prothrombin activation was the binding and localisation of the 
proteins at the phospholipid surface to facilitate their 
interaction. As a result of more recent studies, several models 
have been proposed to explain the role of phospholipids. The first 
of these is the "bound substrate model". In this model the 
phospholipid-bound enzyme-cofactor complex acts on 
phospholipid-bound substrate (nosing et al 1980, Nesheim et al 
1984). The overall substrate density at the phospholipid surface 
determines the rate of substrate activation. Since the bound 
substrate concentration greatly exceeds that in free solution, the 
interaction of substrate with phospholipid-bound enzyme is aided and 
results in an increased rate of factor activation. 
The second model is the "free substrate model", in which the 
enzymatic unit acts on soluble substrate (Nelsestuen 1978). The 
affinity for soluble substrate is determined by the additional free 
energies of substrate binding to the individual components of the 
activating complex i. e. enzyme, protein co-factor, and phospholipid 
molecules. The presence of phospholipids in the enzymatic unit is 
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responsible for the increased affinity of the complete complex for 
its substrate. 
Finally, model three is the "conformation model" in which the 
phospholipid-bound enzymatic unit has a conformational state which 
is different from that of the enzyme molecules in free solution. 
The conformational change induced by binding to phospholipid causes 
an increased affinity for soluble substrate molecules (Forman and 
Nemerson 1986, van Rijn et al 1986). 
There is no reason to suppose that only one of these models is 
correct in all the activator complexes described. It is possible 
that different models work in different complexes or even within the 
same complex, depending on the presence or absence of protein 
co-factor, for example. 
Involvement of Platelets in the Activation of Factor X and 
Prothrombin 
Under normal conditions, platelets circulate in an inactive 
condition, until after 8 to 10 days when they are removed by the 
reticuloendothelial system. Normal adults produce new platelets at 
a rate of 1.5 x 1011 per day. These are flat, discoid cells with 
an average diameter of 2-3 microns and an average volume of 
approximately 8 cu microns (Karpatkin 1977, Stahl et al 1978). The 
plasma membrane of the platelet follows the fluid mosaic model 
described above but differs from other cells in the way in which it 
invaginates into the cell interior to form a system of channels, 
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(White 1972) known as the open canalicular system. This system 
serves to increase the surface area of cell in contact with the 
aqueous environment and to provide channels for products from the 
secretion granules to reach the plasma. A ring of microtubules 
preserves the disc shape. Electron microscopy reveals that the 
plasma membrane shows a typical lipid bilayer structure with an 
electron-dense glycocalyx extending outwards by as much as 25 nm. 
This is the carbohydrate rich domain of some 30 membrane 
glycoproteins exposed at the extracellular surface (Berndt and 
Phillips 1981). Glycoproteins (GP) Ib, IIb and Ills span the 
bilayer and interact with cytoskeletal proteins on the cytoplasmic 
side (Fox 1985, Fox 1985). 
The lipid bilayer of platelets contains 70% phospholipids by 
weight, the remainder being cholesterol and glycolipids. Marcus 
(1978) and Perret et al (1979) showed the presence of five major 
phospholipid classes i. e. PC (38%), PE (27%), SPH (19%), PS (10%) 
and PI (5%). The phospholipids are asymmetrically distributed in 
the bilayer (Zwaal 1978, Perret et al 1979, Zwaal et al 1977, Schick 
1979) (see Chapter 4). The outer leaflet of the plasma membrane 
contains most of the SPH, while PS and PI are mainly confined to the 
inner leaflet. PE is distributed mostly on the inside while PC is 
more or less equally shared. 
When a blood vessel is injured a plug of aggregated platelets 
rapidly forms when platelets contact sub-endothelial structures. At 
the same time the haemostatic mechanism leads to the formation of 
insoluble fibrin which reinforces the primary haemostatic plug to 
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form a stable thrombus. Thrombin, formed in the final stage of 
coagulation, is a potent platelet activator. 
Platelets contain a ntanber of proteins involved in the 
coagulation process. These are mostly located in storage granules 
and are released upon platelet activation. Platelets have three 
types of granules; dense, a, and lysosomal. The dense granules are 
few in number and appear as black round dots on electron 
micrographs. They are the site of storage of ATP-ADP and their 
deficiency results in a bleeding tendency that is proportional to 
the residual dense granule ADP (Akkerman et al 1983). 
The granules contain a variety of proteins, including 
coagulation factors, proteins of the complement and fibrinolytic 
systems, and inhibitors of these systems. Some are specific for 
platelets e. g. platelet factor 4 and ß-thrcmboglobulin. 
Platelet-derived growth factor (PDGF) is also released from 
granules and stimulates proliferation of vessel wall smooth muscle 
cells. This results in thickening of the vessel wall and reduction 
of anti-haemostatic properties and contributes to formation of an 
atherosclerotic plaque. 
Among the non platelet-specific proteins of the d-granules are 
fibrinogen, fibronectin, factor V, plasminogen, high molecular 
weight-kininogen, von Willebrand factor, plasminogen 
activator-inhibitor, antithrombin III and protein S (Akkerman 1988). 
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Another group of a-granule proteins includes vascular 
permeability factor, chemotactic factor and thrombospondin. The 
latter is a protein of molecular weight 420,000 daltons that 
consists of three identical chains, each containing sites for 
binding to heparin, fibronectin, fibrinogen, plasminogen, type V 
collagen, calcium and sulphated glycolipids. The protein has been 
shown in megakaryocytes, aortic smooth muscle, fibroblasts, 
endothelial cells, monocytes and macrophages and its role in 
platelet aggregation is thought to be the reinforcement of the 
complex of fibrinogen with glycoproteins IIb-IIIa (GPIIb-IIIa) 
(Leung 1984, Lawler 1986). 
Many other proteins bind to activated platelets. Fibrinogen, 
von Willebrand's factor and fibronectin bind to exposed GPIIb-IIIa 
(Plow and Ginsberg 1981, De Marco et al 1985). Activated platelets 
also bind HMWK, plasminogen, factors XIIIa, XIa, X, prothrombin and 
protein C though it is not known whether they require specific 
binding sites or bind to exposed negatively charged phospholipids 
(Greengard and Griffin 1985, Miles et al 1986, Greenberg and Shuman 
1984, Harris and Esmon 1985). 
Platelets contain at least 13 different lysosomal enzymes, 
whose importance is not yet established although it seems likely 
that they help to remove the haemostatic plug when damaged tissue is 
repaired (Akkerman 1988). The extent and rate of secretion among 
the three types of granule depends upon the type and concentration 
of the stimulus. Maximal secretion was found after a high dose of 
thrombin (5 NIHu cm 
3) 
which liberated all a- and dense-granule 
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contents after 2 minutes and approximately 50% of the lysosomal 
granules after 5 minutes. With lower doses of thrombin or weak 
activators such as adrenalin or ADP, a- and dense-granule secretion 
was about 50 to 70% and lysosomal secretion no more than 10% 
(Verhoeven et al 1984). 
Two of the important procoagulant activities of the platelets, 
the provision of suitable phospholipid surfaces for the 
prothrombinase complex and the tenase complex, are made available 
when platelets are activated by specific stimuli. The negatively 
charged phospholipids are essential in a procoagulant phospholipid 
surface (Bangham 1961, Papahadjopoulos et al 1962) since they are 
able to bind coagulation factors via a Cat+-mediated interaction. 
In this way the Km for prothrombin and factor X is decreased to 
values below the physiological concentration in plasma (Suttie and 
Jackson 1977). 
Nesheim et al (1982) and Kane and Majerus (1982) showed that 
high-affinity binding of factor Xa to platelets requires the 
presence of factor Va. This is not the whole story, however, since 
des-(1-44)-factor Xa (which is a form of factor Xa lacking the 
N-terminal 44 amino acid residues containing Y-carboxyglutamic acid) 
has a more or less unchanged enzymatic activity towards prothrombin 
and unchanged affinity to factor Va in solution (Kane and Majerus 
1982, Morita and Jackson 1986). It was demonstrated, nevertheless, 
that the modified factor Xa had a 100-fold lower affinity than 
factor Xa for platelet-associated factor Va. The rate of thrombin 
formation by des-(1-44)-factor Xa was shown to be 300-fold less than 
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that measured with factor Xa in a system of phospholipids and Va 
(Skogen et al 1984). In 1983, Dahlback et al partially purified a 
lupus antibody that reacted against negatively charged phospholipids 
and demonstrated that it blocked prothrombinase activity in the 
presence of platelets as well as phospholipids. These observations 
support the idea of an essential role for the negatively charged 
phospholipids for the activation of prothrombin at the platelet 
surface. Rosing et al (1985) and Bevers et al (1982) used 
phospholipases to destroy the prothrombinase and factor X-activating 
activity of nonactivated platelets. They found that attacking 
membrane phospholipids other than PS did not produce this result. 
Proteolytic treatment of unstimulated platelets did not affect the 
ability to stimulate these two platelet activities. These data 
indicate that the binding sites for both complexes of factors Xa-Va 
and factors IXa-VIIIa are not essentially different from each other 
and consist of negatively charged phospholipids at the outer surface 
of the platelet. 
There are severe limitations concerning the accuracy with 
which the amount and composition of phospholipids at the platelet 
outer surface can be detected. One problem is that platelet 
activation will lead to platelet aggregation and the amount of outer 
surface available for probes will be reduced. Another problem is 
that the platelet release reaction involves a secretory event during 
which the granule membranes fuse with the plasma membrane, 
increasing or altering the amount of phospholipids at the surface 
membrane. The use of chemical probes and highly purified 
phospholipases in this work has been described by Schick (1978) and 
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Bevers et al (1983) and is considered in Chapter 4, below. The 
latter group believed that the alterations in phospholipid 
composition of the outer membrane leaflet of platelets, activated by 
thrombin or collagen alone, can be attributed to the secretory event 
which involves fusion of granule membranes with plasma membrane. 
The progressive loss of phospholipid asymmetry in platelets 
activated by collagen plus thrombin, diamide, or Ca ionophore A23187 
presumably reflects an abrupt increase in transbilayer movement of 
phospholipids as a result of the activation procedure. 
The mechanism, or mechanisms, by which the negatively-charged 
phospholipids can move from the inner to the outer leaflet of the 
plasma membrane upon platelet activation are not completely 
understood. One suggestion for such a mechanism is that non-bilayer 
arrangements may be triggered which can facilitate the flip-flop 
translocation of phospholipids. In artificial bilayers, flip-flop 
can be induced by creating different physical properties between 
outer and inner leaflets, by insertion of bilayer-spanning proteins 
or by causing non-bilayer arrangements in the membrane (van Deenen 
1981, Cullis and de Kruiyff 1979). In red cell membranes it has 
been shown that increased flip-flop occurs when the organisation of 
cytoskeletal proteins is disturbed (Haest et al 1978, Franck et al 
1985). 
Chap and Douste-Blazy (1974) treated platelets with a 
phospholipase C from clostridium welchii, which resulted in release 
and aggregation and eventually to lysis of the cells. Comfurius et 
al (1983) used a combination of phospholipases, at sublytic 
30 
concentration and showed that substantial amounts of PS appeared at 
the external surface. The exposure of PS was accompanied by an 
enchanced thrombin formation by the prothrombinase complex. 
Phosphatidic acid is formed during these treatments, although at 
2-4% of total phospholipid, too little to account for the observed 
prothrombinase activity. This is the same quantity of PA that is 
formed in activated platelets during the triggering of the 
phosphatidyl inositol cycle (Lapetina and Cuatrecasas 1979, Bell and 
Majerus 1970). In the initial steps of the PI cycle, 
polyphosphoinositides are converted to diacyl-glycerol by an 
endogenous phospholipase C, followed by a phosphorylation catalysed 
by diacyl glycerol kinase to form PA (Rittenhouse 1983). Enough 
diacylglycerol and PA may be produced to induce the formation of non 
bilayer arrangements and thereby to form a locus for flip-flop of 
phospholipids, PS in particular, to the outer leaflet (a further 
discussion of the PI cycle is to be found in Chapter 8.10). 
It has been demonstrated that, in the red blood cell, 
phospholipid asymmetry depends upon cytoskeletal proteins (Haest et 
al 1978, Dressler et al 1984, Franck et al 1985). SH-oxidising 
agents such as diamide or tetrathionate were employed in these 
studies to induce changes in the structural organisation of the 
cytoskeletal proteins, and phospholipids were found to move from 
inner to outer leaflet following cross-linking of spectrin. Davies 
and Palek (1982) treated platelets with diamide and reported 
polymerisation of cytoskeletal proteins, notably filamin, myosin and 
actin. This process was accompanied by movement of 
aminophospholipids from inner to outer leaflet (Bevers et al 1983). 
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Treatment of platelets with the Ca ionophore A23187 in the presence 
of calcium chloride caused similar polymerisation but also 
hydrolysis of actin-binding proteins filamin and talin under control 
of an endogenous calcium-dependent protease (Truglia and Stracher 
1981, McGowan et al 1983). The endogenous calcium-dependent 
protease can also be stimulated when platelets are activated by 
physiological activators. Proteolysis decreased in the order A23187 
> collagen + thrombin > collagen > thrombin = ADP. The same order 
was found for the ability of these activators to induce exposure of 
anionic phospholipids on the outer leaflet of the platelet plasma 
membrane, and to stimulate platelet procoagulant activity (White 
1980, Fox et al 1985, Comfurius et al 1985). Further proof of the 
involvement of cytoskeletal proteins in maintenance of phospholipid 
asymmetry came from observations made by Solum and Olsen (1985) and 
Verhallen et al (1986) who examined the actions of the local 
anaesthetics dibucaine and tetracaine on platelets. Extensive 
degradation of cytoskeletal proteins resulted and an increased 
ability of treated platelets to stimulate prothrombinase activity. 
Yet another possibility must be considered. Observations with 
red blood cells suggest that movement of aminophospholipids is 
ATP-dependent (Seigneuret and Devaux 1984, Tilley et al 1986). 
Since myosin is the major membrane component with which ATPase 
activity is associated (Peleg et al 1984), it may be that cleavage 
of membrane-bound myosin may inactivate myosin-ATP ase, and deprive 
the membrane of energy, with the result that membrane asymmetry can 
not be maintained. 
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2.2 SOME ANTICOAGULANT MECHANISMS 
The Effect of Dicotmarol on the Biosynthesis of Clotting 
Factors 
Almost seventy years ago, it was observed by the farming 
community of Ontario and North Dakota, that a serious bleeding 
disease of cattle was caused by consumption of spoiled sweet 
clover. The observation was investigated (Schofield 1922, Roderick 
1929) and the disease shown to be associated with a prothrombin 
deficiency. The causal agent from sweet clover was identified as 
3,3-methyl-bis-4-(hydroxycoumarin), called dicoumarol, presumably 
formed by the action of microorganisms on cotanarin (Campbell and 
Link 1941). It was soon pressed into service as an anticoagulant 
(Bingham et al 1941, Butt et al 1941). 
Previously, the work of Dam had shown that the absence of a 
fat-soluble factor caused a defect in blood coagulation. This 
factor was named "Koagulations" vitamin (vitamin K). The active 
compound was phylloquinone (vitamin K1) and its characterisation 
led to Dam and Doisy sharing a Nobel prize in 1943 (Dam and Doisy 
1964). The effect of dicoumarol on the biosynthesis of clotting 
factors II, VII, IX, X, protein C and protein S is similar to a 
deficiency of vitamin K i. e. synthesis of biologically active 




















Fig 2.4 Vitamin K metabolism in rat liver microsomes. 









Stenflo et al (1974) and Nelsestuen et al (1974) showed that 
prothrombin contained a number of residues of a previously 
unidentified amino-acid, y-carboxyglutamic acid (Gla) (See Fig 
2.3). Vitamin K metabolism in hepatic microsomes is illustrated in 
Fig 2.4. In addition to the carboxylase/epoxidase system (labelled 
1 in the figure), liver microsomes contain a dithiol-linked vitamin 
K epoxide reductase (labelled 2a) and a dithiol-linked vitamin K 
quinone reductase (2b). These two dithiol-linked reductase 
activities are strongly inhibited by dicoumarol. The NADPH-linked 
quinone reductase activity (labelled 3 in Fig 2.14) is catalysed by 
at least two different enzymes. These are less sensitive to 
dicoumarol inhibition than, for example, dithiothreitol-dependent 
vitamin K quinone reductase (Fasco and Principe 1982) and provide a 
pathway for vitamin K quinone reduction in anticoagulated patients 
(Wallin et al 1986). The presence of this pathway explains the 
ability of administered vitamin K to counter the effect of 
dicoumarol. Four of the vitamin K-dependent clotting factors, i. e. 
II, VII, IX and X have been described earlier. Two further vitamin 
K-dependent proteins (protein C and protein S) will now be 
considered. 
The Roles of Protein C and Protein S 
Protein C has a molecular weight of 65,000 daltons, is present 
in plasma at a concentration of 4 }ag cm 
3, 
and is composed of two 
disulphide linked chains of 17,000 and 28,000 daltons. Unlike the 
vitamin K-dependent proteins described above, protein C zymogen 
activation leads to the generation of an anticoagulant enzyme. The 
protein can be cleaved by thrombin in the amino-terminal region of 
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the heavy chain. The release of a 14 amino acid activation peptide 
results in the formation of activated protein C, which is able to 
inactivate both factors Va and VIIIa (Kisiel et al 1977, Vehar and 
Davie 1980). 
Thrombin can convert protein C to activated protein C (Kisiel 
1979). In vitro this reaction is quite slow. Esmon et al (1982), 
however, isolated a protein of approximately 74,000 daltons 
molecular weight, from rabbit lungs, which has a high affinity for 
the enzyme. This protein, called thrombomodulin, forms a 1: 1 
stoichiometric complex of enzyme and cofactor that is able to 
activate protein C rapidly in the presence of Cat+. Thrombin 
attached to thrombomodulin can be neutralised by antithrombin at the 
same rate as the free enzyme. The ability of the bound enzyme to 
clot fibrinogen, activate factor V or trigger platelet activation is 
considerably diminished. Thus, the endothelial cell receptor, 
thrombomodulin, has the ability to accelerate the rate of 
thrombin-dependent protein C activation, while allowing inactivation 
of bound thrombin by antithrombin and inhibiting the procoagulant 
activities of the enzyme. 
Once activated, protein C functions as an inhibitor of factors 
V and VIII. One site of action is located at the surface of the 
platelet where factor Va acts as a receptor for factor Xa i. e. the 
prothrombinase complex. Factor Va appears to be particularly 
sensitive to destruction by activated protein C especially in vivo 
when concentrations of the enzyme are very low (Walker et al 1979, 
Dahlback and Stenflo 1980). 
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Another site of action of activated protein C is at that point 
where factor VIIIa regulates the interaction between factor IXa and 
factor X i. e. the tenase complex (Vehar and Davie 1980). 
Protein S acts as a cofactor to facilitate the action of 
activated protein C on factors Va and VIIIa (Suzuki et al 1984). It 
has a molecular weight of 69,000 daltons (DiScipio and Davie 1979) 
and is present in plasma at a concentration of 25 pg cm 
3. 
Thrombin inactivates the anticoagulant activity of protein S (Suzuki 
et al 1983). In plasma about 60% of protein S is bound to 
complement factor M. In this form it does not appear to be an 
active cofactor for activated protein C (Dahlback 1986). 
The Action of Heparin 
The action of heparin appears to depend upon binding to 
antithrombin III (AT-III), a protein of 58,000 daltons molecular 
weight, which is present in plasma at a concentration of 150 dug 
an 
3 (Rosenberg et al 1984). AT-III neutralizes the activity of 
thrombin and the other serine proteases, except factor VII (Hemker 
1987). Heparin acts by facilitating the interaction of the protease 
and the antiprotease. Once the reaction is complete, heparin leaves 
the complex. Griffin (1982,1983) showed that random order kinetics 
apply to heparin catalysed AT-III protease interaction. This 
implies that heparin acts as a template on which the proteins meet. 
Other authors feel that an ordered bireactant model would be more 
appropriate (Jordan et al 1980, Fletcher et al 1985). According to 
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this model, heparin binds first to AT-III to produce an allosteric 
change that increases the efficiency of the inhibitor. Jordan et al 
(1980) showed that, at optimal concentrations, heparin accelerates 
the rates of inhibition of thrombin and factor Xa by AT-III by at 
least 1000-fold. Heparin is a sulphated uronic acid-containing 
polysaccharide with potent anticoagulant activity. The repeating 
subunits of the polysaccharide are the disaccharides D-glucuronic 
acid-D-glucosamine and L-iduronic acid-D-glucosamine, the first pair 
linked by an a -D (1 f 4) bond and the latter by an a -L (1 4 4) bond 
(Kiss 1974). Multiple sulphate groups are linked to both 
glucosamine and iduronic acid residues. Heparin from different 
species may vary in the proportions of the different disaccharide 
subunits and in the numbers of N and 0 sulphate residues (Kiss 
1974). Despite these differences heparins all show anticoagulant 
properties, which appear to be related to the stereochemistry of the 
molecule (Rosenberg et al 1978). 
The region of the molecule that is required for binding AT-III 
has been identified by affinity chromatography of depolymerised 
heparin on columns with bound AT-III (Lindahl et al 1979, Radoff and 
Danishefsky 1984). The AT-III binding region is contained in a 
pentosaccharide sequence in which the central glucosamine has a 
unique 0-sulphate group. Four of the seven sulphate groups in this 
pentasaccharide sequence are critical for binding AT-III with high 
affinity (Lindahl et al 1979, Atha et al 1984). 
The polysaccharide chains in commercial heparins are 
heterogeneous both in composition of the repeat disaccharides and 
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with respect to chain length (Casu 1985, Hook et al 1984). The 
average molecular weight of heparin is 12,000 daltons, but species 
ranging from 6,000 to 25,000 (i. e. chain lengths varying from 18-70 
monosaccharide units) are present in commercial heparin 
preparations. 
Henker (1987) described a series of experiments in which it 
was shown that AT-III-heparin had a pronounced effect on factor 
IXa. He believed that heparin action on free factor IXa is a 
secondary effect while inhibition of thrombin is the major one. He 
concludes that heparin acts on thrombin and on free factor IXa, 
incidentally, but not on factor Xa in the prothrombinase complex, 
nor on factor IXa in the tenase complex. For this reason he sees no 
use for measurement of anti-Xa but prefers the use of the APTT test 
for routine use in measurement of heparin activity. 
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CHAPTER 3 TISSUE THROMBOPLASTIN 
HISTORICAL REVIEW - THE BIOLOGY OF TISSUE THROMBOPLASTIN: 
In 1819, Thackrah reported that blood clotted more rapidly if 
it flowed over an exposed tissue than if it were carefully collected 
in a container. Wooldridge (1893) also noted the potent coagulant 
activity of tissue extracts and thought they contained a substance 
which converted prothrombin to thrombin. He called this substance 
thrombokinase. He went further by injecting tissue extracts, of 
varied origins, into animals and observed no lethal effect if the 
preparations were first extracted with alcohol-ether. Morawitz 
(1904) proposed his "Classical" theory of blood coagulation. He 
believed that thrombokinase, in the presence of calcium ions, 
converted prothrombin to thrombin. The term thromboplastin was 
first coined by Nolf (1908). He had a similar theory to that of 
Morawitz and considered tissue extract to be a "coagulant of the 
third order". 
Howell (1912) believed thromboplastin to be a complex of 
protein and lipid, which had the ability to remove an inhibitor from 
prothrombin, allowing it to react with calcium ions to form 
thrombin. Howell, even in 1952, still used the term thrombokinase 
for the protein of the tissue procoagulant. Thromboplastin was the 
term he applied to the lipid moiety. Mills (1921) confirmed the 
observations made by Wooldridge in his animal experiments. He 
prepared a thromboplastin from bovine lung and treated it with 
alcohol-ether. He was able to recombine his alcohol-ether soluble 
40 
fraction with the alcohol-ether insoluble fraction and recover some 
activity. 
This experiment set the fashion for years to come and a variety 
of workers since then have improved on this basic experiment of 
purifying a lipid component and a non-lipid component and 
recombining the two in an attempt to restore activity. Chargaff et 
al (1944) for example, purified a particulate fraction of lung by 
homogenization, precipitation and differential centrifugation. This 
material contained lipid and proteins. By prolonged extraction with 
organic solvents, a lipid-free protein fraction was obtained, which 
did not possess coagulant acitivity. It was concluded that both 
fractions were necessary for full activity. Studer (1946) extracted 
tissues with alcohol-ether. He obtained two fractions - insoluble 
protein and soluble lipids, neither fraction showing activity. When 
recombined and the solvent evaporated, activity was restored. 
Chargaff (1948) meanwhile was still concerned with attempts to 
reassociate the lipid and protein moieties. Lung thromboplastin 
particles were incubated in 1 mol dm -3 NaCl, 5 mol dm-3 
guanidine HC1 or 0.012 mol dm 
3 
sodium deoxycholate and then 
centrifuged at 31,000 x g. The pellets from the first two 
treatments contained all the activity, whereas the supernatant from 
the deoxycholate treatment was active, i. e., the activity was 
solubilized by the deoxycholate and did not sediment in the 
centrifuge. On removal of the deoxycholate by dialysis, protein and 
lipid reassociated with restoration of coagulant activity. 
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Kuhn and Klesse (1957) were the first to substitute various 
single natural and synthetic phospholipids for the crude lipid 
fractions that had been used previously. Deutsch et al (1964) 
extracted brain particles with pyridine and showed that the protein 
residue required the pyridine-soluble material for activity. The 
nature of the pyridine-soluble fraction was not investigated. 
Williams (1964,1966) working with human lung, placenta and brain, 
and Clarke and O'Meara (1966) also working with placenta, showed 
that the thromboplastic properties of tissue reside in the 
microsomal fraction. 
Nemerson (1968) showed that phospholipids were definitely 
required for tissue factor activity and that it was the extrinsic 
system which was involved. He observed that while a crude mixture 
of brain lipids augmented the activity of tissue factor, PE was most 
effective in restoring activity to the protein residue after lipid 
extractions. PC was also effective, though less so. 
Extending Chargaff's work, Hvatum and Prydz (1966) solubilized 
brain particles in sodium deoxycholate and demonstrated by gel 
filtration, on Sephadex G200, that the activity was associated with 
a protein of molecular weight about 50,000 daltons. If deoxycholate 
was omitted or removed prior to gel filtration, large aggregates 
were formed and the activity emerged in the void volume. 
Nemerson (1969) used deoxycholate solubilization in purifying 
proteins from bovine lung and brain. He removed lipid by 
heptane/butanol extraction from acetone dried powders and 
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solubilized the proteins with deoxycholate. The proteins 
precipitated by ammonium sulphate at 30 - 60% saturation, contained 
less than 1% of phospholipid and were not active as thromboplastin. 
However, when recombined with phospholipids, and deoxycholate 
removed, activity increased by 500 - 1,000 times. PE was the most 
active, followed by PC. PS was inert. Mixed phospholipids were 
more active than PE alone. Nemerson and Pitlick (1970) further 
purified the protein component of bovine thromboplastin and found it 
to comprise two major species of molecular weight 330,000 and 
220,000 daltons, the smaller having the higher specific activity. 
Pitlick et al (1971) reported peptidase activity associated with the 
thromboplastin protein. Several other groups, e. g., Liu and McCoy 
(1975) and Gonmori and Takeda (1976) performed similar purifications 
of thromboplastin protein from various sources and observed activity 
associated with proteins of molecular weights ranging from 56,000 
daltons for bovine brain to 250,000 daltons for human placenta. 
This confusing picture may be due to the hydrophobic nature and 
therefore insolubility in aqueous systems of the apoprotein. If 
decxycholate treatment is insufficient there will be formation of 
large aggregates of protein with apparently very high molecular 
weights. These aggregates may even appear as homogeneous bands in 
polyacrylamide gels. 
Bjorklid et al (1973) used ultracentrifugation and 
solubilization with deoxycholate, combined with gel filtration on 
G200 and G100 columns and finally polyacrylamide gel electrophoresis 
in the presence of SDS (SDS-PAGE) to obtain a protein of molecular 
43 
weight 53,000 daltons from human brain. This protein showed no 
peptidase activity. Bjorklid et al (1987) have recently shown, 
however, that this procedure yields material which is 
heterogeneous. The present author obtained a value of 55,000 
daltons for the molecular weight of human brain tissue factor, also 
using sodium deoxycholate to solubilise the protein (Stevenson 
1978). 
Another advance in methodology came with the use of the 
nonionic detergent Triton X-100 to replace the bile salts. Bach et 
al (1981) described the use of Triton X-100 combined with 
lectin-affinity chromatography and preparative SDS-PAGE to purify 
bovine brain tissue factor to homogeneity. This technique yielded a 
polypeptide with an apparent molecular weight of 40,000 to 43,000 
daltons depending on the gel system employed (Bach et al 1986)'. 
This material was used to produce polyclonal antibodies which were 
used in an immunoaffinity column to purify larger yields of tissue 
factor. Carson et al (1985) produced two monoclonal antibodies 
against bovine tissue factor which were also employed in 
inmmunoaffinity columns, improving the efficiency of the system over 
the polyclonal method. The homogeneity of the bovine brain tissue 
factor was assessed by proteolytic digestion. Tryptic digestion of 
a Triton X-100 solubilised preparation removed a small peptide, 
decreasing the molecular weight from 43,000 to 40,000 daltons, but 
without altering procoagulant activity of the protein. The protein 
and the procoagulant activity comigrated on SDS gels before and 
after proteolysis, establishing homogeneity (Bach et al 1981, Bach 
1988). 
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More recently, Broze et al (1985) and Guha et al (1986) have 
reported the isolation of homogeneous human brain tissue factor by 
affinity chromatography using human factor VII coupled to agarose. 
The procoagulant activity in a Triton X-100 extract bound to the 
column. This binding was calcium-dependent and a highly purified 
protein was eluted from the column after chelation of the calcium. 
Carson et al (1985) have also produced a monoclonal antibody and 
used it to purify tissue factor from human brain and placenta. The 
proteins prepared in this way are identical as judged by amino-acid 
composition, N-terminal sequence, and procoagulant activity. 
Since the tissue factor protein alone was devoid of any 
activity, it was essential to recombine it with phospholipids, 
remove the detergent and look for procoagulant activity. This very 
cumbersome procedure has to be performed at every stage in the 
purification process. A ratio of 1: 80 for human 
apoprotein: phospholipid was shown to be optimal by Bjorklid and 
Storm (1977). While there is not complete agreement on the nature 
of the phospholipids required for optimal reconstitution of 
procoagulant activity, it is clear, however, that mixtures of 
phospholipids containing negatively charged molecules, for example 
PS or PG are most effective (Wijngaards et al 1977, Bjorklid and 
Storm 1977). A requirement for unsaturation has also been 
demonstrated (Nemerson 1968, Wijngaards et al 1977) implying that a 
liquid crystalline phase in the lipid bilayer is essential for 
proper expression of procoagulant activity. 
45 
Some of the earlier work, in which individual phospholipid 
classes were found to confer activity, may not have employed 
sufficiently pure lipids to justify confidence in the results. 
The problem of the anatomical location of tissue factor has 
been addressed by a number of workers over a great many years. 
Bernheim (1910), for example, found that homogenates of aorta 
significantly shortened the clotting time of plasma. Campbell 
(1954) extended this work by dissecting bovine aorta into its three 
layers. He found the adventitia to be most active, followed by the 
media. The intima he found to have little or no activity. Kirk 
(1962) and Astrup and Buluk (1963) performed similar experiments and 
found the opposite to be the case. Astrup (1965) found that brain, 
lung, thyroid gland, adipose tissue and placenta were rich sources 
of tissue thromboplastin while none could be detected in liver. 
Zeldis et al (1972) localised tissue factor with peroxidase 
conjugated antibodies and demonstrated the presence of the protein 
in the plasma membrane of many cell types, e. g., in intimal tissue 
of human vessels, in kidney tubular cells (in medulla and cortex), 
in hepatocytes, in the sarcolemroa of myocardium, in coronary 
arteries and plasma membranes of alveolar cells. Zacharski and 
McIntyre (1973) corroborated these findings and showed the presence 
of tissue factor in cultured human fibroblasts. 
Bjorklid et al (1977) employed goat and rabbit-anti human brain 
thromboplastin antibodies to examine the distribution of 
thromboplastin in human brain. Dissection of thirty four distinct 
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areas of brain provided the test material. The findings were that 
thromboplastin was located in phylogenetically older regions of the 
brain, implying that it represents a primitive or fundamental 
feature in the evolutionary sense, and there was no relationship 
between the distribution pattern of the protein and vascularisation. 
It has been shown that a number of cells and tissues are able 
to synthesize tissue factor. Maynard et al (1977) showed this for 
fibroblasts and smooth muscle cells, while Dalaker et al (1983) and 
Dalaker and Prydz (1983) observed the same phenomenon in glioma 
cells and trophoblasts. 
A second group of cells, which do not normally synthesize 
tissue factor, can be induced to do so by a variety of agents 
generated in pathological states. Prydz et al (1979) showed that 
immune complexes are able to induce tissue factor synthesis. Rivers 
et al (1975) showed that endotoxins were efficient inducers, while 
lymphokines have been implicated by Greczy and Hopper (1981). Other 
agents named as inducers include lectins, e. g., concanavalin A, 
wheat germ agglutinin as well as complement factor C3b, tumour 
promoters, thrombin and the calcium ionophore A 23187. All these 
observations were made in monocytes, macrophages and endothelial 
cells. Galdal et al (1984) showed that endothelial cells treated 
with histamine and epinephrine also synthesized thromboplastin. 
Prydz and Pettersen (1988) suggested that endothelial cells, like 
monocytes and macrophages, respond non-specifically to perturbations 
by synthesizing tissue factor. They point out that tissue factor 
activity peaks after 4- 12 hours with most inducing agents and 
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decays within a similar period, even when the inducer remains 
present. Another aspect of the process is the effect of cellular 
co-operation as demonstrated by Lyberg et al (1983) for mixtures of 
endothelial cells and lymphocytes and by Johnson et al (1983) for 
endothelial cells and platelets. 
Prydz and Pettersen (1988) hypothesise that tissue factor is 
synthesised as any other membrane protein. It contains a signal 
sequence which directs it into the endoplasmic reticulum and a 
hydrophobic domain which provides anchorage in intracellular and 
plasma membrane. The final assembled molecule is located in the 
plasma membrane with its factor VII binding end protruding into the 
extracellular medium. After addition of an inducing agent, a delay 
of about 60 minutes occurs before thromboplastic activity is 
detectable on intact cells. The fate of the formed tissue factor is 
still unknown but the transient nature of the response to induction 
suggests that mechanisms must exist for its rapid decay, even in the 
continuing presence of inducer. 
Hetland et al (1985) have shown that tissue factor from 
monocytes is shed in vesicles from the plasma me brane as well as 
undergoing an apparent intracellular degradation. Bona et al (1987) 
examined the process of shedding in a monocyte-like cell line 
HL-60. They showed that tissue factor was indeed shed in membrane 
vesicles and that this process could be partially inhibited by 
tunicamycin and tunicamycin homologues, presumably by their 
inhibition of glycosylation which, in turn, will regulate 
intracellular transport of the molecule. 
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The next step in the structural characterisation of human 
tissue factor was the isolation of cDNA clones coding for the 
protein. Spicer et al (1987) have published the cDNA sequence of 
human tissue factor. Confirmation of this coding sequence, as well 
as portions of flanking cDNA has been reported by Morrisey et al 
(1987) and Scarpati et al (1987). The consensus of opinion is that 
the tissue factor molecule contains three domains. Firstly, there 
is a short cytoplasmic domain of 21 residues, including one cysteine 
that is probably not disulphide linked in the cell, although 
following cellular disruption it might well participate in 
disulphide linked dimer formation. Secondly, there exists a 
transmembrane region of 23 residues of a highly hydrophobic nature 
that probably forms an o'-helical structure within the membrane and 
acts as an anchor (Spicer et al 1987). Finally, residues 1 to 219 
form an extracellular domain which is hydrophilic. Four N-linked 
carbohydrate attachment sites occur in the sequence. Three of these 
are contained in the extracellular domain and two of these have been 
confirmed by protein sequencing as sites of post-translational 
modification (Spicer et al 1987, Morrisey et al 1987, Scarpati et al 
1987). The fourth of these sites is within the cytoplasmic domain. 
The attachment of carbohydrate to the extracellular domain is 
evidence of the location of this portion of the molecule on the cell 
surface. Removal of carbohydrate from human tissue factor by 
endoglycosidase F caused no effect on its procoagulant activity, 
suggesting that this post-transitional modification must be required 
for some purpose other than expression of biological activity (Bach 
1988). 
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The location of the human gene was mapped by Carson et al 
(1985). This was achieved by a mouse-human somatic cell 
hybridisation experiment which took advantage of the observation 
that mouse tissue factor does not clot human or bovine plasma 
(Kadish et al 1983, Lyberg et al 1982, Janson et al 1984). The gene 
was mapped to the short arm of human chromosome 1 (lpter-1p21). 
This was taken as evidence for a single tissue factor gene in the 
human. This result was confirmed by Scarpati et al (1987). Spicer 
et al (1987) examined the primary sequence of human tissue factor 
for homology against 4,668 sequences in the data base of the 
National Biomedical Research Foundation as well as several 
procoagulant and anticoagulant proteins not yet in the data base. 
No significant homologies were observed, suggesting that the protein 
has its origin, in phylogenetic terms, separate from that of the 
other coagulation factors. This may be consistent with its unique 
role as the initiator of a proteolytic cascade. This role is 
examined in Chapter 2. 
Drake et al (1989) returned to the problem of the anatomical 
localisation of tissue factor. For this work they employed three 
murine monoclonal antibodies that reacted with human tissue factor. 
Two of these antibodies recognised functional epitopes on the 
protein, inhibiting tissue factor initiated coagulation and 
inhibiting specific binding to factor VII respectively. The third 
antibody recognised a distinct nonfunctional epitope and was used to 
ensure that the protein would still be revealed in tissues that may 
have bound factor VII in vivo. 
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This group showed that tissue factor in blood vessels was 
localised in the adventitia, being undetectable in endothelium and 
present in the media, although with large variability. Most 
muscular arteries and larger arterioles had activity in the 
adventitia, less so in kidney and gut submucosa but greater in 
spleen and superficial cerebral vessels. Capillaries and 
postcapillary venules did not react at any site. Adventitial cells 
of small to medium sized veins reacted similarly to those of 
arteries of comparable size and location. Unstimulated peripheral 
blood leukocytes were uniformly negative. Incubation of cells with 
endotoxin induced tissue factor in monocytes but not in neutrophils 
or lymphocytes. Eosinophils, basophils, erythrocytes and platelets 
also were negative. 
Tissue factor was found in epidermis, bowel and respiratory 
mucosa, cerebral cortex, myocardium and renal glomeruli as well as 
in cells composing the fibrous capsules of liver, spleen, kidney and 
adrenals. Expression of tissue factor by connective tissue 
fibroblasts was not common, occurring most prominently in the 
adventitia of blood vessels and in the subepithelial fibroblastic 
sheath of bowel mucosa. Fibroblasts elsewhere were generally 
negative. These workers believe that tissue factor is "anatomically 
sequestered" from the blood in the normal state by this distribution 
pattern, which provides an envelope surrounding blood vessels in 
adventitia, encasing organs in fibrous capsules and showing a strong 
presence in epidermis and mucosal epithelium, thus providing a 
continuous haemostatic barrier with the external environment. They 
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suggest, also, that although much of the distribution of tissue 
factor in normal tissue can be understood in terms of its 
procoagulant function, its selective expression at sites not of 
obvious importance for haemostasis raises the question of whether 
the protein has additional functions. 
Further investigation of the localisation of tissue factor and 
tissue factor mRNA in normal vessels and in human atherosclerotic 
plaques, obtained from carotid endarterectomy, was undertaken by 
Wilcox et al (1989). They found extensive mRNA hybridisation in 
several regions of the atherosclerotic plaque. Positive cells were 
found throughout the fibrous cap, base and shoulder region of the 
plaque, as well as in the necrotic core adjacent to the cholesterol 
clefts. The normal media underlying the endarterectomy specimens 
did not contain mRNA-positive cells or tissue factor protein. The 
necrotic cores of the plaques were characterised by the presence of 
extensive tissue factor deposition. Additional tissue factor 
protein staining was found in the macrophage-rich foam cell regions 
of many plaques. Such foam cell regions often lay underneath the 
fibrous cap and adjacent to the necrotic cores. No tissue factor 
mRNA or protein was detected in either the endothelium lining the 
vascular surface or the small vessels within the plaques. All 
sixteen endarterectomy specimens examined showed positive tissue 
factor staining in some region of the plaque. 
This group believe that tissue factor protein found in the 
necrotic core may be shed from the surfaces of synthesizing cells 
and trapped in the surrounding matrix or, alternatively, that it may 
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originate from cells that have died and left tissue factor-rich 
membranes behind. The production of tissue factor by macrophages 
has been demonstrated by several workers e. g. Tipping et al (1988), 
Levy et al (1981). What could not be demonstrated in Wilcox's study 
was whether the tissue factor was manufactured by macrophages or 
whether it was ingested from necrotic core debris. 
Examination of the normal vessels i. e. human saphenous vein and 
internal mammary artery samples showed that endothelial cells 
contained no tissue factor mRNA or protein. Some saphenous vein 
tunica media cells contained tissue factor mRNA but the 
immunohistochemical reaction was very weak. The strongest labelling 
was seen over the adventitia where intense staining of tissue factor 
protein and mRNA hybridization were found. Adventitial fibroblasts 
contained much more tissue factor protein than did the medial cells. 
It has been suggested that plaque rupture is the event that 
precipitates clot formation (Forrester et al 1987, Friedman and van 
den Bovenkamp 1966). Plaque rupture that exposes the necrotic core 
region to the lumen has been shown by several groups to underlie 
thrombi in coronary and cerebral arteries (Falk 1983, Constantinides 
1967). Tissue factor, therefore, is available in atherosclerotic 
plaque and may be the initiator of the thrombosis associated with 
plaque rupture. 
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THROMBOPLASTIN AS A LABORATORY REAGENT 
As discussed in Chapter 2, the haemostatic mechanism may be 
dramatically retarded by the action of dicoumarol. The laboratory 
control of the dosage of this anticoagulant depends upon the use of 
the prothrombin time test, described originally by Quick (1935). A 
number of modifications of this test have been developed, e. g., 
Owren and Aas (1951) introduced the "P and P" test (prothrombin and 
proconvertin), in which the test sample was diluted and mixed with a 
source of factor V and fibrinogen prior to testing. It was claimed 
that the addition of factor V allowed the plasma to be tested 
several hours after collection. When it became known that the 
coumarin drugs reduced the active level of factor IX as well as 
factors II, VII and X, Owren (1959) devised the Thrombotest reagent 
as a means of monitoring change in all four factors. In the 
Thrombotest, the intrinsic pathway is accelerated by a potent 
partial thromboplastin, while the extrinsic pathway is initiated 
only slowly by a low-activity tissue thromboplastin. The reagent 
also contains bovine plasma stripped of factors II, VII, IX and X. 
This reagent is available commercially in lyophilised form and is 
reconstituted with a solution of CaC12. 
This proliferation of methods caused much confusion for several 
years - confusion, both in techniques and expression of results. 
The test which has been used in the majority of centres throughout 
the world is Quick's one stage prothrombin time, in which tissue 
extract (thromboplastin) is used to accelerate the clotting of 
recalcified plasma. The British Committee for Standards in 
Haematology approved a reference method for the one-stage 
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prothrombin time test on human plasma which laid down a well 
controlled technique (Poller 1970). Given such a technique, and 
assuming the operator to be reasonably skilful, two areas remained 
where standardisation was still required, i. e., expression of 
results and the tissue thromboplastin reagent. The use of the 
"prothrombin index", which is the ratio of prothrombin time of 
normal plasma to the prothrombin time of patients plasma, expressed 
as a percentage, was widespread as was the use of the term 
"prothrombin activity". The latter required construction of a 
dilution curve of normal plasma, employing saline or BaSO4 
adsorbed plasma as diluent, from which the patients prothrombin 
activity could be read. To further confuse matters, a variety of 
tissue thromboplastin reagents were in common use, ranging from 
commercial extracts of animal origin to locally prepared reagents of 
animal and human origin. This was the worldwide position before a 
system of standardisation was initiated in Great Britain. 
The British System 
A scheme to introduce a standard system was begun in Manchester 
in 1962. Hospitals in the Manchester Region were supplied with a 
standardised phenolised human brain thromboplastin reagent for use 
in a Quick test technique and a method was recommended for the 
expression of results, as a ratio of prothrombin time of patients 
plasma to that of normal plasma (Poller 1964). Gradually, the 
scheme spread throughout the country and the thromboplastin became 
known as the Manchester Comparative Reagent (MCR) (Polley 1967). At 
this time the majority of hospitals in an area covering 
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approximately a quarter of the population of Great Britain were 
using the MCR in this way. Most of the remaining hospitals in the 
United Kingdom received the MCR against which they could compare 
their local reagent, whether home-made or obtained from a commercial 
manufacturer. The British Committee for Standardisation in 
Haematology adopted the MCR as the national reagent in 1969, and the 
term British Ratio was used for prothrombin time ratios obtained 
using the standard reagent. 
In order to improve standardisation of reagent and reporting, 
batches of the MCR were subjected to independent monitoring. These 
were renamed British Comparative Thromboplastin (Poller 1970). The 
BCT reagent was supplied to those hospitals not using the routine 
MCR so that they could calibrate their locally prepared reagent or 
commercial reagent to a common standard. This calibration made use 
of an observation by Biggs and Denson (1967) and was based on the 
assumption that there was always a straight line relationship of 
prothrombin time ratios obtained for a set of patients plasmas with 
different thromboplastins. To perform the calibration, prothrombin 
ratios of at least twelve patients plasmas and six normal plasmas 
were obtained with the BCT and the local reagent. These ratios were 
plotted and a best fit line drawn by visual assessment of the data. 
The statistical validity of the procedure was discussed by Alderson 
et al (1970). The calibration could then be used to derive the 
British Corrected Ratio and meant that a result with a locally 
prepared reagent or a commercial reagent could be translated into 
the national scheme. 
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An important task was the monitoring of successive batches of 
the BCT in order to maintain continuity (Hill and Ingram 1973). 
These authors calculated that at least four normal and six patients 
plasmas would be required to detect the critical difference in 
sensitivity between two batches of BCT with an acceptable degree of 
certainty. This quantity of data was required from at least three 
centres. In practice four monitoring centres were asked to test 
five fresh normal and twelve patients plasmas each, as well as a 
lyophilised normal plasma. The maximum permissable difference in 
sensitivity between successive batches of BCT was a matter of 
clinical judgement. It was therefore the practice to accept a new 
batch provided that the 95% confidence limits for the ratio with the 
new batch lay within the range 1.9 - 2.1 for a ratio of 2.0 with the 
current batch. The use of the standardised reagent was supported by 
a series of quality control trials which allowed individual users of 
the reagent to compare their own performance with other participants 
(Leck et al 1976, Poller 1989). The preparation of the BCT and the 
monitoring exercise have been described by Stevenson (1978), 
together with the production of the first lyophilised form of the 
BCT. The first freeze dried BCT, batch 76/005, was prepared by the 
present author early in 1976 and was presented for the monitoring 
exercise in March of that year. 
This was a significant development since it showed that the BCT 
could be produced in a stable form and still possess the character 
of the former wet reagent and its desirable properties, i. e., 
sensitivity to the coumarin-induced defect and ease of use in a well 
defined method, thereby satisfying the conditions proposed some ten 
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years earlier by Bangham (1966), Denson (1966) and Biggs and Denson 
(1966) when they laid down criteria for a standard thromboplastin 
preparation. Biggs and Denson (1967) proposed using, as a reference 
standard, a human brain extract with added calcium chloride, 
fibrinogen and factor V. 
International developments 
The International Committee on Thrombosis and Haemostasis 
(ICTH), in cooperation with the National Institute for Biological 
Standards and Control (NIBS & C), prepared a series of five 
lyophilised thromboplastins between 1967 and 1970. These were 
designed to represent the reagents and methods in popular use at 
this time. One of these was 67/40, a human brain extract as 
described by Biggs and Denson (1967) containing added fibrinogen and 
factor V. This type of reagent was referred to as a "combined" 
reagent to distinguish it from the "plain" reagents which contained 
only thromboplastin, e. g., 69/223, a human brain extract. The other 
three reagents were 70/115 and 70/178, rabbit brain extract, 
combined and plain respectively, and 68/434, bovine combined 
(Bangham et al 1973). 
These materials were characterised in an international trial in 
1974, carried out by an expert panel set up jointly by the ICTH and 
the International Committee for Standardisation in Haematology 
(ICSH). The results of this trial led to the establishment of 67/40 
as the International Reference Preparation for thromboplastins, of 
the World Health Organisation, in 1976. This was the preparation 
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against which all thromboplastins had to be calibrated (WHO 1977). 
Each thromboplastin when calibrated against 67/40 was to be assigned 
a value known as the International Calibration Constant (ICC) which 
was the slope of the calibration line obtained with the IRP on the 
x-axis and the calibrated preparation on the y-axis. The ICC of 
67/40 was defined as 1.0. Armed with an ICC value it was possible 
to convert the prothrombin time ratio obtained with a locally 
produced reagent into the value that would have been obtained using 
the IRP. This calculated value was termed the International 
Calibrated Ratio (ICR) (WHO 1981). 
The WHO also established two secondary reference preparations, 
70/178 (rabbit brain) and 68/434 (bovine brain) with ICC of 0.6 and 
1.0 respectively. The reasons for setting up the secondary 
reference preparations were to prevent the primary thromboplastin 
being used up too quickly and to allow working thromboplastins to be 
calibrated against a reference preparation of a similar tissue 
extract. This scheme was not a success. Thromboplastin 67/40 was 
at the heart of the system and proof was needed of its stability. 
Ingram (1979) examined the evidence and suggested replacement of the 
IRP with a batch of the BCT. Also, 67/40 was a combined reagent. 
Lam-Po Tang and Poller (1975) showed, in an international survey, 
that plain reagents were in common use worldwide while the use of 
combined reagents was limited to Scandanavia and the Netherlands. 
A further difficulty was that the WHO preparations were not 
freely available to commercial manufacturers of thromboplastins. 
Moreover, it gradually became apparent that the calibration model 
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was not adequate. In theory, the calibration line of prothrombin 
ratios should pass through the point 1,1 - this proved not to be the 
case especially when combined and plain thromboplastins were 
compared (Poller and Thomson 1969). A further problem was the 
noticeable curvature that showed when dissimilar thromboplastins 
were calibrated (Exner 1980, Loeliger and Lewis 1982). Kirkwood 
(1983) examined these shortcomings and showed that the existing 
statistical model fell short of the requirements for biological 
standardisation. 
A further calibration study was then undertaken by ICSH and the 
Bureau Comnunautaire de Reference (BCR) of the EEC. Three new 
candidate reference preparations were developed, BCT 099 (human 
brain extract, plain), OBT/79 (bovine, combined) and RBT/79 (rabbit, 
plain) and a new calibration procedure was developed leading to 
revision of the WHO requirements (WHO 1983). This new statistical 
model used logarithms of prothrombin times instead of ratios and the 
linear relationship between thromboplastins was estimated by a 
procedure called orthogonal regression (Kendal and Stuart 1961). 
The preparation of BCT 099 is described in Chapter 7. The new 
technique was employed in 1983 to calibrate BCT 253, a further batch 
of the BCT. The object was to replace 67/40. This calibration was 
an extensive international exercise involving twelve European 
laboratories and five centres from the USA, Canada, South Africa and 
Australia (Thomson et al 1983). The calibration exercise was 
successful and BCT 253 was officially adopted by the WHO as the 
second International Reference Preparation. The two secondary IRP, 
70/178 and 68/434 were also replaced at this time, by RBT/79 and 
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OBT/79 which had been calibrated in the earlier BCR exercise. The 
preparation of BCT 253 is described in Chapter 7. 
Some new terms were introduced as a result of the revised 
procedure. The International Sensitivity Index (ISI) is the slope 
of the calibration line for any thromboplastin. It is obtained with 
logarithms of the prothrombin times of the primary IRP plotted on 
the vertical axis against the logarithms of the prothrombin times 
obtained with the calibrated thromboplastin on the horizontal axis. 
The International Normalised Ratio is the prothrombin ratio it is 
calculated would have been obtained if the primary IRP had been used 
in the test (INR = prothrombin time ratiolSi). 
The limited availability of the WHO preparations still raises 
difficulties and the BCR preparations, for which there is a charge, 
have not been available to Eastern European and developing 
countries. To remedy this situation, the ICSH set up a secondary 
IRP (BCT 441) prepared at the UK Reference Laboratory. This 
material was calibrated in 1985 (Thomson et al 1986) and is 
available, without charge, to designated national control 
laboratories in those countries where financial contraints apply. 
The preparation of BCT 441 is described in Chapter 7. The ISI 
values for the reference materials of human origin are shown in 
table 3.1 
TABLE 3.1 ISI OF REFERENCE THROMBOPLASTINS 
WHO 2nd primary IRP BCT 253 1.085 
BCR secondary reference preparation BCT 099 1.048 
ICSH reference preparation BCT 441 1.04 
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In practice, the current position is that the British System for 
anticoagulant control has become interlinked with the WHO system. 
The 2nd primary IRP (BCT 253) is one of three primary IRP; the 
others being RBT/79 (rabbit, plain) and OBT/79 (bovine, combined). 
The establishment of these three preparations means that any type of 
thromboplastin may be related to an IRP and the use of INR for 
reporting of results means that an internationally acceptable system 
is now in place. 
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CHAPTER 4 PARTIAL THROMBOPLASTIN 
HISTORICAL REVIEW 
In 1953, Langdell et al described a clotting time test which 
they called the "partial thromboplastin time" because the 
phospholipid thromboplastin clotted haemophilic plasma slowly, in 
comparison to the complete tissue thromboplastin of the prothrombin 
time test, which clotted haemophilic plasma in a normal time. The 
partial thromboplastin time test was shown to be sensitive to 
deficiencies of the known factors of the intrinsic and common 
pathways of blood coagulation (Brinkhous 1954). 
The phospholipid requirement of the intrinsic activator is 
provided by the platelet membrane (see Chapter 2, above) and the 
elucidation of its nature has been the subject of considerable 
effort over many years. Some of the key events of this study are 
described in this chapter. The natural starting place for these 
studies was the use of lipids extracted from platelets. 
Studies on lipids derived from platelets 
In the late fifties and sixties a good deal of effort was put 
into a search for a single active fraction of platelet lipid which 
might substitute for the platelets in the clotting mechanism. 
When platelet lipid extracts were fractionated on silicic acid 
columns (Rouser et al 1958, Marcus and Spaet 1958, Barkhan et al 
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1961, Speer and Ridgway 1962, Marcus et al 1962) or by a combination 
of silicic acid column and paper chromatography (Troup et al 1960), 
or by column and counter current distribution techniques (Woodside 
et al 1964), it was found that clot-promoting properties were 
confined to the "cephalin" fractions (the ethanolamine [PE] and 
serine [PS] phospholipids). The choline-containing phospholipids 
and the neutral lipids were inert although combinations of lecithin 
(PC) with one or more of the cephalins did produce an active clot 
promoting preparation. 
Apart from the common diacyl ester form, the 
glycerophosphatides occur in several other variations. One such, 
the monoacyl monoalk-l-enyl ether form, known as plasmalogen, was 
tested for activity by Rouser et al (1958), Zilversmit et al (1961) 
and Speer and Ridgway (1962). None of these groups were able to 
show any contribution to the coagulation sequence by plasmalogens. 
Another variation in form occurs in platelet activating factor 
(PAF) which is 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphoryl choline. 
The alkyl chain is generally C16 or C18. This compound unlike 
plasmalogen, is an extremely potent activator and can activate 
platelets independent of arachidonic acid metabolites or released 
ADP, and can cause shape change, aggregation and the release 
reaction at concentrations between 10 
11mol dm-3 and 10-1%ol 
dm-3. Its structure was independently determined by Demopoulos et 
al (1979) and Benveniste et al (1979). PAF is produced by a variety 
of activated cells, for example, platelets (Chap et al 1981), 
monocytes (Benveniste et al 1972) and endothelial cells (Zimmerman 
64 
et al 1985). The bulk of the work on lipids in coagulation has, 
however, been restricted to the diacyl ester form of the 
glycerophosphatides. 
Studies on nonplatelet lipids 
Experiments were also performed using lipids obtained from 
sources other than platelets. Rouser et al (1958) and Rouser and 
Schloredt (1958) tried to relate structure to activity. Neutral 
lipids such as cholesterol and triglycerides were inactive, as were 
cerebrosides. Saturated fatty acids containing at least sixteen 
carbon atoms showed slight activity. A series of hydrolysis 
products of phospholipids showed no clot promoting properties. 
Individual phospholipids such as PC, SPH, PI, synthetic preparations 
and surfactants with structural similarities to phospholipids were 
also tested and shown to be inactive. Synthetic PE and PS were 
inactive as was liver monophosphoinositide. PE fractions from 
rabbit appendix, leucocytes, soya beans and human platelets all had 
activity (Platelet PE was most active). When the PE was 
hydroxylated with performic acid it was no longer active. 
Hydroxylated PE was soluble, so the implication was that there was a 
requirement for phospholipids to be in a dispersed colloidal 
particle in order to show activity. 
Rouser and Schloredt (1958) studied the fatty acid composition 
of PE from various sources and showed that activity correlated with 
the degree of unsaturation of fatty acids. The suggestion was that 
more unsaturated fatty acids would give rise to a shorter molecule 
of greater diameter -a shape they believed to be more conducive to 
65 
forming a micelle. The active complex in the clotting sequence was 
visualised as a linkage, via divalent calcium ions, between an 
acidic phospholipid and a negatively-charged group on a clotting 
protein. 
Wallach et al (1959) examined further the relationship between 
the colloidal state of purified phospholipids and their 
clot-promoting properties. This group used PE fractions from egg 
yolk, obtained by silicic acid chromatography. Column eluates with 
differing degrees of saturation were studied in a clotting system 
comprising purified factor VIII, factor V, calcium, magnesium and 
the test lipid. Etheral solutions of phospholipids were injected 
into the system and the solvent removed by bubbling nitrogen through 
the suspension. 
The more unsaturated preparations formed stable suspensions at 
neutral pH. A pH of 8 was necessary to prepare a stable emulsion of 
the more saturated material, and synthetic dimyristol-PE could be 
suspended only at a pH of 10. With a rise in pH of the suspending 
medium there was a gradual increase in clotting activity to pH 8, 
then potent activity to pH 10 after which the activity was lost. 
The clot promoting activity of these PE fractions therefore appeared 
to depend mainly on physical characteristics of the emulsion. This 
in turn was shown to be governed by the degree of unsaturation of 
the constituent fatty acids, temperature, pH and ionic composition 
of the aqueous medium in which it was suspended. It was concluded 
that clot promoting PE preparations were micelles in the form of 
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bimolecular leaflets of a definite size, thickness and a unique 
surface configuration. 
Meanwhile, Rouser et al (1961) devised a technique which 
separated PE from PS more efficiently. Using this procedure, Marcus 
et al (1962) found the separated PS to be the most active group of 
phospholipids. Later, Marcus (1965) and Marcus et al (1966) found 
that isolated platelet membranes-were more efficient than platelet 
granules in certain clotting systems. This reinforced the orginal 
proposal of Surgenor and Wallach (1961) that the reactive site of 
the platelet in coagulation is orientated towards the plasma, and is 
perhaps in the platelet membrane. 
Early observations on the charge of phospholipids and its 
relation to clot promoting activity 
In the earlier studies of Rouser and Schloredt (1958) and 
Wallach et al (1959), attention was directed primarily toward the 
hydrophobic region of the phospholipid. Bangham (1961b) examined 
the polar region of the phospholipids. Egg PC was mixed in varying 
amounts with dicetyl phosphate in choloform, taken to dryness and 
emulsified in tris buffer. The zeta potential of these mixtures 
correlated with their activity in the Russells Viper venom test (RVV 
is able to directly activate factor X, bypassing both the extrinsic 
and the intrinsic pathways). When the electrophoretic mobility of 
various emulsions used in the test system was measured, it was found 
that the more negatively charged suspensions produced shorter 
clotting times. There was excellent correlation between the 
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activity of PC: dicetyl phosphate mixtures and other known 
clot-promoting materials. For example the electrophoretic mobility 
of a brain lipid extract (Bell and Alton 1954) resembled that of the 
active PC: dicetyl phosphate and both gave a clotting time of 8 
seconds. Platelets and a PC: PE mixture behaved similarly. 
These observations were confirmed and extended by 
Papahadjopoulos et al (1962), working with phospholipids prepared 
from bovine brain and egg yolk. Four combinations of phospholipids 
were used in a wide range of concentrations - PS in PE, PS in PC, PA 
in PC and PE in PC. Maximal clot-producing properties in a standard 
clotting assay were found with mixtures which showed an 






Thus there was an optimal negative surface charge at which 
phospholipids exhibited maximal clot-promoting properties and the 
clot-promoting properties of various phospholipid mixtures were 
clearly correlated with the surface charge of the micelles they 
formed in aqueous media. 
Recent Studies on Membranes in Blood Clotting 
The work of Zwaal et al (1973), Zwaal et al (1975), Otnaess and 
Holm (1976), Chap et al (1977), Zwaal et al (1977), Schick (1978, 
1979) has shown that the plasma merbrane of red blood cells and 
platelets is based on an asymmetric phospholipid bilayer whose 
leaflets have a distinctly different composition. The choline 
containing phospholipids, particularly SPH, and also substantial 
amounts of PC are located in the outer layer whereas a large 
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fraction of PE and practically all the negatively charged 
phospholipids - PS and PI - are confined to the inner (cytoplasmic) 
surface. 
A number of methods have been employed to investigate plasma 
membrane phospholipid asymmetry. One approach has been to use 
external labelling probes. E. g., in the work of Schick when 
trinitrobenzenesulphonate (TNBS) was employed. This compound reacts 
with primary amine groups and is thus able to form stable covalent 
derivatives with PE and PS. Because of its highly polar nature TNBS 
does not penetrate the surface of intact cells. In his studies 
Schick incubated washed cells with TNBS then extracted labelled 
phospholipids and separated them by thin-layer chromatography. 
Quantitation was by assaying phosphorus and the percentage of PE or 
PS that had formed a derivative with TNBS was calculated. Schick 
(1976), using this method, showed that only small amounts of PE and 
no PS were exposed on the surface of platelets. A second label, 
1-fluro-2,4-dinitrobenzene (FDNB) (Schick 1978) was employed to 
confirm that aminophospholipids are located primarily in the inner 
platelet membrane bilayer. FDNB, like TNBS, forms stable 
derivatives with PE and PS but is able to penetrate the surface of 
intact cells. 
An alternative approach, employed by Zwaal's group, was to use 
purified phospholipases to degrade the surface of cell membranes, 
thereby building up a picture of the distribution of phospholipids. 
These enzyme molecules are too large to penetrate the cell 
membrane. For example phospholipase A2, from Na-ja naja venom, and 
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sphingomyelinase, from Staphylococcus aureus, were used to degrade 
the surface of pig platelets. A purified preparation of 
phospholipase C from Bacillus cereus was also employed (Chap et al 
1977). The results of this study differed from the earlier results 
of Otnaess and Holm (1976). The differences may be due to the fact 
that Otnaess and Holm did not inactivate phospholipase C before 
lipid extraction so that the enzyme continued to hydrolyse the 
extracted lipids, and that there may have been a difference in 
specific activity in the sphingomyelinase preparation, used in the 
two studies. 
The important point, however, is that the results of the enzyme 
study are in good agreement with those from the studies employing 
labelling methods, and both indicate that there is an asymmetrical 
arrangement of phospholipids in the platelet membrane with PE and PS 
located primarily in the inner bilayer. 
Zwaal et al (1977) prepared liposomes having the same 
composition as the outer membrane layer of either platelets or 
erythrocytes. These did not shorten the clotting time in a 
one-stage prothrombinase assay employing Russell's viper venom. In 
contrast, liposomes with the composition of the inner surface 
considerably reduced the clotting time. Also, intact erythrocytes 
and resealed ghosts had no procoagulant activity, whereas 
preparations with the cytoplasmic surface exposed, e. g., non-sealed 
ghosts and inside-out vesicles, markedly reduced the clotting time. 
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It has been pointed out (Schick 1979) that the characteristics 
of the phospholipase C (Clostridium perfringens) - induced platelet 
release reaction are identical to those induced by thrombin. It is 
possible that PC may mask a membrane protein that can serve as an 
active site for platelet activation, or even be a receptor itself. 
Fiedel et al (1976) showed that anti-PC antibodies isolated from 
myeloma paraproteins can inhibit platelet aggregation. Also, Cooper 
et al (1974) demonstrated this inhibition by immuno-globulin from 
patients with myeloma. Another interesting observation (Lubin et al 
1981, Chin et al 1981) concerns alterations in phospholipid 
orientation which occur in irreversibly sickled cells or in 
reversibly sickled cells that only sickle in anoxic conditions. The 
process of sickling is accompanied by an increased exposure of PE 
and PS at the cell exterior, at the expense of some PC, presumably 
by the process known as flip-flop. During sickling, the cells cause 
a reduction in clotting time when used as a source of lipid in a 
one-stage prothrombinase assay. When reversibly sickled cells 
resume their normal biconcave shape following re-oxygenation, they 
have no effect on clotting time. The flip-flop mechanism is not 
well understood, but may well require some sort of control by 
trans-membrane proteins (see Chapter 2). 
In 1964, Papahadjopoulos and Hanahan showed that a complex of 
phospholipids, factor Va and factor Xa was responsible for the 
conversion of prothrombin to thrombin. None of the components of 
this complex, alone, could perform the function of " prothrombinase". 
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In 1967, Henker and Kahn showed that the activation of factor X 
is achieved by a complex of phospholipids, factor VIIIa and factor 
IXa. Again the "tenase" function can not be performed by any of the 
components of the complex alone. 
These two complexes have much in common. They each consist of 
three components - phospholipids, enzyme (Xa or IXa) and an 
"auxiliary" protein (Va or VIIIa). Rosing et al (1980) and Van 
Diejen et al (1981) have shown that the enzyme alone is able to 
convert its product at a very slow rate. Addition of the auxiliary 
protein increases the rate of conversion by one thousand times, 
presumably by directing the vulnerable site of the substrate towards 
the active site of the enzyme. The phospholipids decrease the 
apparent Km of the substrate by a thousand times, causing enzyme 
saturation at much lower substrate concentration at the lipid 
surface. These workers believe that the non-enzyme components in 
the complexes can produce an increase in the actual reaction 
velocity of up to 106 times. 
Only certain mixtures of phospholipids show an optimal 
procoagulant activity. Apart from a net negative charge it is clear 
that fluidity is important. Tans et al (1979) have demonstrated 
that phospholipids in the gel state show very little activity. 
As discussed above, in both platelet and red blood cell 
membranes, PS is preferentially located on the cytoplasmic side of 
the bilayer. This is the reason why lysed platelets and red cells 
which expose cytoplasmically orientated lipids to the clotting 
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factors, are much more active than intact cells when used as a lipid 
source in the prothrombinase complex (Zwaal et al 1977). A similar 
phenomenon was observed when other cells, e. g., leucocytes and 
endothelial cells were used as a source of lipids (Zwaal and Bevers 
1983). This suggests that in these cells also, negatively charged 
phospholipids are absent from the outer cell surface. 
Zwaal and Bevers (1983) and Zwaal et al (1980) have shown that 
after stimulation by a mixture of collagen and thrombin, 
phospholipid orientation in the platelet plasma membrane is 
radically altered. Before. activation, very small amounts of 
negatively charged PS may be found at the exterior, but, following 
activation PS and PE are greatly increased. This leads to increased 
binding of the components of the prothrombinase complex, resulting 
in a higher prothrombin-converting activity. The appearance of PS 
at the outer surface cannot be explained by just the release 
reaction, which involves fusion of intracellular membranes with the 
plasma membrane, since no increase in exterior PS is observed when 
platelets are activated by either collagen or thrombin alone. Zwaal 
and Hemker (1982) suggest that the combined action of collagen and 
thrombin produces sufficient perturbation of the membrane to allow 
flip-flop of phospholipids. PE and PS may flip-flop to the outside 
while PC may flip-flop to the inside layer, in a way similar to that 
observed for sickle cells under anoxic conditions. 
Platelets also function as a lipid source for "tenase". Here 
too, the combination of collagen and thrombin is much more effective 
than thrombin alone. The rise in "tenase" activity seems to precede 
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the rise in prothrombinase activity. Walsh (1978) observed that 
collagen-activated platelets enhance factor X activation prior to 
stimulating prothrombin activation. 
Zwaal and Hemker (1982) suggest that the translocation of PS 
occurs at distinct loci in the membrane. This will lead to local 
high concentrations of PS which facilitate the action of "tenase". 
Due to lateral diffusion of the phospholipid in the plane of the 
membrane the PS concentration in these patches will be diluted to 
become more favourable for prothrombinase. 
CEPHALIN AS A LABORATORY REAGENT 
In the coagulation laboratory the APTT has a number of 
functions. It is used to screen intrinsic coagulation defects, 
i. e., to identify specific clotting factor deficiencies, to detect 
the presence of inhibitors and also for monitoring heparin therapy. 
A great variety of methods and reagents is available with varying 
sensitivities to the different defects and inhibitors. The position 
is not improved by the fact that no international reference 
preparation exists, nor any system of calibration of APTT reagents 
or reporting of results. 
Poller and Thomson (1972) reported on the need to standardise 
both reagents and technique. Subsequently, reports from a large 
number of workers have confirmed the variability in performance of 
commercial and locally produced APTT reagents in the detection of 
intrinsic clotting defects (Sibley et al 1973, Poller et al 1976, 
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Shapiro et al 1977, O'Brien et al 1981). Hoffman and Meulendijk 
(1978) went so far as to say that none of the available commercial 
partial thromboplastins was suitatle for use as a standard. 
Consideration of the APTT method recommended by the UK 
Reference Laboratory for Anticoagulant Reagents and Control (Thomson 
1980), which is designated the Manchester APTT method, will 
demonstrate some of the areas where attention to standardisation of 
reagents and technique is vital. The test system is buffered to a 
physiological pH of 7.35 and activation of the contact factors is 
achieved by incubation for ten minutes in the presence of kaolin. 
Originally, the lipid employed was of human brain origin, extracted 
by ether from an acetone-dried preparation of brain powder. The 
etheral extract was dried on to the walls of a round-bottomed flask, 
then shaken in buffer to suspend the lipids. Fig 8.5 shows an 
electron micrograph of the resultant liposome suspension and details 
of the lipid composition are given in Chapter 8.4. 
The areas of contention in the APTT test concern buffering, 
choice of activator and time of activation, and the composition of 
the lipid reagent. Other issues lacking agreement concern 
collection of plasma, the question of plasma dilution and calcium 
concentration. It appears that buffering is favoured by the 
majority of manufacturers although the choice of buffer is not 
revealed. 
Activators, on the other hand, are generally disclosed. Kaolin 
has proved to be one of the most effective and is the one which has 
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been incorporated in the Manchester APTT method. Both silica and 
ellagic acid are to be found in a number of commercial reagents and 
are favoured for use in automated techniques on account of their 
lower opacity. Margolis (1958 and 1961) first described the use of 
kaolin and of silica in a partial thromboplastin time test, while 
Ratnoff and Crum (1964) first drew attention to the use of ellagic 
acid. A possible physiological activator, suphatides, was more 
recently described by Fujikawa et al (1980) and further 
characterised by Tans and Griffin (1982). This activator has 
already been incorporated in a commercially available APTT test 
system (Behringwerke 1984). 
On the question of the lipid reagent, a variety of sources of 
lipids have been extracted, e. g., animal brains, platelets, and soya 
beans. As a result there are differences in the actual individual 
lipid classes represented in the reagents, as well as in total lipid 
present. This topic is dealt with at length below (see Chapter 8). 
Use of the APTT in the diagnosis of intrinsic clotting defects 
Reports describing the use of the APTT may be divided into 
those dealing with single laboratory data and those concerned with 
multi-centre surveys. Poller and Thomson (1972), Sibley et al 
(1973), Babson and Babson (1974), Hoffman and Meulendijk (1978) are 
examples of the first group which showed the variability in 
performance of commercially available partial thromboplastins. Some 
multicentre reports such as Poller et al (1976) and Koepke (1975, 
1977) give a wider view and do not suffer from any local bias or 
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varying expertise that might colour single centre studies. The 
study of O'Brien et al (1981) is an example of a highly specialised 
study which dealt only with the diagnosis of mild haemophilia and 
was performed in expert centres. 
It is common to all studies mentioned, whether concerned with 
sensitivity of APTT methods to congenital or acquired coagulation 
defects, factor VIII determination or any other intrinsic factor 
measurement, that they demonstrate the varying sensitivities of all 
the APTT reagents studied. Manucci et al (1979) reported the 
variation in response to the circulating anticoagulant of lupus 
erythematosus shown by a number of commercially available reagents. 
This is dealt with in greater detail below (Chapter 8.5 and 8.13). 
Use of the APTT in the Control of Heparin. Therapy 
Heparin is administered in conventional (or high-dosage) 
levels, resulting in blood levels greater than 0.2 units cm 
3, 
or 
in low-dosage levels, resulting in blood levels of 0.01 to 0.2 
units cm 
3. The APTT is the most commonly used method, worldwide, 
for monitoring heparin. Even so, the sensitivity to heparin varies 
considerably in the different reagents. The method should be 
adequately sensitive to heparin over a wide range of concentrations 
and should show a linear relationship with concentration. Triplett 
et al (1978) reported that in a proficiency survey involving over 
2,000 hospitals in the United States, there was considerable 
variation of sensitivity in measurement of conventional dose heparin 
and the non-linearity of a number of commercial reagents to 
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increasing concentrations of heparin up to 0.8 units cm 
3 
was 
shown by Shapiro et al (1977). 
Poller et al (1980) organised a study, involving over 300 
hospitals in the UK and overseas, to assess the sensitivity of APTT 
tests used to measure the anticoagulant effect of in vitro additions 
of differing amounts of heparin to a standard plasma. Participants 
were asked to reconstitute four coded vials of plasma with four 
different reconstitution fluids. In fact, the plasma was all from 
the same donor and the reconstitution fluids were, respectively, 
water and heparin solutions (0.03 u cm 
3,0.06 
u cm -3 and 0.12 u 
cm-3). In this way it was possible to test the same plasma with a 
wide range of heparin concentrations. 
Tests were carried out with local routine APTT reagent and 
technique, and also with the Manchester APTT reagent and technique. 
A sensitivity ratio was calculated, i. e., APTT of heparin containing 
plasma divided by APTT of normal plasma. The results emphasized the 
wide discrepancies which exist between commercial APTT reagents in 
their sensitivity to the anticoagulant effect of in vitro heparin. 
Some thirteen reagents from commercial sources were used by 
participants in this study. None of these showed as great a 
sensitivity as the Manchester Reagent, even though the latter was 
not familiar to over half the participants. Eight of the commercial 
reagents failed to detect the lowest heparin concentration. 
Taberner et al (1979) evaluated the sensitivity of the 
Manchester reagent in the detection of circulating heparin, 
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administered in the low dose regime to patients undergoing 
gynaecological surgery. The Manchester APTT method appeared to 
offer a much simpler and more effective method of control than 
methods designed to assay the concentration of free heparin, i. e., 
anti-Xa test (Denson and Bonnar 1973) and a chromogenic substrate 
assay (Teien et al 1976). 
Poller et al (1982) confirmed the usefulness of the APTT over 
the anti-Xa assay in a study which examined the effects of low dose 
heparin in patients undergoing hip surgery. The study was performed 
to determine the degree of anticoagulation required to protect these 
high risk patients from post-operative deep vein thrombosis. As 
discussed in Chapter 2, Hemker (1987) also prefers the use of the 
APTT for detection of circulating heparin. 
Barrowcliffe and Gray (1981) demonstrated many of the technical 
variables that exist in the APTT in the detection and measurement of 
heparin. They showed that the contact activator was important. 
Reagents that employed ellagic acid were noticeably less sensitive 
to heparin than kaolin-activated reagents. This was tested by using 
the two activators with the same phospholipid reagent. Time of 
activation was also significant. It appeared that ten minutes was 
optimal giving full activation of both heparinised and 
non-heparinised plasma, which is in agreement with the ten minute 
kaolin activation time recommended with the Manchester APTT 
reagent. Buffering increased the sensitivity of the heparin 
measuring system. These authors also found an increase in 
sensitivity with dilution of the lipid reagent. 
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THE NEED FOR STANDARDS 
From the above, it is clear that standardisation of the APTT is 
urgently required. Standardisation must be directed at the 
phospholipid reagent, since this is central to the performance of 
the test system. 
In Chapter 8, a series of experiments is described which show 
the differences between some commonly used APTT reagents in testing 
a variety of normal and abnormal plasmas. The ultrastructure and 
the lipid compostion are examined with a view to correlating 
clotting performance with some physical or biochemical feature of 
the reagents. A range of liposomes of varying composition is then 
examined to determine whether it is possible to manufacture a 
liposome that might provide an optimal surface for clotting and that 
might maximise the sensitivity of the reagent for all its laboratory 
uses. If this proves possible it may be of use in eventually 
formulating a lipid reagent acceptable as an International Reference 
Preparation (IRP). 
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CHAPTER 5 FREEZE-DRYING 
Freeze-drying, or lyophilisation, may be described as the 
removal of water from a frozen material by the sublimation of ice. 
The process may be divided into several stages. 
Stage 1- Pre-freezing. The material to be freeze-dried is 
frozen, generally at atmospheric pressure. During this procedure, 
water separates from solution to form pure ice crystals. The frozen 
material is then taken to stage 2. 
Stage 2- Sublimation. The frozen material is placed in a 
chamber maintained at low water vapour pressure, under which 
conditions ice will sublime directly from solid to vapour phase. A 
correct balance of heat input and vapour removal is important at 
this stage to support sublimation. Excessive heating causes melting 
of the material with disastrous results, while insufficient heating 
will permit the system to equilibrate, with the result that the 
frozen material will not sublime and the process will come to a 
stop. The water vapour evolved from the drying material is removed 
by condensation on a cold trap, by absorption by a desiccant or by 
pumping. When sublimation, or primary drying, is complete, a 
quantity of moisture is still retained (this may be as much as 6 or 
7%), which will not be removed by prolongation of this stage. 
Stage 3- Desorption, or secondary drying. The remaining water 
from stage 2 is removed in the desorption stage. Heat is still 
applied to the material which is at very low vapour pressure and 
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exposed to a desiccant, such as phosphorus pentoxide. 
Alternatively, lowering the temperature of the cold trap may improve 
the efficiency of this stage in the process. Several hours or days 
may be necessary to bring the residual moisture to the optimal level 
required for storage. 
HISTORICAL REVIEW 
Rey (1978) discussed the method used by the Incas, in 
pre-Columbian times, to prepare food for storage. The method 
apparently involved storing food at high altitude so that it froze 
and was then progressively dehydrated by sub'ination of ice, by 
radiant heat at the reduced water vapour pressure of the rarefied 
atmosphere. These are the same conditions that obtain in a 
present-day freeze-drying plant. 
The first modern reported use of freeze-drying was by Altmann 
(1890) who dried frozen tissues in a vacuum desiccator at -20°C 
for preparation of histological specimens. The first patent with 
thorough descriptions of the subject was that of Elser (1934) which 
described a method for drying under a vacuum, of a few mb and a cold 
trap of solid CO2. In the following year Elser et al (1935) 
described the introduction of heat into the system to supply heat of 
sublimation. 
The first commercially practical design, using a cold trap of 
methyl cellosolve, containing dry ice, was described by Flosdorf and 
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Mudd (1935). The same low temperature bath was used to freeze the 
specimens. 
Greaves and Adair (1936) described the "frothing" phenomenon 
which occurs on evaporative freezing of materials for 
freeze-drying. Rapid evaporation under vacuum causes loss of 12.5 
to 20100 of water, causing the remaining solution to freeze. Frothing 
occurs as dissolved air is released from solution. Greaves and 
Adair (1939) described their mechanically refrigerated freeze-drying 
plant and made a full analysis of the physical principles involved, 
on a sound scientific and engineering basis. 
The second World War brought a demand for large scale 
production of dried plasma. Flosdcrf et al (1940) designed a 
production plant for this purpose, using a large mechanical pump to 
substitute for a refrigerated trap or desiccant. The condensed 
water vapour had to be removed from the pump oil by high speed 
centrifugation. Eventually, large mechanically refrigerated 
condensers were preferred for removal of water vapour. Strumia and 
McGraw (1943) produced a small size drying unit, with facilities for 
shell freezing twenty-four bottles of plasma, by rolling them in a 
refrigerated bath. The plasma bottle was supported on rollers and 
rotated at about 30 revolutions per minute, with its axis horizontal 
and partially immersed in a cold fluid. Their plant used a 
mechanically refrigerated cold trap. 
Greaves, meantime, in Great Britain, was examining the same 
problems. He introduced the vertical spin freeze, in which plasma 
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bottles were spun at high speed, in a vertical position, in air, at 
-18°C, to obtain shell freezing with very small crystal size. 
Greaves also made the discovery that a superior rapid freeze, 
without frothing, could be obtained by evaporative cooling under 
vacuum, simultaneous with the high speed vertical spin. The 
original plant was in operation in 1940 and Greaves (1946) reported 
the theory and practice of the work. 
THE SUBLIMATION STAGE OF FREEZE-DRYING (PRIMARY DRYING) 
The aim of this stage is to remove ice with the minimum damage 
to the product. It may be further divided into a number of phases. 
(i) the initial phase corresponding to the start of heating. 
Within a relatively short time the evaporation rate rises rapidly to 
a maximum value. 
(ii) the sublimation phase. The interface between dry and 
frozen substances recedes from the surface to the interior of the 
product. The evaporation rate decreases rapidly because the 
resistance of the pores to heat flow and to vapour flow increases 
rapidly with the distance separating the interface of sublimation 
from the free surface of the product. 
(iii) the desorption or secondary drying phase. The 
evaporation rate decreases rapidly and approaches zero. 
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A plot of the evaporation rate against time would also serve as 
a presentation of mass transfer expressed as the weight of the 
sublimed or desorbed water per unit of time during the various 
phases of treatment. Mass transfer is at all times in equilibrium 
with heat transfer and both result from the action of temperature 
and pressure gradients, and depend on the thickness of product and 
its physical characteristics. 
The parameters which enable us to influence the rate of heat 
and mass transfer can be divided into two groups: - 
(i) those integral to the substance which define its 
structure, i. e., granulation of the product, number, dimensions and 
orientation of the pores. These depend on the method of preparation 
and freezing of the material. 
(ii) parameters external to the product, i. e., temperatures, 
partial pressure of vapour and total pressure during freeze-drying. 
These depend on the freeze-drying plant. 
Whatever the state of the substance being dried there exists an 
'interface' or 'front of sublimation' between dry and frozen 
substance, which is shifting progressively and which, at a given 
time, has a temperature Tý with a corresponding saturation 
pressure of the vapour P1. The mass transfer, MT, results from 
the migration of the vapours through the pores of the dry substance 
under the action of the difference in vapour pressure. P1 minus 
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P2 is at most equal to the total pressure, i. e., the value of the 
vacuum over the dry surface of the product. The mass transfer, MT, 
will be the more intense when P1 - P2 is greater provided it is 
balanced, at every instant, by an identical heat transfer HT. 
Consider the transfer of heat by conduction across the substance 
being dried, under the action of the temperature difference T2 - 
TV (T2 being the temperature at the surface of the substance 
in contact with the heat source). Since in the freeze-drying plant 
in use at the UK Reference Laboratory, this source is the shelf, 
heat transfer takes place through the frozen substance. In this 
case the temperature, T2, the temperature at the shelf/product 
interface must be less than Tf, the lir: ting temperature, the 
temperature of incipient melting. The only parameter external to 
the substance which can be manipulated is F-, the maximum vacuum, 
and this does not influence the heat transfer, HT, through the 
frozen layer of the substance. As HT decreases in proportion to the 
increase in T1, it is therefore advantageous to fix P2 as low as 
possible. The mass transfer is reduced with ýn: reasing depth of the 
interface and in compensation, the value of the interface 
temperature T1 increases. The heat tray fer increases with 
growing depth of the interface, X, but decreases with increasing 
T1. As a result, the rate of drying decreases rapidly towards the 
end of the sublimation period when T1 approaches T2. 
With regard to structural parameters - these only exert 
influence on the mass transfer, but since X is of high value, this 
transfer becomes the limiting factor, especially toward the end of 
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sublimation and the structural parameters eventually exert influence 
on both the rate and the duration of drying. 
Some considerations in equipment design 
The condenser is one of the most important components in a 
freeze-dryer. Despite the significance of the subject, surprisingly 
little has been published on condenser design. Triggs (1944) 
designed a hollow refrigerated condenser in which the ice, as it 
formed, was continually scraped off and removed through a vacuum 
lock. This design was an attempt to overcome the problem of the 
insulating effect of the growth of the condensing ice layer. The 
heat-flow resistance due to the ice layer on the condenser is 
proportional to its thickness and inversely proportional to its 
thermal conductivity. Condensers are designed from the point of 
view of providing the maximum area for the depositon of ice, so 
little attention is given to the question of heat conduction through 
the ice layer. 
Rowe (1976) discussed the efficiency of mechanically cooled 
condensers and believed that the temperature of the condensing 
surface must be maintained lower than that of the product and low 
enough to achieve an accommodation coefficient near to unity, i. e., 
molecules striking the condenser must be trapped and rapidly brought 
to its temperature so that further molecules may then be 
accommodated and so on. He believed that for the majority of 
purposes, a condenser temperature of -45°C to -50°C should be 
adequate. Shumsky (1958) devised a theory for sublimation 
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condensers and presented formulae for calculating the required 
surface area, ice distribution and heat transfer. Ciborowski and 
Surgiewiez (1961) also examined the problem paying particular 
attention to freeze-drying in fluidised beds. 
In 1966, deRoissart and Laederich devised a formula for 
determining the ice capacity and layer thickness on condensers 
cooled by mechanical refrigeration, solid CO2 or liquid nitrogen. 
They introduced the term "temperature deficit", i. e., the difference 
in temperature between the ice surface and the condenser surface. 
Using their equations, it is possible to calculate that at the end 
of sublimation and allowing a temperature deficit of 170°C jr the 
case of liquid nitrogen cooling, the estimated ice layer thickness 
should be 130 crr,;. For a mechanically cooled arrangement the 
temperature deficit might be 20°C resulting in an ice layer 
thickness of 20 mm. 
Rowe (196'4b) suggested guidelines to the design and operation 
of mechanically refrigerated condensers. He suggested that the 
condensing system should comprise an array of coils or plates, that 
the temperature at the ice layer surface should be -40°C, at wich 
point the saturated vapour pressure of ice would be some 0.13 mbar. 
The vacuum pump should maintain a partial pressure of about C. C13 
mbar. Rowe concluded that the surface area of the condenser should 
equal that of the shelves in the drying system, although as little 
as half of this surface may be adequate (see below, chapter 6). A 
further problem discussed by Rowe is that of uneven frosting in 
condensers. No overall solution has been found to this problem. 
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Mellor and Munns (1968) described a system of baffles designed to 
produce uniform build-up of ice in one of their machines, but made 
no suggestion about condenser surface area. 
These findings and observations were a major influence in the 
design of condensers for the freeze-drying machine, which was custom 
built for the UK Reference Laboratory for Anticoagulant Reagents and 
Control, and is described in Chapter 6. 
The mechanically cooled condenser was of copper tube, coiled to 
allow the condensation of some 18 litres of ice. The liquid 
nitrogen cooled trap was of a different design, with similar 
capacity but smaller surface area. A pri_-,. ary objective in the 
design of both devices was that there should be minimum impedance to 
vapour flow into the trap, while at the same time there should be 
maximum capacity for condensate. 
Resistivity control of heating in sublirat_cn 
Typical values of resistance for aqueous solutions are about 10 
- 102 but on freezing the resistance may change to 106n or more. 
It is possible to determine the resistance of the material when it 
is just frozen. The resistance of the raterial can then be 
monitored throughout the sublimation phase and heaters can be 
switched off if the resistance falls below the preset value. The 
switching of the heating can be made automatic, by the use of a 
suitable relay in the heating circuit. The ncr: ral manual control of 
heating is, of course, still necessary after Sublimation, when the 
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resistance will be permanently high. By use of the resistivity 
control, the correct quantity of heat may be applied, always 
maintaining T2 just below Tf for the substance being dried. 
THE DESORPTION STAGE OF FREEZE-DRYING (SECONDARY DRYING) 
Freeze-drying does not stop after the sublimation of all the 
frozen water. All products retain, by adsorption, a quantity of 
water which endangers the good conservation of the material - there 
may be up to 7% of moisture re^aining after sublimation. Secondary 
drying is intended to reduce this to an optimum value for stability 
- between 0.5% and 2.5%. 
Proper desorption is very difficult owing to the very low 
vapour pressure of adsorbed water - generally what is required is an 
increase of temperature to as as high a level as will be tolerated 
by the material, and a high vacuum. The moisture trap in secondary 
drying is usually a trap ccntaining a desiccar. t rather than the cold 
trap of primary drying. Phosphorus pentoxide is the most commonly 
used, and the most effective desiccant - it reacts with water 
irreversibly, to form a series of phosphoric acids. It is an 
unpleasant material to handle, both in its dry and quenched states. 
Damage from freeze-drying 
There are four stages in the freeze-drying process where injury 
can occur - during the initial freezing, during drying, during the 
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subsequent storage or on reconstitution. This area was discussed in 
detail by Stevenson (1978). 
Damage during freezing 
Damage may be prevented or alleviated by the addition of 
cryoprotectives. Unfortunately, the most effective additives such 
as dimethyl sulphoxide and the glycols are not of much use in 
preparations for freeze-drying since they are not easily sublimed. 
Damage from drying 
Dehydration takes place during freezing. dehydration is 
said to be less damaging to microorganisms, fcr example, than the 
dehydration that occurs during freeze-drying. This observation has 
been taken as support for the idea that freeze-drying removed a 
portion of water that was "unfreezable" or "bouný". 
Bound water has been "measured" in ter s of so-called 
unfreezable water. While it is true that in any cooling experiment, 
especiallly one in which some or all of the solutes do not 
crystallize, a certain proportion of water does not appear to 
freeze, the reason is not that this water :s prevented from 
freezing, because it is bound to some non-aqueous species. Franks 
(1986) discussed the cooling of a dilute sucrose solution. Ice 
begins to form at the equilibrium freezing point (which depends on 
the initial concentration). Further cooling lea z to an increase in 
the concentration and the viscosity of the solution. At -32oC the 
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concentration is equivalent to 0.5 g water (unfrozen) per gram of 
sucrose. The time required by a water molecule to diffuse through a 
given distance depends upon the viscosity. At -32°C this is more 
than 3 years/).. an. Water is therefore not unfreezable, but unfrozen 
on the time scale of the observation. It is not bound. Even pure 
water would behave similarly, that is, at -150°C ice crystals 
would grow at 0.3}zm per year. 
During drying, denaturation can take place in the still frozen, 
though undried, portions of the specimens, due to the concentration 
of solutes during freezing. The rate at which adverse reactions 
proceed will be increased by exposure to higher drying 
temperatures. This suggests that susceptible materials should be 
dried at temperatures low enough to reduce rates of reaction, and 
low enough to eliminate all liquid phase, since any liquid phase 
present, from eutectic solutions will enable reactions to continue. 
A further mechanism of drying damage may be from the 
recrystallization c. ° salts or hydrates formed from eutectic 
solutions. Rey (1964) and MacKenzie and Luyet (1964) studied the 
freeze-drying process through time-lapse photomicrographs of the 
progression of drying in a thin film of solution. There are a 
number of interesting observations on their work. 1) as the drying 
boundary passes through a large crystal of ice, the sublimation 
surface appears to be parallel to the crystal planes. 2) individual 
ice crystals dry independently of each other. Isolated crystals may 
remain undried after surrounding crystals have sublimed. 3) when 
solutions are drying, the drying boundary is not a sharp interface, 
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but a zone of uniform width, well demarcated on either side from the 
frozen and the dried portions of the specimen. There is great 
activity within the drying zone, suggesting recondensation and 
recrystallization. The salt or hydrate crystals left behind are 
related in size to the drying temperature at the moment when that 
particular area was drying. Raised temperature produces larger 
crystals. Considerable structural damage may result from the 
crystallization of these salts and hydrates - once again the 
suggestion is that low drying temperatures should be employed when 
drying injury is a problem. 
Damage during storage following drying 
There are a number of deleterious reactions that can take place 
during the storage of dried materials at room temperature. Hannan 
and Lea (1952) emphasize the reactions between proteins and reducing 
sugars as being very important. This reaction may be minimized by 
reducing the amount of carbonyl-containing compounds, such as 
glucose, in the medium and by adding carbonyl acceptors such as 
sodium glutamate. This 'browning reaction' can also occur between 
organic acids and ascorbic acid, proteins and other amine groups, in 
fact, almost all the chemically reactive constituents present in the 
specimen. These reactions will be inhibited at low moisture levels. 
The other main class of adverse reactions involves oxidation, 
which is of the greatest significance in dealing with 
thromboplastins. The exclusion of oxygen from containers of dried 
material is therefore of considerable importance - in freeze-drying 
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of biological materials, vials may be sealed after introduction of a 
partial pressure of nitrogen or argon. The procedure for this step 
is described in some detail below (Chapter 6). 
Damage from reconstitution 
Even though the exact amount of water removed by drying is 
replaced, it cannot be replaced uniformly. This means that as 
reconstitution is going on there will be substantial concentration 
gradients, transport of solutes throughout the specimen and osmotic 
imbalances which may lead to a specimen that differs quite radically 
from the fresh material. This aspect of the work is not discussed 
in any detail in the literature. 
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CHAPTER 6 METHODS AND MATERIALS 
6.1 SEPARATION OF LIPID CLASSES BY THIN LAYER CHROMATOGRAPHY 
No single one-dimensional method was able to resolve the lipids 
of interest. Accordingly, a number of thin-layer chromatography 
(TLC) methods were employed, which are described below. 
For calibration purposes a standard phospholipid mixture was 
prepared which comprised di-PG, PA, PG, PS, PE, PI, PC, SPH and 
lyso-PC in the proportions shown in table 6.1. 
TLC plates were activated at 1200C for 15 minutes before 
use. To maintain saturated conditions in the chromatography tank, a 
piece of filter paper (Whatmans no 3) was cut to 22 x 22 cm and 
placed against one wall. Fresh solvent mixture was added to the 
tank by pouring down the paper, the lid replaced and the tank 
allowed to equilibrate for at least 30 minutes before use. 
Lipids were extracted from test samples of tissue 
thromboplastin, partial thromboplastin or liposomes by the method of 
Bligh and Dyer (1959). Aliquots of lipids, dissolved in chloroform 
or chloroform: methanol (95: 5 v/v), were stored in glass vials at 
-140°C until required for TLC. 
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TABLE 6.1 COMPOSITION OF STANDARD LIPID MIXTURE 










Visualisation of separated spots - Four methods were employed: 
1 Periodic acid - Schiff stain (PAS) 
The dry chromatogram was sprayed with sodium periodate (1% aq) 
and allowed to stand for 5 minutes. It was then dried under a 
stream of warm air, and placed in a perspex box (235 x 235 x 190 mm) 
flushed with sulphur dioxide. After the plate was cleared of excess 
iodine, it was removed from the box, lightly sprayed with Schiffs 
reagent and returned to the SO2. PG stained immediately. Several 
hours were required before all the phospholipids stain to sufficient 
intensity for quantitation by densitometry. PA does not stain ty 
this method. 
2 Charring at 130°C for 30 minutes on a Desaga FP 
Thermoplate (Uniscience Ltd, Cambridge), following spraying with 5C7. 
methanolic sulphuric acid. This method reveals all the organic 
material on the chromatogram. 
3 Charring at 130°C for 10 minutes following a dip in 0.82 
mol dm-3 phosphoric acid containing 0.17 mol dm -3 of cupric 
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acetate. This method produced more dense staining of the neutral 
lipids than did method 2. 
4 Ninhydrin staining of aminophospholipids. A fresh solution 
of 14 mmol dm -3 ninhydrin in 9: 1 (v/v) acetone: lutidine was 
sprayed on to the dried TLC plate and the layer allowed to dry 
before respraying. The plate was then heated at 1000C for 5 
minutes. Amino-containing phospholipids appeared as purple spots 
(Narinetti 1964). 
TLC system 1 
A si ii c* LEJ E-1 at. e (250, u layer) incorporat. irnL amn"oniun, suJ pI at. e 
(Camlab Ltd, Cambridge) was run in the solvent. systen- 
chloroform: methanol: water (65: 25: 4) by volume. Lipid standards, 
individually, or in the mixture described, were applied 15 mm from 
the bottom of the plate. Development under saturated conditions was 
stopped when the solvent front reached 140 mm. Visualisation was by 
method 1. 
This system was developed for routine use in the UK Reference 
Laboratory for examination of amniotic fluid phospholipids 
(Stevenson et al 1987). A reprint of the publication is appended. 
Briefly, it was possible, on one TLC plate, to determine the 
concentration of PG, by PAS staining and densitometry, and to 
calculate the ratio of PC to SPH (the lecithin/sphingomyelin or L/S 
ratio) by planimetry following visualisation by method 2. For 
planimetry, a simple rectangular figure was constructed about, the FC 
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and SPH spots and the ratio of their areas calculated. Assessment 
of foetal lung maturity was possible, based on this information. 
The PAS stain clearly revealed quantities of 0.1 yg of PG and the 
colour was stable for several hours. 
The Rf values of the lipid classes listed above are shown in 
Table 6.2. PS and PE gave discrete Rf values when run as separate 
standards, but tended to comigrate when they occurred in complex 
mixtures. Fig 6.1 shows a plot of the PG concentration against 
integrator counts and the method of quantitation using densitometry 
is described on page 102. 
TABLE 6.2 Rf VALUES FOR LIPIDS SEPARATED BY SYSTEM 1 
Lipid Class Rf value 
diPG . 92 PA . 
86 
PG . 71 PS . 48 PE . 44 PI . 34 PC . 19 SPH . 10 lyso-PC . 06 
TLC system 2 
A Whatman K5 20 x 20 cm silica gel plate (250 )a layer) was run 
in the same solvent system as system 1, under identical conditions. 
Visualization of separated components was by method 2. The Rf 
values for this system are shown in table 6.3. 
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This system has the disadvantage that diPG and PG co-migrate, 
as do PI and PS. PE, however, is clearly resolved, as were lyso-PC, 
PA, SPH and PC. 
TABLE 6.3 Rf VALUES FOR LIPIDS SEPARATED BY SYSTEM 2 
Lipid Class Rf value 
PE . 54 diPG + PG . 43 PA . 38 PC . 26 PI + PS . 22 SPH . 16 lyso-PC . 12 
TLC system 3 
A Whatman K5 plate, was employed in the solvent system 
chloroform: methanol: acetic acid: water (50: 25: 8: 1 by volume). 
Chromatography was under saturated conditions. Visualisation of 
separated components was by method 2 and Rf values for this system 
are shown in table 6.4. PS and PI were clearly resolved. 
TABLE 6.4 Rf VALUES FOR LIPIDS SEPARATED BY SYSTEM 3 
Lipid Class Rf value 
PE . 92 diPG . 90 PA . 
81 
PG . 74 PS . 61 Pi 
. 39 PC . 18 SPH . 09 lyso-PC . 07 
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TLC system 4, separation of neutral lipid classes 
A two-stage, one-dimensional system was employed (Bitman, Wood 
and Ruth 1981) to separate the neutral lipid classes. Whatman K5 
plates were developed in diethyl ether to remove the binder 
incorporated by the manufacturer. Plates were developed to 170 mm 
in the first stage in the solvent mixture chloroform: methanol: acetic 
acid (98: 2: 1 by volume). After air drying, the plate was developed 
in the same direction in the solvent mixture hexane: diethyl 
ether: acetic acid (94: 6: 0.2 by volume) to the top of the plate. 
Development in both stages was under saturated conditions. 
Visualization was by method 3. Table 6.5 shows the Rf values 
obtained by this method. The lipid classes listed were as follows - 
cholesterol ester was 50% cholesteryl oleate, 50% cholesteryl 
linoleate. Triglyceride was 50% triolein, 50% trilinolein. 
1,3-diglyceride was 50% 1,3-diolein, 50% 1,3-dilinolein. 
1,2-diglyceride was 50% 1,2-diolein, 50% 1,2-dilinolein. 
Cholesterol was > 99% as provided by Sigma. Free fatty acid was 50% 
oleic acid, 50% linoleic acid. (It was not necessary to use 
unsaturated fatty acids exclusively, as a good response was also 
noted with saturated species). Monoglyceride was 50% 2-monoolein, 
50% 2-monolinolein. Phospholipid was 50% PC, 50% PE. 
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TABLE 6.5 Rf VALUES FOR LIPIDS SEPARATED BY SYSTEM 4 
Lipid Class 
RF value 
First Stage Second Stage 
Cholesteryl ester . 71 . 80 Triglyceride . 71 . 70 1,3 Diglyceride . 66 . 62 1,2-Diglyceride . 60 . 57 Cholesterol . 52 . 50 Free fatty acid . 40 . 39 Monoglyceride . 22 . 22 Phospholipid origin origin 
TLC system 5 
A Whatman K5 plate was run in two dimensions. In the first the 
solvent system employed was chloroform: methanol: water (65: 25: 4 by 
volume). The chromatogram was developed 125 mm, then dried in a 
stream of nitrogen. Following drying, the plate was placed in the 
second solvent system - chloroform: methanol: acetone: acetic 
acid: water (65: 10: 20: 10: 3 by volume) and developed to 125 mm at 
900 to the first dimension. Both dimensions were run under 
saturated conditions. 
This system resolved the lipid classes of the standard 
mixture. The Rf values are shown in table 6.6. This system was 
used to check the purity of individual lipid standards purchased 
from commercial houses, and to test the systems described above. 
Visualisation was by method 2. 
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TABLE 6.6 Rf VALUES FOR LIPID CLASSES SEPARATED BY SYSTEM 5 
Rf value 
Lipid Class 1st Dimension 2nd Dimension 
diPG . 37 . 51 PA . 34 . 59 PG . 41 . 43 PS . 26 . 16 PE . 52 . 41 PI . 23 . 09 PC . 30 . 19 SPH . 17 . 06 lyso-PC . 11 . 03 
Quantitation 
Quantitation was principally by scanning transmission 
densitometry on a Helena Laboratories Quick-Scan Jnr TLC instrument 
(MI Scientific, Newcastle upon Tyne). 
The instrument comprised a tungsten lamp with facilities for 
filtering of wavelength, over the range 420-675 nm. A beam of light 
passed through a slit (0.2 mm x2 mm) and through the developed 
chromatogram, which was moved across it by a motorised mechanism. 
Transmitted light was collected by a photomultiplier and amplified, 
the spots being translated into peaks on the instrument chart 
recorder. Also on the chart is an integrator read-out, enabling the 
"area under the curve" to be calculated. 
After calibration of the instrument by use of a neutral density 
transparency, supplied by the manufacturer, the machine was ready 
for use. For each lipid class to be quantified, it was necessary to 
run a series of concentrations on each chromatogram. By scanning 
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these standards, a calibration curve could be constructed for each 
class of interest. This ensured that for each run a new calibration 
curve was prepared. See figure 6.2(a-i). A problem in densitometry 
is the difficulty in manually applying standard sized spots to the 
layer. A Desaga Autospotter was employed (Uniscience Ltd, 
Cambridge) to overcome this problem. 
A further method of quantitation was also employed for PS in 
System 3. The plate was sprayed with ninhydrin and warmed, as 
described in visualisation method 4, as above. Aminophospholipids 
such as PS and PE react, giving a purple colour. The PS spots, 
which were elliptical in shape, were clearly visible by this means. 
A rectangular figure was constructed about the spot and its area 
calculated. By running a range of concentrations of a standard 
preparation of PS it was possible to construct a standard curve 
which was linear over a wide range (see fig 6.3). 
Comment 
There were two reasons for separating the lipid classes in the 
manner described above. Firstly, no single one-dimensional thin 
layer chromatographic system, in the authors hands, was able to 
resolve all the lipids of interest. Secondly, because of diffusion 
of separated spots, quantitation by densitometry was not possible in 
two-dimensional systems. This meant that a test sample had to be 
chromatographed in four separate systems. In each case appropriate 
standards were applied to the TLC plate so that a calibration curve 
could be constructed for each lipid class of interest (Fig 6.2a-i). 
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System 1 allowed the quantitation, by this means, of diPG, PG, PC 
and SPH. System 2 was used to separate and quantify PE, PA and 
lyso-PC. System 3 was able to separate and quantify PS and PI. The 
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Fig 6.2 standard curve of PC vs. integrator value. 
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Fi- 6.2c standard curve of SP vs. integrator value. 
107 















0 5 10 15 20 jig PI 
Fig. 6.2e standard curve of PI vs. inte¬rator value. 
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6.2 DETERMINATION OF PHOSPHOLIPID PHOSPHORUS 
TLC plates were sprayed with 50% sulphuric acid in methanol and 
charred at 130°C. Phospholipid spots were marked by drawing 
around them with a fine pencil. Exposing the surface of the plate 
to UV irradiation at 355 nm made this easier since the spots showed 
some fluorescence. An aliquot of lipid mixture under test was then 
applied to the plate in order to provide "total" value of 
phospholipid phosphorus. Digestion and colour development were as 
described by Rouser et al (1966). 
Spots were then scraped from the plate into pyrex tubes (150 x 
18 mm). An equal area of silica gel was removed to provide a 
"blank" value. 0.9 cm3 of 72% perchloric acid was added to each 
tube and digestion of the spots was carried out for 40 minutes at 
1500C in an electrically heated apparatus, in a fume cupboard. 
The fume cupboard was built with this function in mind, since there 
was no exposed wood internally, (surfaces being resin treated) and 
its base was made of ceramic. The fume extract duct was fitted with 
a scrubbing device. 
Following digestion, the walls of the tubes were washed with 5 
cm3 of distilled water and 1 cm3 of 22 mmol dm -3 ammonium 
molvbdate was added and mixed followed by 1 cm3 of 0.57 mol dm-3 
ascorbic acid and 2 cm3 of distilled water. The mixture was 
boiled for 10 minutes in the electrically heated block set at 
1200C. A reagent blank was carried through the process. 
112 
After colour development the tube contents were centrifuged to 
settle particulate material and absorbance read at 820 mm. A 
standard curve was prepared using KH2PO4 (1.3613 g dm-3 is 
equivalent to 310 )jg cm -3 of phosphorus) in the range up to 100 }lg 
of phosphorus. A standard curve is shown in fig 6.4. 
Glassware employed in this assay was scrupulously cleaned using 









Fig 6.4 Standard curve of phosphorus concentration vs. absorbance 
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10 20 30 
, umol phosphorus. 
6.3 DETERMINATION OF PHOSPHOLIPIDS BY REACTION WITH AMMONIUM 
FERROTHIOCYANATE 
The method is based on the formation of a coloured complex 
between ammonium ferrothiocyanate and phospholipids which is soluble 
in chloroform (Stewart 1980). 
Phospholipids were dissolved in 2 cm3 of chloroform, added to 
2 cm3 of ammonium ferrothiocyanate (see below) and vigourously 
mixed on a vortex mixer for 1 minute. On separation, the lower 
chloroform phase was removed using a Pasteur pipette, clarified with 
a pinch of anhydrous sodium sulphate, and the absorbance read at 488 
M. 
Calibration curves were prepared for a range of phospholipids 
and are shown in figure 6.5. The variation in slope of the curves 
presumably results from the formation of a range of complexes. 
Stewart (1980) believed that lyso-PC and SPH probably form 1: 1 
complexes with Fe(SCN) 3 while PE and PS probably form 2: 1 
complexes. 
Ammonium ferrothiocyanate solution was prepared by dissolving 
27.03 g (0.1 mol) of ferric chloride hexahydrate (FeC13.6H20) 
and 30.4 g (0.4 mol) of ammonium thiocyanate (NH4SCN) in deionized 
water and making up to 1 dm3. The solution is stable for at least 
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Fig 6.5 standard curves for phospholipid phosphorus estimation. 
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6.4 ESTIMATION OF FATTY ACIDS BY GAS LIQUID CHROMATOGRAPHY OF THEIR 
METHYL ESTERS ON CAPILLARY COLUMNS 
Apparatus - the gas chromatograph employed was a Pye Unicam 
GCD, fitted with flame ionizer detectors. This instrument was 
designed for use with packed columns and was originally fitted with 
dual injection ports, columns and detectors. The fan assisted oven 
was controllable over the temperature range from ambient up to 
400°C and programming of temperature was possible. Flame ionizer 
detector (FID) temperature and injector temperature were adjustable 
over the same range. 
A number of modifications were undertaken in order to convert 
the instrument to capillary column use. The capillary columns and 
all the materials required for this conversion were obtained from 
Phase Separations, Queensferry. 
Firstly, an "on-column" injector was fitted. This device, 
manufactured by Scientific Glass Engineering, Milton Keynes (model 
no OCI-3) enabled the injection of 1)ul samples directly on to the 
capillary column. A5 pl syringe was used, fitted with a stainless 
steel sheathed vitreous silica needle. The sheath extended to 20 mm 
from the end of the needle, so that the needle was free to penetrate 
into the capillary column. The injector device was cooled by a 
stream of compressed air flowing at 300 cm3 min-1, controlled by 
a needle valve. Cooling in this way prevented heat build up from 
the chromatograph oven, which could have volatilized the lower 
boiling components of the samples under test. The major advantage 
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of the "on column" system was that the entire sample was placed 
directly into the column and there were no losses, as might have 
occurred in a sample splitting system. While sample injection was 
being carried out, a pneumatically operated seal gripped tightly 
around the needle sheath and continued to keep the system sealed 
when the needle was withdrawn. 
Hydrogen was the preferred carrier gas. It was necessary to 
fit an accurate regulator valve to control the H2 supply to the 
injector and column-a regulator calibrated in the range 0-1 
atmosphere was found to be adequate. The FID was originally 
designed to accommodate carrier gas flows of 30-60 cm3 min-'. 
Since the flow of hydrogen from a capillary column was around 2 
cm3 min-1, detector sensitivity was drastically reduced and an 
auxilliary supply of "make-up" gas had to be provided. Nitrogen was 
the gas of choice and was connected, via a T-piece, between the end 
of the capillary column and the FID. The pipework carrying the 
nitrogen make-up was led through the column oven so that the gas was 
heated to column temperature. This was to ensure that no 
condensation of high boiling components took place at the end of the 
column. 
Gases were obtained from the British Oxygen Company and were 
industrial grade in the case of compressed air and oxygen-free 
grades in the case of nitrogen and hydrogen. Molecular sieves were 
employed in the gas lines and particle filters were also fitted to 
trap any entrained dust from the molecular sieves. Molecular sieves 
were regenerated by heating at 350°C for 24 hours. 
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While it was arguable that gas driers were not absolutely 
essential when using silicone gum phases like OV1, dryness was more 
important when the highly polar phase 0V351 was used. Prolonged 
column life justified such precautions. Further, highly polar 
phases were susceptible to oxidation. No problems were encountered, 
however, when oxygen-free grade hydrogen was employed as carrier 
gas. Hydrogen was used as the carrier because of its high 
efficiency (Jennings 1980). The decision to use hydrogen raised a 
number of important questions. Firstly there was the problem of the 
possibility of interaction between the carrier gas and sample 
components or the liquid phase. Grob (1979) addressed this problem 
and concluded that in the absence of a suitable catalyst this was 
unlikely. The other hazard in the use of hydrogen was its capacity 
to form explosive mixtures with air over a wide range of 
concentrations. It may be argued that because of its high 
diffusivity it would be difficult to accumulate enough hydrogen to 
form an explosive mixture, even inside a chromatograph oven. 
Happily, reports of explosions in gas chromatographs are rare but it 
nevertheless remained prudent to take every precaution. 
Gas cylinders, including hydrogen, were stored in a purpose 
built outhouse and connected to the laboratory by metal pipework 
laid underground. Inside the laboratory, the gas pipelines 
terminated on the bench at a set of colour coded screw taps. This 
work was carried out by Medical Gas Installations, Bolton. 
Molecular sieves and filters were connected to these and the 
chromatograph plumbed in using 1/8 inch outside diameter copper 
pipe. A strict routine of checking for leaks was maintained, both 
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in the chromatograph and in the gas supply lines inside the 
laboratory. 
The Pye Unicam GCD was of an old design, originally comprising 
two injectors and two FIDs. There was also a 1/4 inch diameter hole 
in the roof of the oven for inserting a thermometer. Since one 
injector and one FID were redundant this meant that two more ports 
were opened in the oven roof. The oven door was hinged at the 
bottom and secured in place by two magnetic catches. These features 
meant that any leak of hydrogen would have been unlikely to reach a 
critical level in the oven and in the event of an explosion the door 
would have burst open more readily than would be the case with some 
modern instruments which have very tight fitting and securely 
latched doors. 
Two columns were employed. These were flexible silica columns 
("Flexsil", Phase Separations, Queensferry) wall coated with OV1 and 
0V351 respectively, i. e., a non-polar phase and a highly polar 
phase. Each measured 25 metre x 0.32 mm i. d. with a wall-coating 
0.15 microns thick. When using the OV1 column, temperature was 
programmed to maintain 1300C for 2 minutes, then increased to 
300°C at 4°C/min. Detector temperature was 2750C. The 
maximum temperature limit for OV1 was 300°C. 
When the 0V351 column was in use, temperature was programmed to 
maintain 130°C for 2 minutes then increased at 40C/min, to 
2L0°C. Detector temperature was 275°C. The maximum temperature 
limit for 0V351 was 250°C. 
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Test mixtures, obtained from Phase Separations, were applied 
periodically to each column in order to check performance. Tables 
6.7 and 6.8 illustrate the order of elution of their components. 
TABLE 6.7 TEST MIXTURE ON OV 1 












TABLE 6.8 TEST MIXTURE ON OV 351 











It was necessary to calculate, for each column, the response 
factor (RF) for each fatty acid methyl ester and its retention time 
relative to the internal standard. The methyl ester of 
heptadecanoic acid was selected as internal standard. Two 
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concentrations of each FAME, 0.1, pg and 0.25 pg, were run on each 
column. Table 6.9 and 6.10 show the results obtained. This 
information was loaded into the Spectra Physics model SP4100 
computing integrator which was connected to the gas chromatograph. 
The integration program (occupying some 32Kbytes of ROM in the 
SPi4100) was able to identify each component by its relative 
retention time and to quantify each component by its response factor 
value. A further 6.5Kbytes of RAM was available on the SP4100 which 
was sufficient for operating some small statistical programs (see 
Chapter 6.21). Programs were stored on cassette tapes. 
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TABLE 6.9 SUMMARY OF CHROMATOGRAPHIC DATA. OV 1 
FAME RT RRT RF 
10: 0 3.38 0.192 0.750 
12: 0 6.32 0.359 0.541 
14: 1 10.16 0.577 0.395 
14: 0 10.63 0.604 0.472 
16: 1 14.71 0.836 0.396 
16: 0 15.24 0.866 0.407 
17: 0 17.60 1.000 - 
18: 3u6,9,12 18.50 1.051 0.572 
18: 30,12,15 18.99 1.079 0.470 
18: 2 19.02 1.081 0.406 
18: 1 19.24 1.093 0.492 
18: 0 19.84 1.127 0.537 
20: 4 22.37 1.271 0.651 
20: 2 23.28 1.323 0.493 
20: 3 23.43 1.331 0.564 
20: 1 23.55 1.338 0.469 
20: 0 24.16 1.373 0.732 
22: 6 26.21 1.489 0.527 
22: 2 27.05 1.537 0.411 
22: 1 27.68 1.573 0.431 
22: 0 28.14 1.599 0.472 
24: 1 31.22 1.774 0.418 
24: 0 31.89 1.812 0.495 
26: 0 35.29 2.005 0.493 
RT = retention time 
RRT = relative retention time 
RF = response factor 
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TABLE 6.10 SUMMARY OF CHROMATOGRAPHIC DATA. OV 351 
FAME RT RRT RF 
10: 0 4.57 0.244 0.756 
12: 0 7.75 0.414 0.567 
14: 0 11.98 0.636 0.474 
14: 1 12.73 0.678 0.408 
16: 0 16.42 0.874 0.404 
16: 1w9trans 17.00 0.905 0.430 
16: 1w9cis 16.94 0.906 0.358 
17: 0 18.79 1.000 - 
18: 0 20.90 1.114 0.538 
18: 109c1s 21.44 1.137 0.546 
18: 1u 9trans 21.46 1.140 0.397 
18: 1011cis 21.55 1.145 0.531 
18: 2c9,12cis 22.32 1.193 0.281 
18: 2o9,12trans 22.35 1.199 0.527 
18: 3i6,9,12cis 22.92 1.225 0.559 
18: 309,12,15c1s 23.85 1.265 0.481 
20: 0 25.33 1.341 0.736 
20: 1w5cis 25.63 1.357 0.388 
20: 1c11cis 25.56 1.366 0.553 
20: 2 26.64 1.414 0.496 
20: 4 27.52 1.475 0.661 
20: 3 27.96 1.483 0.586 
22: 0 29.47 1.557 0.504 
22: 1'13cis 29.75 1.585 0.434 
22: 1w13trans 29.77 1.593 0.426 
22: 2 30.16 1.598 0.406 
24: 0 34.05 1.803 0.493 
22: 6 34.04 1.820 0.578 
24: 1 34.41 1.832 0.413 
26: 0 40.37 2.152 0.497 
RT = retention time 
RRT = relative retention time 
RF = response factor 
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Preparation of methyl esters of fatty acids (Metcalfe and 
Schmitz 1961) 
14% boron trifluoride in methanol was obtained from Phase 
Separations, Queensferry. Material for esterification, freeze-dried 
or scraped from thin-layer chromatography plates, was placed in a 
pear shaped flask (Quickfit FP50/2). A few glass beads were added 
and 2 cm3 of benzene pipetted into the flask to dissolve the 
material. 2 cm3 of BF3 in methanol was then added. The flask 
was connected to a condenser (Davies type, Quickfit C5/22) and the 
contents refluxed for 60 minutes in a boiling water bath. The flask 
was then removed and the reaction stopped by the addition of 1 cm3 
of water. Centrifugation at 500 xg separated the phases. The top 
layer, consisting of the methyl esters dissolved in benzene, was 
removed by pipette and stored in a tightly stoppered glass vial at 
-40°C until required. 
Sample preparation for gas chromatography 
Fatty acid methyl esters were stored in benzene at -40°C. 
For chromatography, benzene was evaporated under a stream of dry 
nitrogen gas and the residue redissolved with 50 dal of octane. To 
this was added 50 , p1 of a1g dm -3 solution of the methyl ester of 
heptadecanoic acid, as internal standard. 1 pl of this mixture was 
injected via an on-column injector. Figures 6.6 and 6.7 show the 
chromatography, on OV1 and 0V351, of FAMES of an APTT reagent, batch 
117. Tables 6.11 and 6.12 show the identity of the arrowed peaks in 
each of the figures. 
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Fig. 6.6 FAMEa of 117 separated on OV 1 
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92.191: tf 3YI1 f. lic"I 
Fig. 6.7 Fla of 117 separated on 0V 351 
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i:: i": ýQ 3.: a a: 3. s. 
TABLE 6.11 IDENTITY OF PEAKS IN FIG. 6.6 
Peak no. FAME 
1 12: 0 
2 14: 0 
3 16: 1 
ü 16: 0 
5 internal standard (17: 0) 
6 18: 3 w 9,12 
7 18: 1 
8 18: 0 
9 20: 4 
10 20: 2 
11 20: 3 
12 20: 1 
13 20: 0 
14 22: 6 
15 22: 2 
16 22: 1 
17 22: 0 
18 24: 1 
TABLE 6.12 IDENTITY OF PEAKS IN FIG. 6.7 
Peak no. FAME 
1 12: 0 
2 14: 0 
3 16: 0 
4 16: 1 
5 internal standard (17: 0) 
6 18: 0 
7 18: 1 
8 18: 2 
9 18: 3-'6,9 
10 18: 3w9,12 
11 20: 0 
12 20: 1 
13 20: 2 
14 20: 4 
15 20: 3 
16 22: 0 
17 22: 1 
18 22: 6 
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6.5 TESTING OF PURITY OF PHOSPHOLIPID STANDARDS 
Each phospholipid, before use as a chromatography standard or 
as a liposome component, was checked for purity. This was done by 
running it in the two-dimensional TLC system described earlier 
(system 5). A single spot was taken to indicate purity and 
preparations were discarded if other spots e. g. lyso-phospholipids 
or fatty acids were seen. 
A further check was made on phospholipids used in manufacture 
of liposomes. These were examined by gas chromatography as 
described above (Ch 6.4) on receipt from their suppliers (Sigma 
Chemical Co, Poole, or Supelchem, Sawbridgeworth in the case of PG) 
to ensure batch to batch continuity and to determine the fatty acid 
composition prior to their use in a liposome. Table 6.13 shows the 
fatty acid distribution in a number of phospholipids used. 
There were marked differences in the fatty acid distributions 
in the phospholipid standards. The PE preparation had the highest 
USFAR and contained a large proportion of arachidonic acid. The 
lowest USFAR among the natural phospholipid preparations was 0.84, 
shown by the bovine brain PS. Lyso-PS, prepared from bovine brain 
PS9 had a value of 0.28. The synthetic dipalmitoyl PC, obtained 
from Sigma, contained only palmitic acid. 
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6.6 PREPARATION OF LIPOSOMES 
Pure phospholipids in chloroform: methanol (95: 5 v/v) were mixed 
in the required proportions. Cholesterol in the same 
chloroform: methanol mixture was also added at this stage. The 
preparation was thoroughly mixed then taken to dryness under a 
stream of oxygen-free nitrogen. The dried lipid was resuspended in 
saline and thoroughly mixed once again. The suspension was 
sonicated (Dawe Ultrasonic Bath model 6447A) for 5 minutes at a 
temperature five degrees higher than the transition temperature of 
that component of the mixture with the highest Tc. This was done 
by placing a thermostatically controlled heating element in the 
ultrasonic bath (Grant Instruments, Cambridge). The process was 
carried out under a stream of oxygen-free nitrogen. 
Following sonication, the preparations were cooled to 5°C for 
15 minutes prior to use in coagulation studies. A representative 
sample of liposomes was tested for purity and a further sample fixed 
for electron microscopy (see fig 6.8). 
6.7 PURITY TESTING OF COMPLETE LIPOSOMES 
A sample of liposcme suspension was extracted by the method of 
Bligh and Dyer (1959) and the lipids subjected to two-dimensional 
TLC as described (system 5). The appearance of fatty acids or 
lysophosphatides was taken to indicate that some degradation had 
occurred. 
130 
6.8 ELECTRON MICROSCOPY 
Liposome preparations, thromboplastin and partial 
thromboplastin were fixed in 0.22 mol dm-3 cacodylate buffered 
glutaraldehyde (pH 6.5) and centrifuged at 6500 xg for 1 hour. The 
pellet was washed with buffer and post-fixed in 40 mmol dm-3 
osmium tetroxide. Following a further washing step the preparations 
were dehydrated in a graded series of alcohols. In order to 
facilitate this procedure the liposome and activated partial 
thromboplastin preparations had to be embedded in 1% agarose. This 
was not necessary for the tissue thromboplastin reagents. 
The dehydrated blocks were then infiltrated with propylene 
oxide and embedded in Agar 100 resin. Sections were cut on either 
an LKB IV or a Reichart 0MU-4 ultramicrotome, stained with uranyl 
acetate and lead citrate and examined in an AEI EM 801 transmission 
electron microscope. 
Sections of 50 - 60 nm thickness were normally cut except in 
the case of General Diagnostics Automated APTT reagent which 
contained colloidal silica particles necessitating section thickness 
of approximately 100 nm. Fig 6.8 shows an electron micrograph of a 
liposome preparation made as described in Ch 6.6. 
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Fig 6.8 (opposite) An electron micrograph of a liposome 
preparation. Magnification X 5000, scale bar 
500nm. 
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6.9 ESTIMATION OF SIZE DISTRIBUTION OF APTT REAGENT LIPOSOMES 
Measurements of size distribution were made on Malvern 
Instruments Ltd. Autosizer or Zetasizer instruments which work on 
the same principle, as follows: 
Particles suspended in liquid undergo random Brownian motion 
according to their size, smaller ones moving more rapidly than 
larger ones. The light scattered by the particles when they are 
illuminated by a low power laser beam fluctuates in intensity as a 
result of this motion. The technique of autocorrelation 
spectroscopy interprets these fluctuations in terms of particle 
diameters. The Zetasizer instrument reports diffusion coefficient, 
mean particle size and polydispersity. The equivalent normal weight 
distribution is presented graphically with peak particle size and 
standard deviation data. The Autosizer instrument gives a graphic 
presentation of the particle size distribution by weight together 
with a detailed table showing the numbers of particles falling in 
particular size ranges. As described in Ch 8.2, a Zetasizer 2 
instrument was used for the study of two APTT reagents, General 
Diagnostics Automated APTT and Manchester APTT, with a 0.7 mm bore 
capillary cell (PC3). For the other reagents, Actin, Actin FS and 
Activated Thrombofax, an Autosizer 2 instrument was used, with a4 
mm bore PC4 capillary. A typical Zetasizer 2 output for Manchester 
APTT is shown in fig 6.9, while fig 6.10 shows a typical Autosizer 2 
output for Actin FS. The major advantages of using this method for 
sizing are that the sample measured may be many millions in a matter 
of seconds and there is no possibility of samples being degraded by 
any preparative process. 
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Fig 6.9 Size distribution of liposomes of Manchester APTT reagent. 
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Discussion of methods available for estimation of size 
distribution 
The method of negative staining with electron microscopy was 
found to be satisfactory for the analysis of small unilamellar 
vesicles giving values that were within 10% or 20% of values 
obtained by freeze fracture, hydrodynamic studies and nuclear 
magnetic resonance (Bergelson 1979, Huang 1969, Watts et al 1978). 
Olson et al (1979) discuss the difficulties encountered in applying 
this method to multilamellar vesicles. Since these consist of a 
heterogeneous distribution of sizes and shapes, for example large 
elliptical or cylindrical structures are observed, it was necessary 
to take the mean of the major and minor axes of such structures and 
assume that they had originally formed a sphere. The discrepancy 
between this method and freeze fracture in estimating vesicle size 
was the greatest for distributions that contained the largest 
diameter particles and the greatest heterogeneity. A technical 
difficulty in obtaining good negative stains of liposomes is the 
spreading of the vesicles on carbon-coated grids. Gregory and Pirie 
(1973) treated grids with bacitracin and found satisfactory 
spreading resulted. Freeze fracture has been applied to 
morphological studies of liposomes (Luna and McConnell 1977, Van 
Dijck et al 1976) but suffers from the serious problem that the 
fracture plane does not necessarily go through the middle of the 
liposome (Gruner et al 1985). This reduces the usefulness of the 
method for undertaking size measurements. Guoit et al 1980 employed 
mathematical methods to try to correct for this feature. The 
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problem of sampling size is of major concern in microscope 
techniques. Sufficient samples must be taken to exclude any 
possible bias. Gruner et al (1985) believed that 200 measurements 
was the minimum acceptable in freeze-fracture analyses. 
Other methods to obtain size distribution include analytical 
ultracentrifugation (Huang 1969), nuclear magnetic resonance 
(Bergelson 1979) and quasi-elastic laser light scattering (Selser et 
al 1976). 
Huang (1969), Huang and Charlton (1971) and Mason and Huang 
(1978) described hydrodynamic techniques in the analysis of small 
unilamellar vesicles. Gel chromatography on large pore agarose gels 
was described by this group in 1969, for separation of small 
unilamellar vesicles from multilamellar vesicles. Estimates of 
sedimentation coefficients can then be made. Huang and Charlton 
(1971) describe sedimentation analysis using mixtures of hydrogen 
and deuterium oxide. 
Kirkland et al (1982) described a method which they called 
exponential-field sedimentation field flow fractionation (SFFF). In 
a specially designed channel, rotated in a centrifuge, dissolved or 
suspended solutes migrate according to their density, relative to 
that of the mobile phase which is flowing continuously through the 
channel. Smaller particles elute from the channel first, followed 
by components of increasing mass. 
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Gel-exclusion chromatography has been reported using Sephacryl 
S1000 (Reynolds et al 1982) and high performance liquid 
chromatography (Ollivon et al 1986). A drawback to both of these 
however, is the problem of calibration of the columns. The hplc 
technique was very quick, taking only 10 - 20 minutes to run. 
The use of nuclear magnetic resonance to determine size depends 
upon the use of paramagnetic ions to shift or broaden the NMR signal 
from the choline trimethylammonium protons on the phosphate moiety 
of the phospholipid (Bergelson 1979). Use of the technique depends 
on the assumption that vesicles are unilamellar, spherical and of a 
defined bilayer thickness. Gerritsen et al (1979) demonstrated that 
the method could be used to show whether a population of large 
unilamellar vesicles was strictly unilamellar or whether it 
contained any multilamellar vesicles. 
Finally, the use of light-scattering techniques has been 
described by several groups. Bangham et al (1974) used such a 
method and Chong and Colbow (1976) obtained size and heterogeneity 
estimates for polydispersed vesicle preparations. Aurora et al 
(1985) used an argon ion laser as the light source. The intensity 
of the light scattered at 900 was measured and diffusion 
coefficients calculated on a DEC PDP-8 minicomputer and a VAX 11/780 
mainframe computer. Calibration was by the use of latex beads. 
Cornell et al (1986) describe a similar, though less complex, 
arrangement for sizing and the Malvern Instruments devices employed 
in this study use low power He-Ne lasers in conjunction with 
"desk-top" size computers. 
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6.10 THE MEASUREMENT OF ELECTROPHORETIC MOBILITY OF APTT REAGENT 
LIPOSOMES 
The Zetasizer 2 instrument (Malvern Instruments Ltd, Spring 
Lane South, Malvern) was used for this task. It functions as 
follows: - at the crossing point of two beams derived by splitting 
the output of a He-Ne laser, a pattern of interference fringes is 
formed. Particles moving through this region scatter light whose 
intensity fluctuates with a frequency related to the particle 
velocity. This light is collected onto a photomultiplier system and 
processed to produce a short pulse for each photon detected. The 
correlator collects and averages this train of signals and the 
resulting "correlator function" is analysed to determine the 
frequency spectrum which is directly related to the velocity of the 
particles. Since the applied electric field is known, the 
electrophoretic mobility can be 'calculated. The complete 
measurement takes only seconds but is made over a sample of many 
millions of particles; an impossible feat with manual methods. It 
therefore represents a comprehensive and accurate assessment of the 
complete sample and the mobility spectrum of all its constituent 
particles. A printout showing the mobility data for Actin FS is 
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6.11 TESTING COAGULANT ACTIVITY OF LIPOSOMES 
The activated partial thromboplastin time (APTT) was used as a 
measure of coagulant activity. The APTT of a fresh normal plasma 
was determined using a batch of the Manchester APTT reagent (batch 
117). This normal time was assigned a value of 100%. Buffer or 
saline was substituted for the APTT reagent and the test repeated. 
This APTT result was assigned a value of 0%. The test liposome was 
then substituted for batch 117 and the resulting APTT converted to % 
activity of 117. 
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6.12 FREEZE-DRYING 
Note on pressure measurement - manufacturers of vacuum 
equipment and related apparatus calibrate gauges in millibars not 
the SI unit which is Newtons per square metre (1 mb = 10 
2Nm -2 ). 
Apparatus 
Fig 6.12 shows a freeze-drying plant at the UK Reference 
Laboratory for Anticoagulant Reagents and Control. The plant was a 
Polyvac PVFD 6x4, built by Jones Bros, Bury, to specifications 
decided in collaboration with the author. It comprised four 
identical chambers which could be independently isolated, thereby. 
allowing the drying of any volume up to approximately 18 dm3. The 
maximum drying capacity of a freeze-drying plant depends upon the 
capacity of the refrigerated condensing surface used to entrap 
subliming vapour. Ours had a capacity of 18 dm3 and was operated 
using either a mechanical refrigeration system, employing a 2.25 
kJs-1 compressor, capable of cooling the condenser to -65°C, or 
a liquid nitrogen cooled system capable of cooling to lower than 
-190°C. 
Each chamber contained six shelves (fig 6.13) which were 
adjustable to accept vials up to 47 mm in height. When required, 
two shelves could be removed from the assembly to accommodate 
vampoules of 64 mm height. For bulk drying, all six shelves could 
be removed. 
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Each shelf had an integral heating element and a thermocouple 
for measurement of shelf temperature. In total, 3.6 kJ/s of heat 
were available, i. e., if all chambers and shelves were in use 150 
J/s were available into one shelf. A reliable guide is 1 J/s dries 
1 ml in 1 hour (Rowe and Snowman 1976). On this basis the plant 
would theoretically be able to sublime 18 litres of ice in 5 hours. 
Chamber 3 was modified slightly, to accommodate a connecting 
strip, which can be seen to the top left of fig 6.13. Into this 
strip were plugged resistance bulb thermometers, randomly placed in 
the load, and the resistivity probe, for control of heating. This 
is described in some detail below. 
One resistance bulb was connected to the chart recorder on the 
top right of the trolley shown in figure 6.12. Six other resistance 
bulbs were connected into the temperature indicator seen on top of 
the trolley in fig 6.12. A further chart recorder was used to 
record the following parameters - 
1. shelf temperature (from a resistance bulb sensor placed in a hole 
drilled in shelf number 3 in chamber number 3). 
2. condenser temperature (from a resistance bulb sensor strapped to 
the condenser coil). 
3. load temperature 
4. load temperature 
These were from resistance bulb sensors placed randomly in the load. 
5. pressure at head 1 (P1 in fig 6.15) 
6. pressure at head 2 (P2 in fig 6.15) 
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These two readings were from a Pirani vacuum gauge which 
provided output in the 0-10 mV range from each of two sensing 
heads. One of these was placed in close proximity to the vacuum 
pump, the other in a position at the centre of the pipework 
connecting the four freeze-dryer chambers. The other pressure gauge 
(P3 in fig 6.15) was of the Bourdon type and gave an indication of 
the pressure in the system, useful when pumping a "rough" vacuum. 
A further pressue gauge of the Bourdon type (obtained from 
Bailey and Mackey, Birmingham) was subsequently fitted to the 
machine. This was to measure pressures in the range from 
atmospheric pressure to 800 mbar. This gauge was therefore 
accurately calibrated over this range, while being robust enough 
mechanically to withstand being subjected to a high vacuum. The 
purpose of the gauge was to indicate pressure when breaking vacuum 
with nitrogen or argon after a freeze-drying run, in order to 
introduce a partial pressure of one or other of these gases into the 
freeze-drying vials, prior to sealing. 
Each of the four chambers had separate switching and 
thermostatic control of the heating supply, and one master control 
(black knob at centre right of fig 6.12) determined the current 
available for heating. 
Resistivity control of freeze-drying temperature 
The technique of resistivity measurement of lowest eutectic 
temperature is outlined below. 
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Consideration of a hypothetical freeze-drying operation will 
illustrate how this measurement may be of practical use. Suppose a 
solution of sodium chloride is to be freeze-dried. The lowest 
eutectic temperature, determined by resistivity measurement, was 
-220C. This means that during the primary drying stage the 
temperature must not be allowed to rise above -22°C, the 
temperature of "incipient melting". From the warming curve (broken 
line fig 6.22) it may be seen that at -22°C, the temperature of 
incipient melting, the resistance of the frozen NaCl solution falls 
very quickly indeed. Thus, if melting is to be avoided, the 
temperature must be maintained below -22°C, or alternatively, the 
resistance must be maintained above 10,000 ohms. The resistivity 
controller, which is continually monitoring resistance, contains a 
relay which is able to switch the heating circuit of the freeze 
drying machine on and off, thereby controlling the heat input 
keeping it at all times below the level which would cause melting. 
The resistivity controller may be seen at the top left of the 
trolley in fig 6.12. 
Some considerations on condenser design 
As discussed in Chapter 5, a number of authors have examined 
condenser design and efficiency. Rowe (1964b) believed that the 
surface area of the condenser should equal that of the shelves, 
although as little as half this surface may be adequate. In our 
freeze-drying plant, the shelf area is 3.88 m2. The condenser is 
a 22 m length of 16 mm outside diameter copper pipe, formed into a 
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helical shape with the tubing spaced so as to allow an ice layer 
thickness of 20 mm. The surface area of this condenser is 1.11 m2 
or 28.6% of shelf area. 
The mechanically cooled condenser was replaced by a liquid 
nitrogen (LN2) cooled model for a number of experiments described 
below (fig 6.14). Careful design of this apparatus was essential, to 
avoid excessive pressure build up within it. 
The liquid nitrogen cooled condenser was made from 316 grade 
stainless steel. Two plates were formed into cylinders, one of 321 
tin outside diameter, the other of 305 mm. These were welded 
together, top and bottom, and joined by 3 rows of ten "ties" in the 
form of lengths of 13 mm tubing welded in place. The nitrogen 
coolant was admitted, via a solenoid valve, through a 13 mm pipe 
which was connected to a 250 litre liquid nitrogen dewar. Exhaust 
nitrogen vapour emerged through a 32 mm pipe to the outside of the 
building. A thermocouple of copper/constantan placed in the exhaust 
of the condenser maintained the LN2 level within it by switching 
the solenoid valve when the temperature exceeded the set value. 
This method of construction resulted in a very strong vessel able to 
withstand the rigours of very low temperature use. Its surface area 
was 0.74 m2 or 19.07% of shelf area. 
The temperature of the liquid nitrogen cooled condenser could 
be set at any level down to -1900C. When defrosting, care had to 
be taken to raise the temperature slowly, so that any residual 
3 
liquid nitrogen inside did not vapourize too violently (1 cm of 
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liquid nitrogen will expand to 680 cm3 of vapour). A further 
consideration was that extreme changes in temperature could weaken 
the welding holding the condenser together. Accordingly, the 
condenser was first cleared of liquid nitrogen by "blowing" through 
with nitrogen gas. 
The condenser temperature was then allowed to rise to about 
-100°C before flooding with water at 45 
°C to clear the ice. (In 
the mechanically cooled condenser, the lowest temperature attained 
was -68°C, so that defrosting was easily performed by flooding 
with warm water, without any likelihood of damage. ) 
Precooling of chambers 
Each chamber of the freeze-drying plant was able to be 
independently cooled, before loading. A 250 Js _1 freezer unit, 
charged with R502, was provided for each chamber, enabling shelf 
temperature to be controlled, by means of thermostats, down to 
-25°C. Fig 6.13 shows the door mounted fan unit, necessary for 
circulation of the cold air in the chamber, and the two cold 
"radiators" may be seen on either side of the shelf assembly. 
Operation of the freeze-drying machine 
(Labels refer to fig 6.15, a schematic diagram of the 
apparatus). 24 hours before loading, the plant was switched on by 
starting the vacuum pump and condenser. Valve V5 was opened and 
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Chamber I Chamber 3 S3 
S4 
Fig 6.15 Schematic diagram of freeze dryinz plant. 
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the plant allowed to run in this stand-by condition until loading. 
Any necessary pre-cooling of chambers was also undertaken at this 
stage. Valves V1, V21 V3 and V41 were opened if the run 
required the use of all four chambers. 
The material to be freeze-dried was then loaded, in the frozen 
state, from a "holding freezer" running at -80°C (Kelvinator model 
UC517, Laboratory Impex Ltd, Teddington). Any connections, of 
resistance bulb thermometers and resistivity probes, which were 
necessary, were made at the time of loading. The chamber doors were 
then clamped and the plant switched to the primary drying mode. In 
this mode, valves V1 to V6 were open. Subliming vapours were 
drawn toward the vacuum pump and were condensed on the cold surface 
of the condenser unit. Vacuum gauges were situated at P1, P21 
P3 (Pirani type) and P4. P3 and P4 (Bourdon type) were used 
at a later stage, while P1 and P2 were referred to throughout 
the primary and secondary stages of drying. P1 indicated the 
pressure at the pump, P2 indicated the pressure in the pipework in 
proximity to the chambers. While sublimation was proceeding at a 
high rate, P2 showed a higher pressure. This difference in 
pressure was an indication of the progress of the freeze-drying 
process. When primary drying was complete, i. e., when sublimation 
was complete, no further vapour was evolved so P1 was equal to 
P2. 
A second important observation was the change in the 
temperature of the material being dried. After sublimation, the 
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material should be at ambient temperature, indicating that no ice 
was present in the material. 
At this stage the plant was switched to the secondary drying 
mode. V5 and V6 were closed and V7 opened. After a 30 second 
delay, to evacuate the P205 trap, V8 was opened. In this 
mode, desorbing vapour was held by the desiccant. Desorption was 
aided by the application of heat to the material. At this stage the 
condenser was defrosted. Indications that secondary drying was 
complete were, once again, the material temperature, which should 
have reached the set value, and the pressure in the system, i. e., 
P1 was equal to P2. If necessary, during secondary drying, the 
P205 trap may be isolated and recharged. 
When drying was complete the vials were sealed in vacuo. To do 
this, valves S1 to S4 were opened, allowing pure, dry nitrogen to be 
drawn in to an inflatable bladder, situated in each chamber at the 
bottom of the shelf assembly. The inflating bladder compressed the 
shelves upwards pushing the stoppers firmly home. 
Valve VA was then opened, allowing the chambers to fill with 
air to atmospheric pressure. Following this operation, the plant 
was emptied, cleaned and made ready for the next drying sequence. 
Alternatively, vials were sealed in a partial pressure of either 
nitrogen or argon. The selected gas was introduced by opening valve 
VG, which allowed the vacuum to be broken and a partial pressure, 
indicated on gauge P41 obtained. The vials were then sealed, as 
described above. 
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The freeze-dried material was then subjected to a number of 
tests, i. e., a random sample was removed for testing of inter-vial 
variation and measurement of residual moisture. 
The random sampling of vials for inter vial variation was as 
described by Stevenson (1978). Measurement of residual moisture and 
the difficulties of sealing of vials and testing for leaks are 
discussed below. 
This description applies to the "standard" lyophilisation 
method, employing a mechanically cooled condenser during sublimation 
and P205 as desiccant during desorption (see Chapter 9.1). 
An alternative to the use of P205 during desorption was a 
liquid nitrogen cooled apparatus. This took the form of a finned 
element, cooled by LN2. LN2 was pumped into a reservoir within 
the element, under the control of a thermostatically controlled 
valve. The fins, of nickel-plated brass, were designed to present 
the maximum possible cold surface within the trap. Excess LN2 
vapour was piped to the outside of the building. Fig 6.16 shows the 
design of the finned element. The temperature controller was 
obtained from Eurotherm Ltd, Warrington. 
Vials, stoppers and overseals 
Glass freeze-drying vials of 2 and 10 cm3 nominal capacity 
were obtained from FBG Trident Ltd, Bristol (see fig 6.17). A 
polypropylene vial of 4 cm3 nominal capacity was obtained from 
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Fig 6.16 (opposite) Liquid nitrogen cooled trap for 









vial ABC material 
type ©m 
1 13 37 14 glase 
2 9 64 9 glass 
3 13 38 17 polypropylene 
4 20 34 24 glass 
Fig 6.17 enclosures used in freeze drying 
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Dougherty Bros, Buena, New Jersey. Finally, a1 cm3 nominal 
capacity "vampoule" was obtained from Verretubex, Nogent-le-roi, 
France. Butyl rubber stoppers were obtained from West Pharmarubber, 
St Austell in sizes to fit the glassware described, i. e., 9 mm for 
the vampoule, 13 mm for the 2 cm3 glass and 4 cm3 polypropylene 
containers and 20 mm for the 10 cm3 glass vials. These were as 
shown in figure 6.18. 
Rubber stoppered vials were provided with aluminium tear off 
overseals (West Pharmarubber, St Austell). These were crimped in 
place using a crimping vice powered by compressed air (Jones Bros, 
Bury). 
Sealing of vampoules 
A device for sealing of vampoules was manufactured by Jones 
Bros, Bury (see fig 6.19). Vampoules, containing thromboplastin, 
were stoppered in vacuo following freeze-drying, then placed one at 
a time into a rotating chuck, and held by a vacuum. The stoppered 
end of the neck of the vampoule was gripped firmly by a 
spring-loaded device which maintained a constant tension on the 
constriction as a flame was moved close enough to melt the glass. 
The flame was natural gas, supplemented with compressed air and 
adjusted to a very fine point. As the glass melted, the stoppered 
end was drawn upward and a seal was made as the tip of the vampoule 




IG: - tC 
Fig 6.18 Rubber stoppers for freeze-drying vials 
showing stopper design and partially and 
fully stoppered positions. 
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Several very important features of the process deserve further 
consideration. It was essential that the freeze-dried material in 
the vampoule must not be exposed to heat. This was ensured by 
making the chuck from a substantial piece of stainless steel with 
fins to improve heat transfer. The vampoule was held deep in the 
chuck so that the freeze-dried material was as far away from the 
flame as possible. 
Following sealing, the vampoules were placed in an aluminium 
rack and allowed to stand at room temperature for twenty minutes. 
This allowed time for the glass to cool and avoided breakages which 
occurred if hot glass was placed at -20°C. Vacuum testing was 
then performed, as described below, before placing the sealed 
vampoules at -20°C. 
Vampoules which had not retained their vacuum following 
stoppering were easily identifiable, since, on warming, enough 
pressure developed inside them to blow off their rubber stoppers. 
Leak testing 
The Edwards High Vacuum Model T2 high frequency spark tester 
was used for some experiments and was superseded by the Model ST4M 
when this improved model became available. The tester contained a 
Tesla coil, coupled to condensers which fed the output to an 
electrode. The output frequency was 3.8 MHz. In use, the electrode 
was passed over the surface of the vial under test which was 
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evacuated to a pressure of approximately 10-2 mbar. A discharge 
indicated that the vial was evacuated. 
The spark tester worked efficiently if the pressure within a vial 
was less than approximately 100 mbar. No discharge was visible, 
however, if there had been leakage into a vial sufficient to raise 
pressure above this level. To determine whether there was still 
negative pressure in such vials the method of Barbaree and Smith 
(1981) was used. In this method, a2 cm3 syringe (Becton 
Dickinson and Co, Cowley, Oxford) was attached to a no. 23G1 needle 
and the plunger withdrawn to the 2 cm3 mark. The needle was then 
inserted into the vial. A negative pressure in the vial caused the 
plunger to close. The method was used in this purely qualitative 
way, no attempt being made to use it to quantify the pressure in the 
vial. 
Moisture determination 
The method of choice was the "heat and weigh" method based on 
the technique described by Beckett (1954). An improved apparatus 
was built for this task by Jones Bros, Bury, according to 
specifications drawn up by the author, since the earlier method for 
residual moisture measurement described by Stevenson (1978) employed 
valuable freeze-dryer space for long periods. The new apparatus is 
shown in fig 6.20. Briefly, it comprises a glove box with a vacuum 
oven attached. Inside the glove box was a Mettler H80 balance. Air 
was drawn through a filter and dried in a column of molecular seive 
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(type 4A Union Carbide) before being pumped into the glove box. 
There were two columns in the apparatus, one of which was recharged 
by heating while the other was in use. Switching from one column to 
the other was under the control of an interval timer device. 
Moisture extracted from the air was collected in the glass jar, to 
be seen at the bottom of the lower box. A one-way valve was 
situated at the back of the glove box so that excess air pressure 
was periodically relieved. A hygrometer monitored the relative 
humidity inside the glove box, which achieved a minimum dewpoint of 
approximately -58°C. This was equivalent to a relative humidity 
of 0.057% (at 21°C) or, more important, to a water vapour pressure 
of 0.013 mbar, which was approximately equal to the pressure that 
obtained in the freeze-drying plant at the end of a typical drying 
sequence. 
The apparatus was switched on and allowed to equilibriate 
overnight. The vacuum oven temperature was set at 45°C. Vials of 
freeze-dried material, stoppered in vacuo, were placed in the glove 
box and allowed to equilibriate for one hour to dry off the outside 
of the vial. The stoppers were then withdrawn to the "partial 
stoppered" position as shown in fig 6.18, and the vials and their 
contents weighed. This weight was the "freeze-dried weight". The 
vials were then placed in the vacuum oven which was evacuated by 
connecting to a rotary pump (NGN model PD-2). After 24 hours, vials 
and contents were weighed and the weight recorded. The vacuum oven 
process was repeated until no further weight loss was noted. This 
weight was taken to be the "true dry weight". The difference 
between the "freeze-dried weight" and the "true dry weight" was 
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taken to be due to residual moisture. Vials and stoppers were then 
washed, oven dried and weighed to enable the weight of freeze-dried 
material to be calculated, and the residual moisture expressed as 
weight change/orginal freeze-dried weight x 100%. 
Pemberton (1976) discussed a number of factors in the 
vacuum-oven technique which influence the estimation of moisture in 
freeze-dried materials. He was unhappy with reported methods in a 
survey of manufacturers of veterinary vaccines and cautioned that 
sufficient numbers of vials must be tested in order to arrive at a 
good estimate of the average moisture content of a batch. He 
believed that it is essential that manufacturers be aware of any 
"shelf-to-shelf" or "front-to-back" or "edge-to-middle" variations 
within their freeze-drying plant (see Chapter 9). 
Another important area was the handling of vials throughout 
testing. Glass surfaces are avid desiccants (Pemberton 1976), so 
care was taken to dry off the outside of the vials before any 
weighing. Gloves were worn as a further precaution to prevent 
contamination of the glass surface. 
The apparatus described here was able to accommodate large 
numbers of vials and since the entire process was confined to the 
glove box or the vacuum oven there was no danger of contamination by 
atmospheric moisture. 
To calculate the coefficient of variation (CV) of the method, 
20 lots of 5 vials were removed from a batch of lyophilised 
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thromboplastin and the residual moisture calculated. The mean value 
for the 20 observations was 2.10% with a standard deviation of 
0.064. The coefficient of variation was 3.04%. 
Temperature measurement 
Platinum resistance temperature sensors were used. These were 
1.59 mm diameter x8 mm in length, to British Standard BS1904. 
(This standard is more exacting than the relevant German and 
American standards, DIN 43760,1968 and RC21-4-1966) respectively). 
Platinpan resistance temperature sensors were preferred for 
measurement of material temperature during drying, for a number of 
reasons. Firstly, no compensation was needed for junctions - 
theoretically any number of junctions in the sensor cable would have 
been tolerated - use of thermocouples would have been difficult for 
this reason. 
A second advantage of resistance bulbs for this function was 
the fact that they were connected to the temperature indicating 
device by very fine wires, allowing them to be placed at any 
position in the freeze-drying load. Thermocouples are less flexible 
in use and are better suited to fixed positions such as monitoring 
of shelf temperature (see fig 6.13). 
Resistance bulb sensors were periodically checked, using 
boiling water as the high temperature standard and solid CO2 as 
the low temperature standard. Solid CO2 was prepared in a 
Frigimat device obtained from Radley Ltd, Sawbridgeworth. This was 
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connected to a siphon cylinder of CO2 and produced a dense pellet 
of solid CO2 of some 450 g. 
Resistivity measurement of lowest eutectic temperature 
The conduction of electricity through a solution is dependent 
on the mobility of ions in the solution. If there is liquid 
present, the electric current can pass unhindered, but when the 
solution is completely solidified, i. e., at and below its lowest 
eutectic temperature, the ions are immobilized and the resistance of 
the material will be very high. Due to the differing degrees of 
movement and, hence, energy levels of molecules and ions in solids 
and liquids, there is an easily measurable difference in the 
electrical conductivity and hence resistance between solids and 
liquids. More precisely, the measurement depends on the resistivity 
of the test material, which is constant for a material at a 
particular temperature, but is not dependent on the physical size of 
the conducting medium, as is resistance. However, as during one 
measurement the same diameter probes with the same spacing between 
them are used, the resistivity is directly proportional to the 
resistance. 
R =pL 
where R= resistance 
p= resistivity 
A= presented probe area 
L= distance between probes 
As A and L are constant Roc f 
173 
The equipment (Edwards High Vacu. m Ltd) comprises a Wheatstone 
bridge circuit with the probes in one leg of the bridge and a 
variable resistor in the other as shown in fig 6.21. 
Fig 6.21 circuit for res: stivity measurement. 
1: probe, 2= balancing meter, 3= variable res-stance. 
The probes were paced in a vial of test material and the vial 
cooled in a cooling mixture of industrial methanol and solid CO2. 
At various stages of cooling the temperature was recorded by 
means of a resistance bulb thermometer (Jones Bros, Bury) placed 
between the probes, and the variable resistance adjusted to obtain a 
balance on the galvononeter. This indicated that the adjustable 
resistance had the same value as the resistance of the test 
material. A complete set of readings was made to below the eutectic 
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temperature of the test material and again as the material was 
subsequently warmed. 
The equipment was calibrated by measuring the eutectic 
temperatures of a number of electrolytes whose eutectic temperatures 
were known from tables (Meryman 1966). 
TABLE 6.14 EUTECTIC TEMPERATURES (°C) OF FOUR COMMON ELECTROLYTES 





The curve for warming (broken line in graph) is the curve used 
for control of freeze-drying temperature. See fig 6.22. 
Modification to the Comp-u-pet apparatus to enable dispensing 
into vampoules. 
The glass vampules shown in figure 6.17 were designed to allow 
freeze-drying and stoppering in vacuo to be carried out in exactly 
the same way as when standard freeze-drying vials were used. 
Following stoppering, however, they may be flame-sealed at the 
specially constricted neck. A major problem was the difficulty 
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Fig 6.22 Resistivity curves for some common electrolytes. 
A_KC1, B=NaC1, C_? tgC12'D=CaC12. The warming curves (broken 
lines in the figure) show the lowest eutectic temperature. 
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Accordingly, a device was manufactured, by Jones Bros, Bury, to 
the authors specifications. See fig 6.23. The device comprised a 
polypropylene sheath, long enough to reach into the bottom part of 
the vampoule, past the constriction. This outer sheath, some 45 mm 
in length was placed as far as possible into the vampoule and the 
dispensing head pushed downward. This pushed an inner dispensing 
needle clear of the bottom of the outer sheath by some 5 mm, as 
shown in fig 6.23, and activated a microswitch so that the 
Comp-u-pet dispensed an aliquot of thromboplastin, down the inner 
dispensing needle and into the bottom of the vampoule. There was no 
possibility of contamination of the constriction when this device 
was used. 
Pressure was then released from the dispensing head allowing 
the dispensing needle to retract inside the protective outer sleeve 
and the entire dispensing head was then moved to the next vampoule. 
The dispensing head switch replaced the footswitch that was normally 
used to activate the compupet dispensing sequence. 
Liquid nitrogen storage 
Liquid nitrogen was stored in BOC Cryoproducts 
self-pressurising dewars of 75,125 and 200 dm3 nominal capacity 
(models EC75PC, EC125PC and EC200PC respectively, obtained from BOC 
Cryospeed Worsley, Manchester). Each vessel was fitted with a 
valved high pressure dispenser (model VHPD4) and a capacitance gauge 
(Model TCG1). 
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Fig 6.23 (opposite) Pipetting device fitted with 




These dewars were manufactured from stainless steel. Each had 
a pressure gauge and two "over-pressure" protection devices, i. e., a 
relief valve, which was a simple one-way spring-loaded valve which 
opened if the pressure exceeded one atmosphere, and, in case of 
failure, a "bursting" valve, in which a plastic membrane ruptured if 
a pressure of three atmospheres was exceeded. 
Liquid nitrogen was pumped, at delivery rates up to 12 dm3 
per minute through 1/2 in nylon pipe lines. These were covered with 
expanded foam insulation and were fitted with pressure relief valves 
so that in the event of a pipeline being closed at both ends there 
was no possibility of pressure within it reaching dangerous levels. 
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6.13 THE ACTIVATED PARTIAL THROMBOPLASTIN TIME (THOMSON 1980) 
Reagents 
1 Owren's buffer (see Ch 6.16) 
2 Calcium chloride 0.025 mol dm -3 
3 Kaolin (0.25 g/100 cm3 in Owren's buffer) 
4 APTT reagent. The Manchester APTT reagent is a lipid 
suspension which is described fully in Chapter 8. 
Method 
Plasma was tested as soon as possible after collection as 
described in Chapter 6.19. Kaolin suspension and calcium chloride 
were warmed, in separate test tubes, in a water bath at 370C. 
Reagents were placed into a prewarmed glass test tube in the 
following order - 0.1 cm3 test plasma, 0.1 cm3 APTT reagent, 0.1 
cm3 kaolin suspension and a stop-watch started. The tube was 
tilted three times immediately and subsequently at approximately one 
minute intervals to resuspend the kaolin activator. At exactly 10 
minutes 0.1 cm3 of calcium chloride was added. The tube was 
tilted three times then left undisturbed for 20 seconds from the 
time of addition of calcium chloride. After this time the tube was 
tilted gently until a solid clot formed. The time from addition of 
calcium chloride to clot formation was the activated partial 
thromboplastin time. Each plasma was tested in duplicate. If 
duplicates differed by more than 5% then a further test was 
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performed, and so on, until a satisfactory agreement between tests 
was achieved. Normal range was 36 to 48 sees. 
The APTT test is discussed in detail in Chapter 4. 
6.14 THE PROTHROMBIN TIME TEST (QUICK 1935) 
Reagents 
1 Tissue thromboplastin reagent 
2 Calcium chloride 0.025 mol dm-3 
Method 
Plasma was tested as soon as possible after collection as 
described in Chapter 6.19.0.1 cm3 of plasma was added to a glass 
test tube and allowed to warm for 30 seconds in a water bath at 
37°C. 0.1 cm3 of thromboDlastin reagent was added and allowed 
to warm for 30 seconds. Finally, 0.1 cm3 of calcium chloride was 
added and a stop watch started simultaneously. The tube was tilted 
until a solid clot was seen to form, whereupon timing was stopped. 
Tests were repeated until duplicates were obtained with prothrombin 
times within 5% of each other. The normal range was 12 to 15 
seconds. 
The thromboplastin reagent is discussed in Chapter 3, above. 
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6.15 ASSAY OF FVIII: C AND FIX - ONE STAGE METHOD 
Reagents 
1 Substrate plasma was obtained from Immuno Ltd and was from a 
patient with a severe haemophilia A. 
2 Kaolin 0.1 g/100 cm3 in imidazole buffer. 
3 Calcium chloride 0.033 mol dm-3 
4 Partial thromboplastin reagent - batch no. 117 of the 
Manchester APTT reagent. 
5 Imidazole buffer - see Chapter 6.16. 
6 Normal plasma pool - equal volumes of plasma from four blood 
group 0, four blood group A and one blood group B were mixed 
and frozen to -80°C in 1 cm3 aliouots. Plasma was 
collected from healthy adults into 0.109 mol dm -3 sodium, 
citrate (9: 1 v/v). The factor level was determined before 
use in the assay. 
7 Standard reference plasmas. Plasmas with values of 100% and 
20% were included. 
Method 
1 in 5,1 in 10,1 in 20,1 in 40 and 1 in 80 dilutions 
(representing 200%, 100%, 50%, 25% and 12.5% activity respectively) 
of normal pool plasma in imidazole buffer were prepared and stored 
on ice prior to testing. 
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Mixtures of 0.1 cm3 factor deficient substrate, 0.1 cm3 of 
APTT reagent, 0.1 cm3 of normal plasma dilution and 0.1 cm3 
kaolin suspension were prepared in glass tubes. The tests were 
performed in duplicate and stopwatches started on addition of 
kaolin. The tubes were incubated at 37°C and tilted at 
approximately 1 minute intervals for 10 minutes. 
After 10 minutes 0.1 cm3 of calcium chloride was added and a 
stopwatch started. After 20 secs the tubes were tilted and the time 
taken for a clot to form was recorded. 
1 in 10,1 in 20 and 1 in 40 dilutions (representing 100%, 50% 
and 25% activity respectively) of the "normal" and "low" plasmas in 
imidazole buffer were prepared and stored on ice prior to testing. 
These were then tested as above in the same way as the normal pool 
dilutions. 
A graph of clotting times of the normal pool dilutions vs % 
concentration was prepared on double log graph paper. The clotting 
times of the normal and low reference plasmas were plotted on the 
same graph. These lines should be straight and parallel. The 
presence of inhibitors against any of the intrinsic clotting factors 
will show itself in increased factor level results in the lower 
dilutions causing non-parallelism. 
The assay described may be used for FVIII: C or for FIX by 
employing relevant substrate and reference materials. 
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6.16 BUFFERS AND REAGENTS 
Owren's buffer pH 7.35 
sodium diethylbarbituric acid 
sodium chloride 
0.1 mol dm -3 HC1 
distilled water to 1 dm3 




0.2 mol dm -3 Sodium cacodytate 165 cm3 
2.5 mol dm-3 c3lutaraldehyde 100 cm3 
distilled water to 500 cm3, adjust pH to 7.4 with 0.1 mol 
dm 3 HC1 
Imidazole buffer pH 7.35 
imidazole 3.4 8 
sodium chloride 5.85 g 
distilled water 500 cm3 
0.1 mol dm -3 HC1 186 cm3 
distilled water to 1 dm3 
The following reagents were obtained from Sigma Chemical Co., 




















The following was obtained from ICN Biomedicals Ltd, Castle 
Street, High Wycombe, Bucks 
1,1,3,3-tetraethoxypropane 
The following were obtained from BOC Ltd, Worsley Road, 
Worsley, Manchester. 
liquid nitrogen 
hydrogen gas, high purity 
nitrogen gas, high purity 
compressed air, industrial grade 
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The following was obtained from Distillers CO2 Co. Ltd, 15 
Pollard St East, Manchester. 
CO2 liquid, in siphon cylinders 
The following were obtained from Alitech UK, Units 6-7, Kellet 
Road Industrial Estate, Carnforth, Lancs. 
fatty acid methyl esters, saturated from 12: 0 to 22: 0 and 
unsaturated from 14: 1 to 24: 1. 
The following was obtained from Supelchem, Radley and Co. Ltd, 
Louden Road, Sawbridgeworth, Herts. 
phosphatidyl glycerol 
The following were obtained from EM Scope Laboratories, 


































potassium dihydrogen phosphate 
sodium chloride 






6.17 pH MEASUREMENT 
pH measurements were made using a Philips PW 9409 pH meter, 
fitted with an Amagrass El 3509 combined glass reference electrode 
(Whatman Labsales, Maidstone). The instrument was calibrated by the 
use of standard buffer solutions in the range pH 5.0 to pH 10.0, 
obtained from BDH, Poole. 
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6.18 MICROBIOLOGY TESTING 
Colony counts of microorganisms in thromboplastin were 
performed by the Microbiology Laboratory, Withington Hospital. 1 
cm3 of thromboplastin was added to 19 cm3 of cooling melted 
nutrient agar, shaken and poured into a sterile Petri dish. When 
the agar had set, the plate was incubated at 32°C for 48 hours and 
a count of colonies of microorganisms was made. Thromboplastin 
preparations containing more than 50 colonies cm -3 were discarded. 
The Public Health Laboratory at Withington Hospital tested both 
thromboplastin reagents and human plasma donations for the presence 
of hepatitis virus and, when a test became available, HIV. The 
hepatitis testing was based on a radioimrriunoassay technique for 
hepatitis B surface antigen while testing for HIV employed a 
competitive ELISA method. 
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6.19 BIOLOGICAL REAGENTS 
Preparation of tissue thromboplastin and partial thromboplastin 
reagents and freeze-drying of the former is described fully in the 
experimental section. 
The other biological reagents used were plasmas, employed in 
degradation studies and tests of procoagulant activities of 
thromboplastin and partial thromboplastin reagents. 
Plasmas were collected, prepared for freeze-drying, and 
freeze-dried as already described (Stevenson 1978). Following 
lyophilisation, 28 vials of each batch were tested for inter-vial 
variation by measuring the prothrombin time of their contents. The 
minimum sample of vials was calculated so that the possibility of 
falsely accepting a batch was kept as low as possible (Stevenson 
1978). 
Fresh normal plasma was collected from healthy volunteers, by 
venepuncture, into 0.13 mol dm -3 sodium citrate (9: 1 v/v) and 
centrifuged immediately at 2000 xg for 20 minutes at 4°C, to 
obtain platlet-poor plasma. When platelet-free plasma was required, 
for example in the experiments described in Chapter 8, plasma was 
filtered through a Minisart NML cellulose acetate membrane 
(Sartorius Instruments, Sutton, Surrey) at pore size 0.2 U. 
Filtering was not an efficient method when large volumes of plasma 
were to be processed. In this case, the plasma was centrifuged at 
40,000 xg for 30 minutes at 4°C, and dispensed into suitable 
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containers (Sarstedt Ltd, Leicester) for storage in liquid nitrogen 
or, alternatively, for freeze-drying, as previously described 
(Stevenson 1978). 
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6.20 MALONDIALDEHYDE ASSAY (BASED ON METHOD OF DEKONING AND SILK 
1963) 
The method utilizes the capacity of malondialdehyde (ADA) to 
react with thiobarbituric acid to give a characteristic colour. 
Thiobarbituric acid reagent (TBA) - 800 mg TBA was dissolved in 
10 cm3 of 2.5mol dm -3 NaOH and 50 cm3 water was added. The pH 
was adjusted to 7.4 by the addition of concentrated perchloric acid, 
and the volume brought to 100 cm3 with distilled water. 50 cm3 
of 7% perchloric acid was added and the reagent stored in a 
glass-stoppered bottle at room temperature. 
Assay of MA -2 cm3 of test solution was placed in a test 
tube. 2 cm3 of TBA was added, mixed on a vortex mixer, stoppered 
and heated at 100°C for 15 minutes. The tubes were then cooled 
and centrifuged at 12000 xg for 10 minutes. The absorbance of the 
supernatant was read at 532 nm. 
A standard curve was prepared, using tetraethoxypropane which 
yields one mole of tWA per mole. Concentrations of 2, ü, 6,8 and 
10 moles of tetraethoxypropane were used to prepare the curve. A 
standard curve of MDA concentration against absorbance is shown in 
fig 6.24.. 
Sinnhuber et al (1958) suggested that the red compound formed 
in the thiobarbituric acid test was probably a 2: 1 adduct of 
thiobarbituric acid and malondialdehyde. This was confirmed by Nair 
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and Turner (1984) who believed that formation of the 2: 1 adduct 
probably is initiated by nucleophilic attack involving carbon-5 of 
thiobarbituric acid onto carbon-1 of malondialdehyde followed by 
dehydration and similar subsequent reaction of the intermediate 1: 1 










Fig. 6.24 Standard curve for malondialdehyde. 
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6.21 STATISTICAL METHODS 
1 Analysis of variance (ANOVA). 
In performing ANOVA, the null hypothesis, Ho, is that all our 
samples have been drawn from the same population and that the 
variability caused by the "within sample" variability is the same as 
that caused by the "between sample" variability. Ho is rejected 
if these are not the same. The principle of the technique is to 
compute the separate variances due to the variability within the 
samples and that between the samples. The significance of any 
departure from a ratio of 1 for these variabilities is tested by 
means of the F test. The technique was applied to results of 
changing relative concentrations of fatty acids in stored 
thromboplastin, to data on the effect of reducing 
condenser-temperature on residual moisture in freeze-drying, and to 
analysis of possible intrinsic variation in the freeze-drying 
machinery. The analysis was performed as described by Scheffe 
(1959) using a computer program known as GLIM 3.77, run on the 
University of Manchester Computing Centre's facilities into which 
the UK Reference Laboratory is connected via a system called 
"Systime". 
GLIM 3.77 was produced by the Royal Statistical Society of 
London, which holds the copyright (1985). 
2 Tukey test (Fowler and Cohen, 1986) 
The analysis of variance does not provide a complete answer to 
the search for statistically significant variation between the means 
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of the sample groups tested, i. e. it may be that all possible 
combinations of pairs are different from each other or maybe just 
one is different from all the others. The Tukey test is performed 
to show which is the case. A test statistic T is computed according 
to the formula 
T_ (q) X 
Jwithin variance 
'n 
where n is the number of sampling units in each sample. The "within 
variance" is obtained from the ANOVA calculation and the value of q 
is found from a table of the probability distribution of q for 
varying numbers of samples and degrees of freedom. If any of the 
mean differences in the data exceed the value of T, then they are 
significantly different at p=0.05. 
3 Linear regression analysis was performed, to obtain 
correlation coefficients, as described by Bailey (1968). In Chapter 
7 the technique was employed to determine the significance of the 
relationship between loss of procoagulant activity of stored tissue 
thromboplastin reagents and changing concentrations of some lipids 
and malondialdehyde. A program, written in BASIC, was used for this 
method and was run on the Spectra Physics SP4100 Computing 
Integrator described in Chapter 6.4. Significance was assessed by 
referring to the Biometrika tables (table 13. Percentage points for 
the distribution of the correlation coefficient). 
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4 Normal range determination (Wetherill 1981). 
In Chapter 8, normal ranges were calculated for a number of 
partial thromboplastin reagents. The distribution of the data 
proved to be non-Gaussian so a transformation was undertaken, 
according to Box and Cox (1964). Each normal clotting time (x) was 
transformed to x(ý) using the formula x(l) _ (xZ - 1)/a. 
The value for A chosen was the one for which the distribution 
of x(l) most resembled a Gaussian distribution. The method for 
finding the best value for \ for a particular reagent was to 
calculate the function L(O) for a range of I and to select the value 
of "A which gave the highest value of M). This function was 
calculated by 
L(A) =2 loge (SDý) 
2+ (ý - 1) loge Xi(ý. 
) 
1=' 
where n is the number of normal values and SDA is the sample 
standard deviation of the transfcrred values. A suitable range of 
to use was -3 to +3 in steps of 0.25. When 0 the transformation 
( ^A 
was x= logex The normal range for transformed data was 
given by 
(X(A) - SDýt(n-1)I X(X) + SD), t(n-1)) 
where t(n-1) may be obtained from standard statistical tables 
(Pearson and Hartley 1976) x() = mean of the transformed values. 
In order to present the above range in seconds, the transformation 
needs to be reversed: if a is the lower limit of the range, then 
the lower limit of the normal range, in seconds, is 
(aý +1) or ea if \-0 
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Similarly, if b is the upper limit of the above range, then the 
upper limit in seconds is 
(bý +1)' or eb if -0 
These calculations were performed on the University of Manchester 
Computing Centre's computer via the "Systime" link from the UK 
Reference Laboratory. The transformation used i. e. the value of 
for the reagents was as shown in table 6.15. 
TABLE 6.15 TRANSFORMATION (y x 
reagent 
Actin 2 
Actin FS 1.75 
Activated Thrombofax 2 
Automated APTT 2.5 
Manchester APTT 2.5 
5 Ranking of reagent performance (Siegel 1956). 
The performance of the reagents examined in Chapter 8 was 
correlated with particle size, electrophoretic mobility, and a 
variety of lipid compositional data. Using Spearman's rank 
correlation test (Spearman 1904), two sets of measurements could be 
compared. Differences between rank order were calculated, squared, 
and the correlation coefficient calculated from the formula 
rs -1-6 
d1 
n (n1- 1) 
where d is the difference between ranks for each reagent and n is 
the number of ranks. The range of rs is from -1 (complete 
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discordance) to +1 (complete concordance). A program, written in 
BASIC, was employed for this test and was run on the Spectra Physics 
SP4100 computing integrator. 
Following the establishment of correlations between clotting 
performance and physical and chemical composition of the reagents, 
they were ranked according to the formula 
rank %= (rank sum/highest possible rank sum) x 100 
The result may be seen in fig 8.10. 
6t test (Swinscow 1976) 
The paired t test was used in Chapter 9.3 to determine whether 
there was a significant difference between two sets of residual 
moisture data obtained when a batch of tissue thromboplastin reagent 
was lyophilised using either a P205 trap during the desorption 
stage or a liquid nitrogen-cooled trap. The calculation was 
performed using a program, written in BASIC, that ran on the Spectra 
Physics SP4100 computing integrator. 
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CHAPTER 7 EXPERIMENTS ON TISSUE THROMBOPLASTIN 
The preparation and use of the British Comparative 
Thromboplastin (BCT) have been presented in Chapter 3. The 
experiments described in this chapter have been designed with the 
following aims: 
1 to reveal the nature of the BCT by electron microscopy of 
fresh and aged preparations and 
2 to show whether the loss of procoagulant activity on ageing 
correlates with changes in the lipid moiety of the material. 
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7.1 TO INVESTIGATE THE MORPHOLOGY OF BRITISH COMPARATIVE 
THROMBOPLASTIN (BCT) 
Aim - to examine the ultrastructure of the BCT by electron 
microscopy. 
Procedure - an aliquot of a single, freshly prepared batch of 
BCT was subjected to electron microscopical examination. The 
material was fixed and prepared for microscopy as described in 
Chapter 6.8, and examined in an AEI EM 601 transmission electron 
microscope. 
Results - Fig 7.1 shows an electron micrograph of BCT at a 
magnification of 12,500 times. This field was typical of those 
examined. Myelin sheaths (MS) are present in abundance, some still 
surrounding debris from nerve cells. Two oligodendroglial cell 
nuclei (N) are to be seen and a variety of membranous fragments and 
occasional vesicles make up the remainder. There is no evidence of 
sub-cellular organelles, other than the nuclei already mentioned. 
Discussion - The method for extraction of human brain with 
phenol-saline, to produce a thromboplastin reagent, was originally 
described by Poller (1970) and later by the present author 
(Stevenson 1978). The most striking features are the quantity of 
myelin sheaths in the reagent and the degree of order in their 
structure (see fig 7.1). While there are some fragments of myelin 
and some membranous vesicles, it is clear that the bulk of the 
membranous material in BCT is in a highly ordered state. This batch 
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Fig 7.1 (opposite) Electron micrograph of a fresh 
preparation of BCT. Magnification X 12 500. 





of BCT had been prepared four weeks prior to the micrograph being 
taken. The procoagulant activity of this batch was optimal (see 
Chapter 7.3) which had been confirmed by successful external 
multicentre monitoring (see Chapter 3) designed to monitor its 
performance in the prothrombin time test. Two other groups of 
workers have published morphological studies of tissue 
thromboplastin; Hvatum et al (1969) and Hasegawa et al (1977). In 
the first of these, the human brain thromboplastin reagent studied 
had been subjected to a purification sequence that involved 
centrifugation, gel filtration and solubilisation with sodium 
deoxycholate followed by dialysis to remove the detergent and 
recover thromboplastic activity. With hindsight it is possible to 
say that this treatment will have formed liposomes (see Chapter 8) 
and that all that was observed was a pattern of concentrically 
arranged membranous structures, typical of liposomes. Indeed, the 
authors stated that the structures resembled the smectic mesophases 
(liposomes) described by Bangham and Horne (1964) and also observed 
some resemblance to myelin sheaths, a belief not shared by the 
present author. 
Hasegawa et al (1977) used a commercially manufactured 
thromboplastin reagent extracted from rabbit lungs. Concentrically 
arranged membranous structures were observed which, once again, did 
not resemble myelin. Neither Hvatum and colleagues nor Hasegawa's 
group observed any subcellular structures in their preparations, 
presumably a consequence of the extraction methods used. 
204 
BCT was a suspension of human brains macerated in phenol-saline 
and had no detergent added and no gel filtration steps in its 
preparation. The resulting suspension, therefore, was comprised of 
myelin sheaths in a wide range of size, cell nuclei and a great deal 
of membranous debris. 
The possibility that changes in morphology may be related to 
chemical changes in the reagent, e. g. oxidation of fatty acids, and 
to loss of procoagulant activity is discussed in the next section. 
Conclusion - BCT was found to be comprised of myelin sheaths 
with cell nuclei and various membranous debris in attendance. No 
subcellular structures other than nuclei survived the extraction 
process intact. 
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7.2 OBSERVATIONS ON THE MORPHOLOGY OF TISSUE THROMBOPLASTIN REAGENT 
STORED AT 40C 
Aim - to show whether there is a discernable change in the 
morphology of myelin figures in BCT preparations during long-terc, 
storage at 4°C. 
Procedure - three BCT preparations were sampled and prepared 
for electron microscopy, as described in Chapter 6.8. These were 
batches numbered 30,16 and 1 which were respectively 1,51 and 102 
months old at the time of testing (see table 7.1). 
Results - electron micrographs of BCT reagent myelin figures 
are shown in figures 7.2,7.3 and 7.4 at magnifications of 32,000, 
40,000 and 40,000 times respectively. Fig 7.2 shows a typical 
myelin sheath from the fresh extract, BCT batch 30. There is a 
highly ordered structure to be seen in the micrograph, with the 
membranes tightly associated and with little sign of degradation. A 
typical myelin sheath from BCT batch 16, which had been stored for 
some 51 months may be seen in fig 7.3. No subcellular structures of 
any kind were recognizable in this preparation, the myelin figures 
being the only structures which had maintained any form. It is 
noticeable that the membrane lamellae are less ordered than in the 
fresh preparation and are loosening and opening. 
A myelin figure from BCT 1, stored for 102 months, is 
illustrated in fig 7.4. Further degradation than that observed in 
fig 7.3 is evidenced by loss of the regular ordered form of the 
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Fig 7.2 (opposite) Electron micrograph of a myelin 
sheath from a fresh BCT preparation. 
Magnification X 32 000. Scale bar is 500nm. 
Fig 7.3 (p209) Electron micrograph of a myelin sheath 
from a BCT preparation stored at 40C for 
51 months. Magnification X 40 000. Scale bar 
is 500nm. 
Fig 7.4 (p210) Electron micrograph of a myelin sheath 
from a BCT preparation stored at 40C for 102 


























fresh preparation. Remarkably, even after this extended storage 
time, there are still segments of the sheath where the lamellae are 
tightly associated. These observations were made during examination 
of large numbers of fields in the electron microscope and the 
figures show typical features seen. 
Discussion - the highly ordered structure of myelin sheath 
membrane has been commented on previously (e. g. Boggs and Moscarello 
1978). It is this feature that is the most striking in this series 
of electron micrographs (figs 7.1 to 7.4), which reveal a clear 
trend towards loss of order in the myelin figures with time of 
storage. Changes in the lipid composition of the reagents, with 
time are considered in the next section. 
Conclusion - the major change that is to be seen in tissue 
thranboplastin preparations undergoing long term storage at 4°C, 
is the degradation of the highly ordered arrangement of membranes 
that make up the myelin sheath. The oldest preparation examined, 
BCT 1, had few recognizable myelin figures remaining. 
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7.3 THE LIPID COMPOSITION OF NEW AND AGED BATCHES OF THE BCT AND 
ITS RELATIONSHIP TO PROCOAGULANT ACTIVITY 
Aim - to determine the lipid composition of BCT batches, both 
fresh and stored at 4°C for up to 102 months and to examine 
whether there is any correlation between change in lipid composition 
with time of storage and loss of procoagulant activity. 
Procedure - lipids were extracted from the batches of BCT 
listed in Table 7.1. Also shown in the table are the monitoring 
dates of each batch and their age at testing. The methyl esters of 
the fatty acids were derived as described in Chapter 6.4. The lipid 
class composition was determined by thin-layer chromatography and 
densitometry as described in Chapter 6.1. Fatty acid methyl esters 
were separated and quantified by gas chromatography on capillary 
columns as described in Chapter 6.4. Malondialdehyde (mda) was 
determined as described in Chapter 6.20. Two statistical methods 
were employed. Firstly, analysis of variance was used to show 
whether changes in fatty acid composition with time were significant 
and, secondly, to determine whether a change of concentration of a 
particular lipid class, or mda, with time was significant, the 
correlation coefficient was calculated and the level of significance 
obtained by consulting tables (see Chapter 6.21). 
For measurement of procoagulant activity, three lyophilised 
plasmas were prepared, the first from a normal healthy donor, the 
second from a patient stabilized on oral anticoagulants and the 
third a pool of plasma from a colony of beagle dogs congenitally 
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deficient in factor VII. The prothrombin time of each plasma was 
measured using each test batch of BCT in the one-stage prothrombin 
time test. Preparation of the plasmas is described in Chapter 6.19 
and the prothrombin time test in Chapter 6.14. Loss of procoagulant 
activity (as shown by lengthening prothrombin time of the normal 
plasma) was correlated against change in concentration of some lipid 
components and mda and the level of significance of the correlation 
coefficient obtained from tables. This was to determine which 
component in the BCT correlated best with loss of procoagulant 
activity. 
TABLE 7.1 BATCHES OF BCT USED IN THE STUDY - 
MONITORING DATE AND AGE AT TIME OF TESTING 
BCT No. Monitoring date Age at testing (months) 
1 November 1969 102 
4 November 1970 90 
8 January 1972 76 
12 March 1973 62 
16 February 1974 51 
20 June 1975 35 
23 March 1976 26 
26 February 1977 15 
29 January 1978 4 
30 April 1978 1 
Results - the lipid composition of BCT (batch 30) is given in 
Table 7.2 
TABLE 7.2 LIPID COMPOSITION OF BCT 30 (g dm 3) 
PC PE SPH PS PI FFA Chol MG DG TG Sul Cerb 
1.84 2.10 0.87 1.02 0.16 0.05 0.24 0.18 0.36 0.36 0.12 0.48 
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The decreasing concentration of those phospholipid classes 
which changed significantly on storage are illustrated (fig 7.5). 
The increasing FFA concentration is also shown. Components which 
did not change significantly are not presented. The increasing 
concentration of mda with time of storage is the subject of fig 
7.6. Correlation coefficients, obtained when changing 
concentrations of PC, PE, PS, PI, FFA and MDA were correlated with 
time, and listed in Table 7.3. These were very highly significant. 
TABLE 7.3 CORRELATION COEFFICIENTS AND SIGNIFICANCE LEVELS OBTAINED 
BY CORRELATING CHANGING CONCENTRATIONS OF LIPIDS AND MDA 
IN STORED BCT WITH TIME OF STORAGE 
Component Correlation coefficient Significance level 
PC -0.9714 p < 0.001 
PE -0.915 p < 0.001 
PS -0.986 p < 0.001 
PI -0.931 p < 0.001 
FFA 0.976 p < 0.001 
MDA 0.956 p < 0.001 
The loss of procoagulant activity according to time of storage 
of BCT is given in fig 7.7. Prothrombin times of lyophilised, 
calibrated plasmas lengthen with storage time. 
When the decreasing procoagulant activity of a normal plasma is 
correlated against changing concentrations of lipids in fig 7.5, and 
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Fig 7.6 Increase in malondialdehyde concentration with 
time of storage of BCT. 
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TABLE 7.4 CORRELATION COEFFICIENTS AND SIGNIFICANCE LEVELS OBTAINED 
BY CORRELATING CHANGING CONCENTRATIONS OF LIPIDS AND MDA 
IN STORED BCT WITH DECREASE IN PROCOAGULANT ACTIVITY 
Component Correlation coefficient Significance level 
PC -0.8954 p < 0.001 
PE -0.8223 p < 0.005 
PS -0.9501 p < 0.001 
PI -0.9041 p < 0.001 
FFA 0.8896 p < 0.001 
MDA 0.9388 p < 0.001 
Only the correlation of PE concentration with decreasing 
procoagulant activity falls below the very highly significant level 
of p<0.001. 
Table 7.5 shows the distribution of the fatty acids of tissue 
thromboplastin and the change in their distribution with time of 
storage. A summary of the results when analysis of variance was 
applied to the data is given in table 7.6. An upward trend 
indicates that a particular component is increasing in relative 
concentration with age, while a downward trend is the reverse. The 
ratio of unsaturated to saturated fatty acids (USFAR) decreases as 
the time of storage increases, due to the loss of unsaturated fatty 
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TABLE 7.6 SUMMARY OF FINDINGS BY ANALYSIS OF VARIANCE (ANOVA) 
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significant downward trend p < 0.001 
significant downward trend p < 0.05 
significant upward trend p < 0.001 
significant upward trend p < 0.001 
no significant trend p > 0.05 
insufficient data - 
significant downward trend p<0.05 
significant downward trend p<0.001 
no significant trend p > 0.05 
significant downward trend p < 0.05 
significant downward trend p < 0.01 
no significant trend p > 0.05 
no significant trend p > 0.05 
no significant trend p > 0.05 
insufficient data - 
significant downward trend p < 0.01 
no significant trend p > 0.05 
no significant trend p > 0.05 
significant downward trend p < 0.001 
significant downward trend p < 0.001 
USFAR significant downward trend p<0.001 
Discussion - Monitoring of the first batch of BCT (No 1) 
occurred in November 1969. Aliquots of this batch, and of 
successive batches, have been stored at 4 °C since their 
manufacture. The last batch, number 30, was monitored in April 
1978. The liquid BCT was then replaced by a lyophilised 
preparation, batch 76/005 (Stevenson 1978). 
BCT preparations stored at 4°C for several years are subject 
to degradation. The shelf life of the liquid BCT was approximately 
six weeks and the reagent was never used beyond this time. Aliquots 
of BCT stored at 4°C for up to 102 months provided the material 
for this study. The procoagulant activity of the reagent was found 
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to decrease with time. Coincident with this decrease was a change 
in the lipid composition. A reduction in some of the phospholipid 
classes was found to be statistically significant, as was change in 
concentration of some of the fatty acids. The free fatty acid 
component of the material increased, as did the mda level. These 
findings are strongly indicative of an oxidative mechanism in the 
stored material. The reagent is extracted from human brains which 
have been stripped of their blood vessels and washed free of blood, 
before being subjected to maceration in phenol-saline. This process 
causes the breaking down of cell membranes and the release of many 
potentially oxidative compounds from sub-cellular particles. The 
electron micrographs in figs 7.1 to 7.4 support the idea of a 
massive disruption of cell membranes and show that sub-cellular 
particles do not survive the extraction process. It is unlikely 
that the washing procedure will remove all of the haematin compounds 
from the brains. These are reported to be powerful catalysts for 
the oxidation of unsaturated lipids (Tappel 1953). Haemoglobin and 
cytochrome C, according to Tappel (1955), have catalytic activity of 
the same order of magnitude and equal to that of iron 
protoporphyrin. Tappel showed that the rate of oxidation of 
colloidal linoleate in the presence of these catalysts correlated 
with the square root of the catalyst concentration. 
Mda concentration was measured by the thiobarbituric acid 
reaction (Buege and Aust 1978, DeKoning and Silk 1963). Dahle et al 
(1962) showed that this reaction provided a semiquantitative measure 
of the autoxidative splitting of fatty acids with three or more 
double bonds. The results, illustrated in fig 7.6 are consistent 
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consistent with an oxidative degradation of the stored BCT, and show 
an "induction period" of about 15 months of storage, during which 
the mda level was unchanged, followed by an increasing concentration 
that coincided with loss of procoagulant activity in the stored 
reagents. Barber and Wilbur (1959) showed that, in general, tissue 
homogenates from brain, liver and kidney readily undergo 
peroxidation while those from testis and intestine do not. 
Maceration of the human brain tissue and extraction into phenol 
saline may have destroyed the normal protective mechanisms that 
militate against autoxidative changes, e. g. glutathione peroxidase 
will not be available once generation of NADPH is ceased (Cohen and 
Hochstein 1961). Autoxidation of contaminating haemoglobin in the 
reagent may lead to formation of superoxide anion radical. This 
will not be removed after residual superoxide dismutase has lost its 
activity. Any formation of H20 2 may serve to generate radical 
species with the capacity to initiate peroxidation. Hochstein 
(1981) discussed the ability of haemoglobin to enhance the formation 
of hydroxyl radical, from H202 by acting as a Fenton reagent. 
Mead (1982) discussed the rate of oxidations in biological membranes 
and suggested that phospholipases A2 and C may be involved in 
cleaving oxidised fatty acids from phospholipids or in removing the 
diglyceride, in the case of phospholipase C. The latter could then 
by acylated and triglyceride formed. O'Brien (1987) also reported 
that fatty acid epoxide is a ten-fold better substrate for epoxide 
hydrolase than phospholipid epoxide. 
The highly reactive nature of mda has been noted by several 
workers. Chio and Tappel (1969) and Tappel (1973) showed that mda 
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facilitates reaction of phospholipids with proteins by crosslinking, 
through Schiffs base formation, the amino groups of phospholipids 
and proteins. Nair et al (1981) showed that mda reacts rapidly at 
the c+. -amino group of amino acids to form 1: 1 adducts, and Nair et al 
(1986) described a variety of adducts formed by such reactions. The 
polymerisation of the erythrocyte membrane protein, spectrin, 
through mda crosslinking, has been described by Rice-Evans and 
Hochstein (1981). 
The oxidation process, therefore, could cause destruction of 
the membrane lipids and lead to polymerisation of proteins and 
interactions, through mda crosslinking, between phospholipid and 
protein components of the reagent resulting in the loss of 
procoagulant activity of the material. Loss of procoagulant 
activity correlated with reduction in concentration of some 
phospholipid components i. e. PC, PE, PS and PI and loss of some 
unsaturated fatty acids. An increase was noted in the 
concentrations of FFA and mda. 
Stevenson (1978) reported this oxidative process, which has been 
extended in the present work to include further details of the 
change to the fatty acid components. It was demonstrated in the 
earlier study that oxidation could be retarded by the addition of 
antioxidant compounds such as propylgallate, nordihydroguaiaretic 
acid and ascorbic acid. Unfortunately such additions had an 
adverse effect on the procoagulant activity of tissue thranboplastin 
reagents. 
222 
Conclusion - The shelf life, of six weeks, assigned to the 
liquid BCT preparation was a safe one. Loss of procoagulant 
activity on long-term storage coincided with the loss of some 
phospholipid components, a reduction in unsaturated to saturated 
fatty acid ratio and an increase in free fatty acids and 




The preparation, from human brains, of tissue thromboplastin 
reagents i. e. British Comparative Thromboplastin (BCT), the 
international reference preparation, and the Manchester Comparative 
Reagent (MCR), the routine working thromboplastin, ceased in 
December 1985. Up to this time a majority of hospitals in the UK 
used MCR and BCT was despatched to over 70 countries overseas. 
Three batches of lyophilised BCT prepared prior to this date are 
currently still serving as Reference Preparations (see Chapter 3) of 
the WHO, EEC and ICSH. It appears unlikely however, that further 
human brain-derived thromboplastin reagents will be issued for 
routine or reference purposes on account of the possibility of 
transmittable viruses, notably HIV. 
BCT was externally monitored by the prothrombin time test in a 
series of regular, multicentre exercises to ensure reproducibility 
between batches (Poller 1970, Stevenson 1978). The shelf life of 
BCT was stated to be six weeks. The data in this chapter indicate 
that this was a conservative and safe choice. 
The morphology of the reagent is depicted in figures 7.1 - 
7.4. The low power electron micrograph (fig 7.1) shows two nuclei 
and many myelin figures. No subcellular organelles survive the 
extraction procedure, apart from nuclei. Although the background of 
the figure is filled with membranous structures these are likely to 
be vesicles of membrane formed from fragments broken from the myelin 
sheath membrane rather than subeellular formed elements. Changes to 
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myelin sheath membrane are evident in figures 7.2 - 7.4, where a 
degradation with time of storage at 4°C, with loss of order in the 
membrane organisation increasing with time, can be noted. The 
oldest preparation, BCT 1, stored for 102 months is remarkable in 
that some segments of the sheath membrane are still tightly 
associated. 
The experiments in Chapter 7.3 demonstrate that an autoxidative 
process is responsible for the change in the lipid components of the 
stored reagent. With increasing time of storage the concentration 
of several phospholipid classes decreased, e. g. PC, PE, PS and PI. 
Free fatty acids and mda increased over the same period. 
Phospholipid-bound fatty acids altered too, showing loss of 
unsaturated components. Several highly significant correlations 
were seen between these changes and loss of procoagulant activity. 
It may be that a combination of potentially oxidative compounds in 
the reagent, combined with an inability to deal with radical 
production, leads to production of mda and free fatty acids. Mda is 
able to crosslink phospholipids and proteins, and will combine with 
amino acids. Free fatty acids may inhibit interaction of clotting 
proteins with thromboplastic surfaces which themselves will be 
altered by the loss of the zwitterionic phospholipids PC and PE, and 
the negatively charged classes PI and PS. The significance of these 
phospholipids in the clotting sequence is examined further in 
Chapter 8. 
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CHAPTER 8 EXPERIMENTS ON PARTIAL THROMBOPLASTIN 
This chapter is concerned with attempts to elucidate the 
morphology, lipid composition, and performance in the activated 
partial thromboplastin time test, (APTT), of a number of widely used 
commercially available methods and the Manchester APTT. The aim is 
to develop a reagent, made from pure lipids, which may substitute 
for these and, moreover, which may have a role as a possible 
International Reference Preparation for the APTT. 
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8.1 EXAMINATION OF THE STRUCTURE OF SOME COMMONLY USED APTT 
REAGENTS 
Aim - to determine whether APTT reagents show any formal 
structure by the use of electron microscopy. 
Methods - Five APTT reagents, Actin, Actin FS, Activated 
Thrombofax, Automated APTT and Manchester APTT, were prepared for 
electron microscopy as described in Chapter 6.8. Four of these were 
produced by commercial manufacturers and were among the most popular 
APTT reagents in current use. The fifth was the Manchester APTT 
reagent, the most widely used in the UK, which has been evaluated in 
several international collaborative trials (Poller et al 1976, 
Poller et al 1980). Table 8.1 gives some features of the reagents. 
TABLE 8.1 APTT REAGENTS EMPLOYED IN THE STUDY 
Reagent (batch no) Manufacturer Source of 
Lipids 
Actin Dade rabbit brain 
(APAC-415B, APAC-429B 
Actin FS Dade soya bean 
(SA-54B, SA-66C) 
Activated Thrombofax Ortho bovine brain 
(3A443,1B464) 
Automated APTT General Diagnostics rabbit brain 
(3806062,5328113) 
Manchester APTT UK Reference Lab human brain 
(303) 
Ultra-thin sections of 50-60 mm thickness were prepared, with 
the exception of the Automated APTT reagent, which contained silica 
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particles as activator in the test system. Sections of this 
material were cut at a thickness of 100 nm. 
Results - the morphology of the reagents is depicted in figures 
8.1 to 8.5. Actin (fig 8.1) contains small fragments of membranous 
material, vesicular or tubular in structure, but poorly organised 
and widely dispersed. Sheets of electron dense and medium electron 
dense material are interspersed with the membranous components. 
Actin FS (fig 8.2) shows a more even distribution of membranous 
vesicles with single, double or occasionally multilamellar walls. 
The liposomes are of a fairly restricted size range and no non-lipid 
material is evident. The question of sizing is evaluated in the 
next section. Activated Thrombofax (fig 8.3) contains a great deal 
of non-lipid material. Myelin sheaths are to be seen, comprising 
tightly associated membranes, surrounding nerve axons often 
containing microtubules. The surrounding material is membranous in 
nature, containing vesicles ranging from small unilamellar to large 
multilamellar structures. Automated APTT looks markedly different 
from the other reagents. Its structure resembles a dense foam or 
honeycomb, comprised of electron dense wall material surrounding 
many fairly uniformly sized vesicles. Occasional large 
electron-lucent vacuoles are present, probably due to the loss of 
this reagents silica activator during preparation for microscopy. 
Automated APTT is shown in fig 8.4. The Manchester APTT is shown in 
fig 8.5. This preparation is characterised by the presence of 
discrete liposomes of varying complexity and size, from small 
unilamellar forms to large multilamellar. There is no evidence of 
non-lipid contaminants. 
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Fig. 8.1 (opposite) Electron micrograph of Actin at a 
magnification of 32 000. Scale bar is 500 nm. 
Fig. 8.2 (p231) Electron micrograph of Actin FS at a 
magnification of 22 000. Scale bar is 500 nm. 
Fig. 8.3 (p232) Electron micrograph of Activated Thrombofax 
at a magnification of 32 000. Scale bar is 500 nm. 
Fig. 8.4 (p233) Electron micrograph of Automated APTT at 
a magnification of 50 000. Scale bar is 500 nm. 
Fig. 8.5 (p234) Electron micrograph of Manchester APTT at 


















































Discussion - the electron microscope examination shows that 
APTT reagents possess a discrete structure. The liposomes that 
comprise these preparations come in many sizes and forms, ranging 
from small unilamellar vesicles to large multilamellar vesicles 
built up of whorls of membranous material. Actin FS and Manchester 
APTT appear to have the most ordered structures. From the 
morphology, neither contains any non-lipid contaminants and their 
constituent liposomes are discrete and highly ordered. Actin FS 
appears to be more homogeneous in its size distribution (see Ch 8.2) 
than any of the other preparations. Manchester APTT is prepared 
from human brain lipids while Actin FS is made from soya bean. None 
of the other three reagents are as highly ordered as Manchester APTT 
and Actin FS. Actin and Automated APTT are both manufactured from 
rabbit brain lipids. They do not resemble each other however, with 
Actin shown to be widely dispersed vesicles of small size 
interspersed with membranous sheets while Automated APTT appears as 
a dense foam with electron lucent vacuoles. This may be due to the 
loss of the silica particles employed as activator in this reagent, 
which may fall out during processing. 
The remaining preparation, Activated Thrombofax, was prepared 
from bovine brain and contains large fragments of nerve cells, 
nuclei and myelin sheaths. This indicates that insufficient care 
was taken to remove these contaminants, which may adversely affect 
the clotting time test in which the preparation is used, by 
contributing non-lipid components. Recent concern over bovine 
spongiform encephalopathy may also influence the choice of this 
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particular reagent (Scott 1988). A common feature of all of these 
preparations is that they are comprised of liposomal type structures 
which are highly suited to the provision of a surface for the 
reaction of the blood clotting proteins. 
Conclusions - all the reagents examined were in the form of 
liposome suspensions. Two of the reagents, Actin FS and Manchester 
APTT show a more homogeneous appearance than the others, while 
Activated Thrombofax appears to be a crude extract containing a good 
deal of cell debris. 
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8.2 TO DETERMINE THE SIZE OF THE LIPOSOMES IN SOME COMMONLY USED 
APTT REAGENTS 
Aim - to estimate the size range of some APTT reagent 
1iposomes. 
Methods - the APTT reagents described in Chapter 8.1 were 
examined using a Zetasizer 2 instrument in the case of Automated 
APTT and Manchester APTT and an Autosizer 2 instrument with Actin, 
Actin FS and Activated Thrombofax. These machines are described in 
Chapter 6.9 and 6.10. 
Results - There is a wide range of particle size over all the 
reagents examined and each reagent also shows a wide size 
distribution. Table 8.2 shows particle size distribution in the 
reagents. 
TABLE 8.2 PARTICLE SIZE DISTRIBUTION IN APTT REAGENTS 
Range Particle size distribution (nm) 
mean range 
Actin 166 65 - 800 
Actin FS 269 120 - 640 
Activated Thrombofax 132 50 - 800 
Automated APTT 460 50 - 1250 
Manchester APTT 938 65 - 2500 
A typical Zetasizer output and Autosizer output are shown in 
figs 6.10 and 6.11. As may be seen in table 8.2 Actin FS has the 
smallest size range of any of the materials tested while the 
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Manchester APTT shows the largest. This reagent also contained the 
largest mean particle size. The smallest mean particle size was 
found in Activated Thrombofax. 
Discussion - The method of extraction to obtain the 
phospholipid is only known for the Manchester APTT, produced in the 
UK Reference Laboratory. These details are not available for the 
four commercial reagents. Manchester APTT was manufactured by 
extracting acetone dried human brain powder with diethyl ether. The 
ethereal solution was subjected to rotary vacuum evaporation, 
depositing the lipids as a thin film on the walls of a round 
bottomed flask. Owren's buffer was added and the flask shaken by 
hand until the walls of the flask were freed of lipid. The electron 
micrograph (fig 8.5) and the data for size distribution in table 8.2 
show that a variety of forms and sizes results from this procedure. 
The finding that the other four reagents have narrower size 
ranges may be due to the way in which they were produced, e. g., it 
is unlikely that hand shaking of liposomes occurs in an industrial 
scale technique (Fildes 1981). More vigorous shaking, for example, 
by mechanical means, would result in smaller sized liposomes (Sjoka 
and Papahadjopoulos 1980). Alternatively, ultrasound probes or 
baths may be used to produce small sized particles and ultimately, 
narrower size ranges. Extrusion through polycarbonate filters or 
columns of Sepharose will also reduce the size range of liposome 
populations. Olson et al (1979) discuss the use of these methods. 
Sonication is difficult to standardize (Saunders et al 1962, 
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Papahadjopoulos et al 1967) so this group preferred a method 
employing extrusion through polycarbonate membranes. 
The Malvern Instruments machines employed in the present study 
(see Chapter 6) proved useful for the size distribution estimation. 
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8.3 TO DETERMINE THE ELECTROPHORETIC MOBILITY OF APTT REAGENT 
LIPOSOMES 
Aim - to obtain values for the electrophoretic mobilities of 
the liposomes of the five APTT reagents described in 8.1. 
Methods - the Zetasizer 2 instrument was employed (see Chapter 
6.10). 
Results - all the reagents show a negative charge, Automated 
APTT being strongest, while Manchester APTT was weakest and similar 
to Actin FS. 
Table 8.3 shows the electrophoretic mobilities of the reagent 
liposomes. Fig 6.9 shows a typical output from the Zetasizer 2 
instrument. 
TABLE 8.3 ELECTROPHORETIC MOBILITY OF REAGENT LIPOSOMES 
(micrcns/sec/volt/cm) 
Actin -3.65 
Actin FS -2.70 
Activated Thrombofax -3.24 
Automated APTT -4.68 
Manchester APTT -2.14 
Discussion - the reagents all show a negative charge. Bangham 
(1961) prepared liposomes of egg lecithin containing graded 
concentrations of dicetyl phosphate. The electrophoretic mobility 
of these preparations was obtained by the use of the 
microelectrophoresis apparatus described by Eangham et al (1958). A 
Russels Viper Venom activated clotting time was then performed with 
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each of the liposome preparations in turn providing the 
phospholipid. Bangham found that as the negative charge on the 
lipid suspension increased so did its ability to accelerate the 
clotting time. Papahadjopoulos et al (1962) prepared a series of 
mixed phospholipid emulsions from beef brain and egg yolk. They 
used the microelectrophoresis apparatus described by Bangham to 
measure the electrophoretic mobility correlated with activity in a 
clotting test. They found that each phospholipid mixture had an 
optimal negative charge at which the particles exhibit their maximum 
activity. Variation of this charge resulted in diminished activity. 
The microelectrophoresis method employed by these early workers 
involved directly observing individual particles using a microscope 
and timing their progress over a fixed distance. Considerable time 
and patience was required to accumulate a statistically satisfactory 
sample. The technique also required that particle concentration be 
reduced to allow an individual particle to be observed unequivocally 
for the duration of the measurement. 
Use of the Zetasizer instrument provided a comprehensive 
assessment of the mobility spectrum of the entire sample without 
dilution and laborious microscopical monitoring of particle 
movement. 
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8.4 TO DETERMINE THE LIPID COMPOSITION OF FIVE COMMONLY USED APTT 
REAGENTS 
Aim - to determine the phospholipid class composition, fatty 
acid composition and neutral lipid class distribution in the five 
APTT reagents described in Chapter 8.1. 
Methods - the method used for determination of phospholipid and 
neutral lipid class distribution was thin-layer chromatography 
(TLC), with quantitation by densitometry. Gas liquid chromatography 
(GLC) on capillary columns was employed for the fatty acid 
analyses. Phospholipid assay was by the method of Stewart (1980) 
and phosphorus estimation was by the method of Rouser et al (1966). 
These methods are described in detail in Chapters 6.1,6.4,6.3 and 
6.2. 
Results - table 8.4 shows the total phospholipid in each 
reagent per test. The Manchester APTT contains the smallest 
quantity and Actin FS the largest. Fig 8.6 shows the total 
concentration, per test, of phospholipids, fatty acids and neutral 
lipids. It is clear that the Manchester APTT contains the least 
amounts of the majority of those components while Actin FS contains 
the most. The distribution of the phospholipid classes is pictured 
in fig 8.7 and in table 8.5. PC was the major lipid class in the 
vegetable reagent, Actin FS. SPH was not detected in this reagent 
whle PG and PA were present in reasonable amount. The other four 
reagents, of animal origin, contained no detectable PG or PA and had 
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Fig.. 6.7 Phospholipid class distribution in APTT reagents 1= PC 
2=SPE, 3=PIA 4=PES 5=PS6=PG, 7=PA. Key as in fig8.6 
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concentration of PS per test in the reagents. This indicates that 
the Manchester APTT reagent has the lowest concentration and 
Activated Thrombofax the highest. The concentration of the neutral 
lipids, per test, is shown in table 8.7. All reagents contained 
cholesterol esters and barely detectable quantities of free fatty 
acids and monoglycerides. Actin FS, the soya bean material, showed 
the presence of monogalactosyl diglyceride and digalactosyl 
diglyceride and small amounts of triglyceride were found in 
Activated Thrombofax and Manchester APTT. The fatty acid 
composition of the reagents is the subject of table 8.8 and fig 
8.8. The ratio of unsaturated to saturated fatty acids (USFAR) is 
given and its highest value is seen to be 2.54 for Actin FS. 
Linoleic acid (18: 2) was the major component of this reagents 
unsaturated fatty acid group. The other reagents USFAR range from 
0.779 for Actin to 1.442 for Activated Thrombofax. In these 
reagents, of animal origin, the major unsaturated fatty acids were 
oleic (18: 1), arachidonic (20: 4) and docosahexaenoic (22: 6). The 
major saturated fatty acid in the animal extracts was stearic acid 
(18: 0). By comparison Actin FS contained less than 6% of this acid. 
Discussion - the five APTT reagents employed in this study were 
used at their manufacturers' stipulated concentration. In order to 
make comparisons easier, the results for total phospholipid (table 
8.4), total phospholipds, fatty acids and neutral lipids (fig 8.6) 
are given as values "per test". The main difference demonstrated is 
between Actin FS, which is of vegetable origin, and the other four 
reagents, made from rabbit, bovine and human brains. There was 253 
times more total phospholipid in Actin FS than in Manchester APTT 
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although this factor is reduced to 41 times when relative 
concentrations of PS are compared. The phospholipid class 
composition shown in fig 8.7 reveals a broadly similar pattern in 
the four reagents of animal origin, with PE the major component. 
APTT reagents were known as "cephalin" reagents for many years, not 
unreasonably given that mixtures of PE with PS and PI were also 
known as cephalin by earlier workers (Thudichum 1894, Renall 1913, 
Baumann 1913). PC is the major phospholipid in Actin FS. Soya 
beans are reported to contain relatively large amounts of this 
component (Galliard 1973) but the present very high level observed 
may be due to the addition of an extra quantity of PC as a 
stabilizer. This use of PC was noted by Mead and co-workers in 
their studies of pulmonary surfactant (Wu et al, Huang 1969) and 
autoxidation of pure liposomes of soya bean PC (Wu et al 1982). PG 
and PA are to be found at 2.46 and 4.4 mol% respectively in this 
preparation. The form of liposomes is known to depend to a large 
extent upon the relative proportions of the phospholipid classes 
they contain (Szoka and Papahajopoulos 1981, Chapman 1984). All the 
preparations examined contain sufficient quantities of PC and PE, as 
well as SPH in the animal brain extracts, to form liposomes. 
Several other considerations are worth noting, e. g., Zwaal (1978) 
described instability of liposomes containing over 30 mold of PS. 
Also, the presence of negatively charged phospholipids is essential 
for the binding of the clotting proteins via calcium ions. In the 
four reagents of animal brain origin the major negatively charged 
component is PS, which represents only a small percentage of the 
Actin FS phospholipid. This small proportion was increased, 
however, by the presence of PG and PA which were absent from the 
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other reagents. Despite its very high total phospholipid content, 
Actin FS provides just 1.55 »g of PS per test. The Manchester APTT 
provides 0.05, pg of PS per test. In Chapter 8.3 the question of 
electrophoretic mobility was considered, and it was shown that 
negative charge was a feature of all these reagent liposomes. 
TABLE 8.4 TOTAL PHOSPHOLIPID PER TEST (}pg) 
Actin Actin FS Activated Automated Manchester 
Thrombofax APTT APTT 
9.88 63.31 18.6 12.28 0.25 
TABLE 8.5 PHOSPHOLIPID CLASS DISTRIBUTION (mol %) 
Actin Actin FS* Activated Automated Manchester 
Thrombofax APTT APTT 
PC 27.23 66.0 17.73 25.61 30.78 
SPH 11.22 - 6.70 14.65 8.76 
PI 0.86 8.05 3.54 1.79 1.82 
PE 38.59 16.43 42.51 29.99 38.58 
PS 22.07 2.45 29.52 27.97 20.06 
PG - 2.46 - - - 
PA - 4.40 - - - 
* In the case of Actin FS, some 6.5% by weight of phospholipid was 
not positively characterised. The mol% values in the table were 
calculated from the identifiable components. 
TABLE 8.6 CONCENTRATION OF PHOSPHATIDYL SERINE PER TEST ()ag) 
Actin Actin FS Activated Automated Manchester 
Thrombofax APTT APTT 
2.17 1.55 5.49 3.43 0.05 
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TABLE 8.7 NEUTRAL LIPID PER TEST ()ag) 
Actin Actin FS Activated Automated Manchester 
Thrombofax APTT APTT 
Cholesterol 0.225 - - 0.725 0.076 
Cholesterol 0.750 5.9 0.07 4.600 0.001 
Esters 
Free Fatty tr tr tr tr tr 
Acids 
Monoglycerides tr tr tr tr tr 
Monogalactosyl - 2.4 - - - 
Diglyceride 
Digalactosyl - 3.7 - - - 
Diglyceride 
Triglycerides - - 0.09 - 0.005 
tr = trace observed on TLC plate 
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TABLE 8.8 FATTY ACID COMPOSITION (% of total fatty acids, by weight) 
Fatty Acids Actin Actin FS Activated Automated Manchester 
Thrombofax APTT APTT 
Unsaturated 
14: 1 0.37 - - - - 
16: 1 1.83 0.11 0.99 0.61 0.64 
18: 1 19.64 9.03 26.97 25.39 30.19 
18: 2 1.74 57.11 0.30 0.68 0.72 
18: 3 4.09 3.73 0.66 1.05 1.25 
20: 1 1.51 0.34 1.60 1.46 3.15 
20: 2 1.18 0.50 0.50 0.83 0.13 
20: 3 0.14 0.02 0.93 1.13 1.33 
20: 4 7.64 0.43 11.56 13.52 8.43 
22: 1 0.95 - 0.52 0.47 0.12 
22: 2 0.47 0.44 0.17 0.04 0.42 
22: 6 4.24 0.04 14.85 9.92 9.09 
24: 1 - 0.01 - 0.18 - 
Saturated 
10: 0 - - - 0.02 - 
12: 0 1.21 0.07 0.50 0.33 0.18 
14: 0 2.43 0.12 0.58 0.30 0.76 
16: 0 24.42 20.95 7.77 15.83 13.43 
18: 0 26.00 5.68 30.95 27.01 28.93 
20: 0 1.69 0.37 0.63 0.72 1.07 
22: 0 0.24 0.67 0.52 0.49 0.16 
24: 0 0.13 0.38 - 0.02 - 
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Fig 8.8 Fatty acid distribution in APTT reagents. 
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8.5 TO OBSERVE THE PERFORMANCE OF FIVE APTT REAGENTS IN TESTING THE 
APTT OF A VARIETY OF NORMAL AND ABNORMAL PLASMAS 
Aim - to observe the performance of the five APTT reagents 
described in Chapter 8.1 in testing the APTT of plasmas from a 
variety of normal and abnormal sources. 
Methods - APTT tests were performed in accordance with 
manufacturers' recommended techniques, using a manual method. Tests 
were carried out on plasmas obtained from 62 normal healthy donors 
and from patients with a range of clinically important congential 
and acquired coagulation abnormalities. There included 6 mild and 4 
moderate to severe haemophiliacs, with factor VIII levels ranging 
from < 1% to 26%, 2 von Willebrand's disease patients, 3 factor XI 
deficiencies, 5 factor VIII inhibitors, 7 lupus-like inhibitors and 
22 heparinised patients. In additior, the effect of heparin in 
vitro was studied over a range from 0.1 to 0.35 units cm 
3, by 
addition of standard heparin (3rd. International Standard prepared at 
the National Institute for Biological Standards and Control). The 
blood was collected and platelet poor plasma obtained as described 
in Chapter 6.19. 
Normal ranges for each reagent were derived, also as described 
in Chapter 6.21. Clotting time ratios were obtained by method A or 
method B, as follows: - A was the APTT of abnormal plasma/upper 
limit of manufacturers' normal range and B was the APTT of abnormal 
plasma/upper limit of normal range which had been transformed to 
correct non-Gaussian distribution. The APTT ratios of the 
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individual plasmas with each of the five APTT reagents were ranked, 
a value of 5 being given to the highest and 1 to the lowest. Within 
each coagulation defect the ranks were summed for each reagent and 
the sums converted to a% scale (see Chapter 6.21 for further 
explanation). 
Results - table 8.9 shows the results of the testing of 62 
normal plasmas. The distrubtion of these normal values showed some 
skewness and kurtosis and therefore required transformation (Box and 
Cox 1964, Wetherill 1981). Statistical methods are described in 
Chapter 6.21. Corrected normal ranges were calculated from the 
transformed data and are shown with the manufacturers stated values 
in table 8.10. Also included is a normal range based on the data 
from this study, before transformation, for comparison. It may be 
seen that for the Manchester APTT these three ranges are very 
similar. Actin and Actin FS gave a narrow normal range and short 
times. Manchester APTT gave much longer times and a wider range. 
Limits of the normal clotting times with the different reagents 
varied from extremes of approximately 22 sec, the lower limit with 
Activated Thrombofax, to 48 sec, the upper limit with Manchester 
APTT. 
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TABLE 8.9 APTT OF NORMAL PLASMA 






30 30.5 37 37 26 25.5 35 34.5 45 45 
27 26 31 30 23.5 23 28.5 29.5 37.5 37 
28 28 34.5 35.5 24 24.5 29 29.5 39 39 
32 31.5 39 39 26.5 26 36 36.5 47 46 
29 29.5 35 34.5 26.5 27 31 32.5 43 43 
31 31 37.5 37 26.5 26.5 34.5 35 42.5 43.5 
28 27.5 33 32.5 24 24.5 30 30 40 40.5 
30 30 37 37 27 26 34 35 43 43.5 
30 30 37 36 24 24 35 35 46 46.5 
30 30 35 35 27 26.5 34 34.5 41 41.5 
29.5 30 33 33 25 24 34 34.5 41 42 
28 28 33 33 24.5 25.5 31.5 31.5 42 42.5 
31.5 31 36.5 36.5 27 27 34.5 35.5 44 44 
29 29.5 34 34 26 26 32.5 32.5 42.5 43 
31 31 37 37 26 26 37 37 43 43.5 
30 29.5 34 33 25.5 25 33 33.5 39 39 
24.5 25.5 28 29 22.5 23 28 28 37 37.5 
32 33 36.5 37 28.5 28.5 40 39.5 44 43 
28 28.5 32 31 24.5 25 30 31.5 39 39 
32 31 35 36 28.5 27.5 37.5 37 45 45.5 
27.5 26.5 32 32 23.5 23.5 31 32 37 37 
28.5 29 36 35 25.5 25.5 33 33 40 41 
32 33 38 37 28 27 38 39 46.5 47.5 
28.5 28 35.5 35.5 26 26 33 34 42.5 43 
28 29 33.5 33.5 26.5 26 35 34.5 44 45 
27.5 28 35 35 24.5 24.5 34 33 37.5 38 
32.5 33 39.5 38.5 27.5 28 43 43.5 46 46.5 
32 31 36 35.5 27 27 38 37 46.5 47 
29 29.5 34.5 34 26.5 25.5 34 34 43 44 
28.5 29 36.5 36 25.5 24.5 35.5 35 44 45 
30.5 30 34 35 26.5 25.5 34 33 40.5 41 
32 32.5 39.5 39.5 27.5 27 36 36 45 45.5 
27 27.5 33.5 33 23 22.5 30 30 38 38 
26 25.5 31 31 24 24 29 30 37 36.5 
30 30 37 36 26 26.5 35.5 36 41.5 42 
28.5 29 34.5 34 24 24 34 33 46 46.5 
26 26 33 32 23.5 23.5 31 31 39 39.5 
32 32 38 37.5 27 26.5 38 37 46 46 
28.5 28.5 32 33 24 25 31.5 32 39.5 39 
29 28 30 30.5 24 24 34 33.5 37 38 
27 27 32 32 23.5 23 29 30 37.5 38 
28 28 33 33 25.5 25 33 32 43.5 44.5 
26.5 27 31.5 32 24 24.5 30 30 42 42 
27 27 33 33 22 21.5 27.5 27.5 42 42.5 
26 26 30 29 23 23.5 25 24 36.5 37.5 
29.5 29.5 33 33 22.5 23 27.5 28 41.5 42.5 
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TABLE 8.9 APTT OF NORMAL PLASMA (continued) 






26.5 27.5 31 31 22.5 22 27 27 41 41 
30 29.5 35 36 26.5 27 35.5 35 42 43 
32 31 39 40 26 27 37.5 38.5 45 46 
28 28 36 37 25 25 32 32 42.5 43 
29 29.5 37 37.5 25.5 26 35 36 46.5 46.5 
33 33 38.5 39.5 28 28 37 38 44 45 
32.5 32 37 36.5 26 26.5 37 36.5 43.5 44.5 
33 33 40 40 28.5 29 40 40 46 46.5 
31 31 39 38.5 26.5 27 36 36 44.5 45.5 
27.5 26.5 33.5 33.5 24 23 31 31 39 39 
28 27.5 35 34 24.5 23.5 30.5 31.5 39.5 40 
31 30 35 35 26 25 37 36 143.5 44.5 
30.5 30.5 35.5 35.5 27 27 37 36 44 45 
31 31 36 37 27 26 39 38 43 43.5 
26 25 30 31 23.5 24 28 27.5 36 36.5 
31 32 36.5 37 23.5 23 30.5 29.5 49.5 50.5 
TABLE 8.10 NORMAL RANGES OF THE APTT METHODS (see) 
Reagent Manufacturer's Range of normal Corrected 
range plasmas tested range 
(n= 62) 
Actin 25.50 - 34.70 25.26 - 33.41 25.20 - 32.91 
Actin FS 29.20 - 37.10 29.29 - 40.04 29.33 - 39.81 
Activated Thrombofax* 24.00 - 30.41 22.10 - 28.56 22.18 - 28.29 
Automated APTT 25.00 - 43.00 25.61 - 41.07 26.37 - 39.39 
Manchester APTT 36.00 - 48.00 36.00 - 48.62 35.59 - 47.89 
*normal range for manual technique not given. The range shown is 
the average of those given for automated methods. 
Fig 8.9 shows the distribution of the normal values obtained 
when using Actin FS. The manufacturers given normal range is shown 
by the solid arrows and excludes several data which are normal and 
therefore should be included. The corrected range, following the 
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Fig 8.9 Frequency distribution. APTT of normal plasmas 
with Actin FS. Solid arrows show the manufacturers 
giver. range while the dotted arrows show the 
transformed range. 
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Tables 8.11 to 8.17 show the performance of each of the APTT 
reagents with the different coagulation abnormalities under test. 
The bar charts (fig 8.10) indicate the ranking of the reagents 
with each coagulation defect. Results based on manufacturers' 
normal values are shown alongside those derived by use of a 
corrected normal range. Table 8.18 shows the number of 
abnormalities detected by the various APTT methods according to the 
upper limit of the manufacturers' normal range (A) and that 
calculated in the present study (B). 
The APTT methods differed in their ability to detect the range 
of coagulation defects included. The correction of the normal range 
improved the success rate of Actin, Activated Thrombofax and 
Automated APTT in detecting mild coagulation abnormalities. In mild 
haemophilia all the reagents detected the abnormality in all 
samples, but the ease of detection indicated by the ranking suggests 
that Automated APTT and Activated Thrombofax were the least 
sensitive and Actin FS the most. In severe haemophilia Actir FS and 
Manchester APTT performed well whereas Automated APTT and Activated 
Thrombofax were again the least sensitive. A similar pattern was 
evident in von Willebrand plasmas when the results were based on the 
manufacturers' normal ranges. Automated APTT failed to detect the 
abnormality in both plasmas and Activated Thrombofax in one. Using 
the corrected values the performance of these two reagents was 
improved. 
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Fig. 8.10 (opposite) Ranking of reagents. Column A used ratios 
based on manufacturers given ranges while Column B used corrected 
ranges derived as described in the text. Key as in fig. 8.6 
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TABLE 8.11 APTT OF FVIII DEFICIENT PLASMA 








26 42.5 44 56.5 57 37 37 49 51 54 55 
13 37.5 38 51 50 33 32.5 45.5 45.5 61.5 62.5 
4 59.5 58.5 79 80 42.5 43 56.5 58 90.5 93 
<1 79.5 78 90 93 47.5 49 94 95 192.5 191.5 
12.2 44 44.5 50 50 36 35.5 46 46 68 68 
10.5 46 46 60 59.5 37.5 38 53 54.5 65.5 66 
9 45 44 57 57 35.5 36 49.5 48 62 62 
24 41 42 57.5 57.5 48 46.5 47 47 52 51 
<1 85 84 99 103.5 56.5 59 81 79 190 191.5 
2.8 79 81 116 118 51.5 51.5 73 71 117 112 
TABLE 8.12 APTT OF VON WILLEBRANDS PLASMA 
Actin Actin FS Activated Automated Manchester 
Thrombofax APTT APTT 
36.5 36.5 42.5 42 30 29.5 41.5 43 50 51 
37 37.5 46.5 47 33 33.5 42 42.5 55 54.5 
TABLE 8.13 APTT OF FXI DEFICIENT PLASMA 
Actin Actin FS Activated Automated Manchester 
Thrombofax APTT APTT 
39 39 53.5 53 34 33.5 41.5 42 57.5 58.5 
90 87 177 182 116 111 83.5 85 246 254 
49.5 50 69 68.5 53.5 54 57 58 94 95 
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TABLE 8.14 APTT OF FVIII INHIBITOR PLASMAS 
Actin Actin FS Activated Automated Manchester 
Thrombofax APTT APTT 
118 119 156.5 149.5 64 64 133 141 257 258 
94 97.5 114.5 118 52 53 122 127 271 270 
95 93 109 104.5 54 54.5 122.5 123 268.5 268 
81.5 79 99 100.5 49.5 51 97 96 160 162.5 
57 56.5 70.5 71 49.5 49 69.5 69.5 119.5 120 
TABLE 8.15 APTT OF LUPUS-LIKE INHIBITOR PLASMAS 






44.5 44.5 61.5 60 45.5 44.5 58 59.5 76 78 
38 39.5 45 46 32 32 45.5 46 50 52 
43.5 44.5 63 63.5 46 46.5 60.5 59 84 82.5 
58.5 60 42 43 38 37 60 61 56 57 
49 49 72 74 46 47.5 85 87 108 106 
29 29 30.5 31 27 26.5 32 32.5 51.5 53 
49.5 49.5 39 39 34.5 35 56 57 75.5 75 
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TABLE 8.16 APTT OF PLASMAS FROM HEPARINISED PATIENTS 






37 36 60 58.5 35.5 35.5 49.5 50.5 79 79 
51 50 81 81 42.5 42.5 80.5 82 81 80.5 
52 52 64 66 47 48 82 80 76 78 
43.5 45 61 61.5 40 38.5 60 65 64 66 
90 95 160 165.5 48.5 46.5 97 101 134 132 
93.5 95.5 96.5 97 59 59 136 141 90 89.5 
116.5 115 144 133 72 74 204 211.5 133 135 
35 34.5 47.5 46.5 32.5 32.5 54 54.5 58 58.5 
29.5 29.5 38.5 39 27 27 43 44 48.5 49 
30.5 31 39.5 40 28.5 29 40.5 41 65.5 66.5 
49 49 58 59 38.5 39 72.5 74 72.5 73 
31 31.5 37 37 27.5 27.5 41 40.5 46.5 46.5 
35.5 35 42 42.5 30 29.5 44.5 44 51.5 51.5 
32.5 32.5 43.5 42.5 29 29.5 47.5 48 53.5 54 
33 33.5 36.5 37.5 27.5 28 44.5 45 52 51 
41 41.5 44 43 36 35 53 53 68.5 70.5 
36 35 38.5 39 30.5 31 46 46 46.5 L6.55- 
33 32 35 35 27.5 27 44 45.5 45 45 
32 31.5 33 33 28.5 28.5 0 44 39 39 
31 31.5 38.5 39 28 28.5 45.5 44.5 49.5 49. r, - 
60.5 61.5 68 68.5 55.5 55 125 126.5 116 117.5 
35.5 37 45 46 31 31 51 51.5 58.5 58 
TABLE 8.17 APTT OF PLASMA WITH HEPARIN ADDED 
Actin Actin FS Activated Automated Manchester 
Thrombofax APTT APTT 
heparin 
added 
0.1 u/ml 35.5 36 57.5 57 38 37 48 49 78 79 
0.2 u/ml 42.5 43.5 87 86.5 51 51 65 67 110 111.5 
0.3 u/ml 52.5 54 133 135 61 62.5 83 83.5 138 140 
0.1 u/ml 34.5 35 50.5 52 34 34 50.5 49.5 76 74.5 
0.15 u/ml 39 37.5 63.5 63.5 40.5 40 55 54 102 101.5 
0.3 u/mi 48 47.5 90.5 95.5 50.5 50.5 77.5 80.5 158.5 156.5 
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With factor XI deficiencies, Automated APTT was the least 
sensitive. With factor VIII inhibitors, Activated Thrombofax was 
least sensitive and Manchester APTT the most. With lupus-like 
inhibitors Actin FS gave the poorest response and Manchester APTT 
the best. The other reagents failed with one plasma. The order of 
ranking with heparin in vivo differed from that in vitro. In 
heparinised patients Automated APTT gave the best ranking. 
Activated Thrombofax and Actin were the least sensitive to heparin 
both in vivo and in vitro. 
Discussion - this study reveals the extent of the differences 
in coagulation response between five of the most widely used APTT 
reagents and supports previous observations on their varied 
sensitivities to a spectrum of coagulation disorders (Sibley et al 
1973, Hoffmann and Meulendijk 1978, Hathaway et al 1979, Mannucci 
1982, Thomson and Poller 1985). The APTT methods included differ in 
several respects e. g. source of phospholipid (animal or vegetable, 
type and concentration of activator, type of buffer, presence or 
absence of protective additives and in their activation times. Some 
or all of these features may contribute to the variation in 
performance observed. It appears that calculation of the normal 
range should not be based simply on a mean value ±2 SD, but should 
be calculated with a correction for non-Gaussian distribution, as 
with the Manchester APTT. When this approach is used the major 
change observed was a lowering of the upper limit of normal in 
Actin, Automated APTT and Activated Thrombofax, with a concomitant 
increase in success rate in the detection of mild or borderline 
coagulation defects. The upper limit of normal was increased for 
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Actin FS, however, which should reduce the incidence of incorrectly 
classified normal plasmas at the upper limit of the range. 
The study also confirms that APTT methods exhibit variable 
abilities in the detection of coagulation abnormalities. The main 
function of the APTT test is to screen for intrinsic coagulation 
disorders. A reagent which is reliable over a wide range of 
coagulation defects would therefore be preferable. Ranking of the 
reagents was based on their relative performance within the 
individual coagulation defects. The rankings for the various 
defects have not been summed because a poor performance with one or 
more defects could be masked by good performance with others and may 
not be a reliable guide to the value of the APTT method as an 
overall screening procedure. 
There were some inconsistent results over the spectrum of 
clotting defects with some reagents. For example, Automated APTT 
obtained a good score with samples from heparinis, ed patients but was 
relatively poor in the detection of FVIII and FXI defects. On the 
other hand Actin FS performed well with FVIIIC defects but 
relatively badly with lupus-like inhibitors. The Manchester APTT 
performed reasonably well with all defects and gave the highest 
ranking with FVIII inhibitors, lupus-like inhibitors, moderate and 
severe haemophilia and FXI deficiencies. 
The response to in vivo and in vitro heparin was in most. 
instances paradoxical. A high ranking with in vivo studies was not 
necessarily reflected in vivo, or vice versa. In vitro studies were 
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included because of their popularity in measuring heparin effect by 
the APTT (Poller et al 1980, Stevenson et al 1983, Brandt and 
Triplett 1981, Triplett et al 1978, Shapiro et al 1977). The 
present study indicates, however, that the performance of APTT 
reagents on plasma samples heparinised in vitro cannot be regarded 
as a reliable guide to the results from heparinised patients. 
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8.6 TO DETERMINE WHETHER ANY STATISTICALLY SIGNIFICANT 
RELATIONSHIPS EXIST BETWEEN PERFORMANCE IN THE APTT TEST AND 
THE STRUCTURAL AND CHEMICAL CHARACTER OF THE TEST REAGENTS 
Aim - to test for correlation between the sensitivity of the 
reagents to a variety of coagulation defects and normal values 
reported in 8.5 and observations on size distribution, 
electrophoretic mobility and lipid composition described in Ch 8.1 
to 8.4. 
Methods - the method employed was Spearman's Rank Correlation 
test (Spearman 1904, Siegel 1956) which is described in Ch 6.21. 
Rank in clotting performance was compared with 
1 size of particles 
2 electrophoretic mobility 
3 total phospholipids (yg/test) 
4 mol % PS 
5 PS conc (, ag/test) 
6 mol % PC 
7 mol % PE 
8 mol % PI 
9 mol % SPH 
10 ratio of mol % PS to mol % PI 
11 ratio of negatively charged phospholipids to total 
phospholipids 
12 total neutral lipids (, ug/test) 
13 total fatty acids ()ig/test) 
14 ratio unsaturated/saturated fatty acids 
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Results - significant correlations between clotting studies and 
particle size, electrophoretic mobility and lipid composition, as 
listed above, are shown in table 8.19. These correlations were 
significant at the 5% level. There was a highly significant 
negative correlation between the quantity of PS per test and the 
normal control times; the less PS the longer the normal APTT. In 
testing of the severe haemophiliac plasmas a negative correlation 
was seen between APTT prolongation and mol % of PS, PS concentration 
per test and the ratio of negatively charged to total 
phospholipids. A strong positive correlation was seen between APTT 
prolongation and mol % of PC. Plasmas with FVIII inhibitors also 
showed negative correlations between APTT prolongation and PS 
concentration per test and ratio of negatively charged to total 
phospholipids. A strong positive correlation existed between APTT 
prolongation and liposome size within this group, the only 
correlation seen with particle size. 
Negative correlations existed between APTT prolongation and 
electrophoretic mobility in the FXI deficient plasmas and plasma 
heparinised in vitro. A negative correlation was also seen between 
APTT prolongation in the plasmas with lupus-like inhibitors and the 
total concentration of phospholipid per test. There were no 
significant correlations between clotting performance and the 
concentrations of PE, PI, SPH, ratio of PS to PI, total neutral 
lipids or total fatty acids. Further, it was not possible to 
correlate the ratio of unsaturated to saturated fatty acids in the 
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Discussion - the number of significant correlations between 
lipid content and reagents' procoagulant activities confirms the 
view that the performance of an APTT method is to a large extent 
dependent upon its lipid compositon (Stevenson et al 1983, Stevenson 
and Poller 1982, Barrowcliffe and Gray 1981a, 1981b, Slater et al 
1980). 
For example, the finding of a significant correlation between 
the concentration of PS and APTT prolongation in severe haemophilia 
supports the observations of Wagenvoord et al (19E3) and Yashioka et 
al (1983) that PS appears to have a specific associaticn with 
FVIII: C. 
Features that influence charge i. e. proportion and absolute 
concentration of PS and ratio of negatively charged phospholipid to 
total phospholipid, together with measurement of electrophoretic 
mobility dominate the table of correlations (Table 8.19). These 
correlations emphasize the importance of negative charge on the 
reagent liposomes, a finding described by Bangham (1961) and 
Papahadjopoulos et al (1962). 
The APTT test is the most common screening test for the 
detection of lupus-like inhibitors. The concentration of total 
phospholipid in the test is well known to govern the sensitivity of 
the method to the inhibitor (Kelsey et al 1984, Mannucci et al 
1979). This was confirmed in the present study by the observation 
that the five reagents evaluated contained markedly different 
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amounts of phospholipid. Actin FS had the highest concentration and 
performed least well, whereas Manchester APTT, with the lowest 
phospholipid concentration gave the highest ranking. 
Only one group of plasmas, the FVIII inhibitor group, showed 
any correlation with liposome size. This was a strong positive 
correlation i. e. APTT reagents with larger liposomes gave greater 
prolongation in the APTT test. Table 8.12 shows the size 
distribution in the various reagents and it is evident that there is 
a very wide range of size in each reagent, with considerable 
overlap. It might have been expected, therefore, that the reagents 
would perform in a broadly similar way, but this was not the case as 
fig 8.10 shows, with the Manchester reagent's performance being much 
better than that of Actin FS, Automated APTT and Actin whilst 
Activated Thrombofax performed relatively badly. 
The work described in sections 6.1 to E. 6 formed the basis for 
a paper entitled "The Reliability of Activated Partial 
Thromboplastin Time Methods and the Felationship to Lipid 
Composition and Ultrastructure" published in Thrombosis and 
Haemostasis, vol 55, pp 250 - 258 (1986), a reprint of which is 
appended. 
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8.7 PREPARATION OF A LIPOSOME WITH NEITHER PROCOAGULANT NOR 
ANTICOAGULANT ACTIVITY 
Aim - the value of a liposome with neither procoagulant nor 
anticoagulant activity in the APTT test would be considerable. Such 
a preparation could be used as a vehicle, into which other 
phospholipids could be incorporated to test their activity in the 
APTT test. 
Procedure - stock solutions of dipalmitoyl PC, PE and Chol were 
prepared, at a concentration of 10 g dm -3 in chloroform/methanol 
(95: 5 v/v). Aliquots from each stock were mixed in the proportion 
1: 1: 2 by volume (equivalent to a molar ratio of 17.55: 17.94: 64.52). 
Liposomes were prepared as described in Chapter 6.6 and three 
aliquots removed for testing of purity by two dimensional TLC, 
determination of the USFAR by GLC and for electron microscopic 
examination. These techniques are also described in Chapter 6.1, 
6.4 and 6.8. 
The liposome, in the range of concentrations from 100 mg dm 
3 
to 10-5 mg dm -3 of total lipid, was used to determine the APTT 
of a normal plasma and the clotting activity expressed as % of batch 
117 (see Ch 6.11). 
Results - purity testing by TLC revealed no evidence of 
degradation of the liposome components, i. e., there were three spots 
on the plate, with no evidence of free fatty acids or 
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lysophospholipids. Table 8.20 shows the results from the TLC 
examination. 
TABLE 8.20 LIPIDS EXTRACTED FROM 10 ml OF TEST LIPOSOME 
(100 mg dm- concentration) 
dipalmitoyl PC 246 ug 
PE 256 ug 
Chol 485 ug 
A number of conclusions may be drawn from this data. Firstly, 
there was no degradation of the lipids due to the manipulation 
required to prepare the liposome. Secondly, recovery of the 
individual components was good since the actual concentrations used 
were 250 ug of dipalmitoyl PC, 250 ug of PE and 500 ug Chol, i. e., 
some 98.7 % recovery on average. 
The ratio of unsaturated to saturated fatty acids in the 
mixture is shown in table 8.21 
TABLE 8.21 UNSATURATED TO SATURATED FATTY ACID RATIO OF TEST 
LIPOSOME 
0.51 
An electron micrograph of the test liposome is shown in fig 
8.11 and the results of the coagulation testing are shown in fig 
8.12. It may be seen that liposomes are formed from the hydration 
of this mixture of lipids, some multilamellar in form while others 
are less complex, comprising a unilamellar structure. A variety of 
intermediate forms is evident. 
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Fig. 8.11 (opposite) Electron micrograph of vehicle liposomes at a 
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Fig 8.12 Showing lack of activity of the vehicle 
lipcsome in the AP'IT test. 
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The coagulation testing reveals that there is negligible 
activity in the liposome, at high lipid concentration, and none 
whatever at concentrations less than 1 mg total lipid per litre. 
Discussion - the test mixture of lipids formed liposomes that 
had no activity, neither procoagulant nor anticoagulant. Fig 8.11 
shows that liposomes were formed, some multilamellar, some 
unilamellar, with a variety of intermediate forms also present. In 
testing of clotting activity, no difference was seen between the 
test mixture and saline control. Several important observations 
follow. Firstly, lipcsomes were formed, i. e., a lipid surface was 
provided and was svailatle in the test. Clearly, this particular 
surface made no contritution to the APTT test system. 
Secondly, a mixture of lipids was employed. Some early 
experiments, describing the use of individual lipid classes in 
clotting studies may not have been relevant or realistic since it is 
unlikely that in any natural system there will be single lipid 
classes available as clotting surfaces (see Ch 2). The mixture 
employed here comprised dipalmitoyl PC, chosen because of its 
saturation and stability, PE from bovine brains because of its 
degree of unsaturation, and cholesterol. All these components are 
to be found in natural membranes, although not in these 
proportions. The combination was useful also since the degree of 
unsaturation could be subsequently adjusted either by substituting 
synthetic unsaturated FCs or by adding natural unsaturated 
phospholipids in to the mixture. Tans et al (1979) have commented 
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on the relationship between procoagulant activity and lipid phase 
transitions. They observed that when the phospholipids in their 
test system were in the liquid phase i. e. the Lc* or liquid 
crystalline state (described in Chapter 2) there was a sharp 
increase in procoagulant activity. Demel and de Kruyff (1976) 
showed that introducing cholesterol into layers of PC had a 
condensing effect on bilayers in the liquid crystalline phase and a 
liquefying effect on bilayers in the gel state. They found that 
this effect was complete at cholesterol concentrations of 33 mol % 
and above. In the experiments described in the present work it was 
decided to include cholesterol at relatively high concentration so 
that the lipid mixture employed should be in the "intermediate" 
state described by Demel and de Kruyff and therefore show no marked 
procoagulant activity due to altered phase transition. Cholesterol 
has also been shown to confer structural stability on phospholipid 
bilayers, e. g. Papahadjopoulos et al (1973 a, b) Blok et al (1975). 
Inoue (1974) showed that diffusion of a variety of solutes through 
such bilayers is greatly reduced by incorporation of cholesterol and 
susceptibility towards phospholipase action is diminished (Op den 
Kamp et al 1975). Scherphof et al (1979) showed that cholesterol 
was protective against the plasma-induced solubilisation of 
multilamellar liposomes at the phase transition temperature. 
Gregoriadis and Davis (1979) reported a stabilising effect of 
cholesterol on small unilamellar vesicles made of egg PC and 
Finklestein and Weissmann (1979) reported on the beneficial effect 
of cholesterol on liposomal integrity in the presence of plasma or 
plasma constituents. Cholesterol was added to the lipsomes in this 
study with the above observations in mind. Thirdly, since the 
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liposomes formed by this mixture showed no clotting activity this 
meant that. it could be used as a "vehicle" for the testing of other 
lipid classes. 
Conclusion - it proved possible to construct a vehicle liposome 
with no clotting activity, but with a structure, confirmed by 
electron microscopy, into which other lipid classes could be 
inserted for testing of their coagulant properties. 
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8.8 TO DEMONSTRATE THE PROCOAGULANT PROPERTIES OF THE VEHICLE 
LIPOSOME INCORPORATING PHOSPHATIDYL SERINE 
Aim - to show whether phosphatidyl serine was able to confer 
procoagulant activity on the vehicle liposome. 
Procedure - the vehicle liposome was prepared as in the 
previous experiment but with the addition of PS, from bovine brain, 
in a range of concentration i. e. 0,1.1,1.6,1.8,3.1,3.75.6.25, 
11.25,16.95 and 20.4 mol %. Each lipsome was tested over a range 
of concentration from 100 mg to 1075 mg dm -3 of total lipid by 
measuring the APTT of normal plasma. Procoagulant activity was 
expressed as % of that of batch 117 of Manchester APTT reagent (see 
Ch 6.11). The USFAR for each mixture was calculated after gas 
liquid chromatography of the fatty acid methyl esters on capillary 
columns (see Ch 6.4). 
Results - some examples are given of the performance in the 
APTT test of the vehicle liposome in the absence of PS and with 
increasing relative concentration of PS. Fig 8.13a shows the 
clotting times given when the APTT of a normal plasma was measured 
using batch 117 (top line) and Owren's buffer (bottom line). The 
results when 117 was replaced by the vehicle lipsome at various 
concentrations of total lipid are shown by the broken line. It is 
clear that the vehicle liposome without PS shows no activity in the 
test system. Fig 8.13b shows the clotting times when the vehicle 
lipsome comprises 1.6 mol % of PS. It may be seen that there is now 
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Fig 8.13 Clotting activity of vehicle liposome without 
(a) and with increasing concentration of PS. b=1.6mol% PS, 
c=3. lcnol% PS, d=6.25mol% PS, e=20.4mol% PS. 
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falls below 1 mg dm-3. Fig 8.13c shows the performance of the 
vehicle liposome containing 3.1 mol % of PS. In this clotting time 
sequence the liposome at 100 mg dm-3 had the same activity as 
batch 117 and showed strong procoagulant activity down to 0.1 mg 
dm-3 of lipid. In Fig 8.13d, the PS level in the vehicle liposome 
was 6.25 mol %. This liposome had activity comparable to batch 117 
at 100 mg and 10 mg dm-3 concentrations and had to be diluted to 
levels of 10 }ag dm-3 or less before activity was extinguished. 
Fig 8.13e shows the result of using PS at 20.4 mol % in the vehicle 
liposome. Again, activity was high at the more concentrated end of 
the range. The best activity in each instance was shown at 
concentrations of 100 mg dm-?. 
It may be seen that the line indicating the APTT of plasmas in 
Fig 8.13, when Owren's buffer is used in place of an APTT reagent, 
is not at the same level in each experiment. The APTT using batch 
117 is the same as for the plasma in Fig 8.13a, c and d, which was 
from the same donor. The Owren's buffer value may differ because 
there may be some residual platelets or platelet fragments still ir, 
the plasma samples following centrifugation. These may accelerate 
the APTT by providing lipid surfaces. 
Fig 8.14 shows a plot of molar concentration of PS against 
percentage activity in the APTT test. The result for the liposomes 
containing 100 mg dm-3 of total lipid was used. From this plot it 
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Fig. 8.15 concentration of PS vs. USFAR 
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activity of the liposomes. The maximum activity is reached when PS 
is at, or above, a molar concentration of 1.8%. 
Fig 8.15 shows a plot of mol % of PS against the USFAR. This 
plot rises steadily and is not coincident with the activity plot 
that shows a steeply rising curve followed by a long plateau. 
Discussion - procoagulant activity was conferred on the vehicle 
liposome by the incorporation of PS. This activity reached the 
equivalent of 100% of that of batch 117 of the Manchester APTT 
reagent at a molar concentration of 1.8% and thereafter did not 
significantly alter over the range up to 20.4 mol %. Other workers 
have commented on the instability of liposomes containing large 
quantities of PS (Zwaal et al 1978) so it was decided not to proceed 
beyond this value. The dramatic increase in activity over the 
narrow range from C-1.8 mol % of PS demonstrates that PS is 
essential for procoagulant activity of liposomes and that, at low 
relative concentration, too little is available at the liposome 
surface for optimal coagulation to take place. At 1.8 mol % there 
is enough PS available at the liposome surface to provide an cptimal 
environment and there is no advantage in increasing the relative 
concentration of PS beyond this level. Presumably the available PS 
on the lipcsome surface must match the clotting proteins that 
interact with the phospholipid surface at 1.8 mol %. Above this 
level PS is in excess. The curve in Fig 8.14 resembles the 
classical curve of initial velocity versus substrate concentration 
seen in studies of the kinetics of enzyme-substrate interactions. 
In this study the requirement for PS in the lipid surface is 
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analogous to the requirement for substrate in kinetic studies. 
Above 1.8 mol % PS is in excess and the PS requirement is satisfied. 
With the incorporation of PS into the liposome there is a 
steady increase in the level of unsaturation. While this increase 
is maintained in a linear fashion with increasing PS concentration, 
it is clear that the activity of the liposome peaks at the 1.8 mol % 
PS level. The two curves in Fig 8.14 and Fig 8.15 therefore do not 
correlate. However, if the first four points on Fig 8.14 are 
analysed with respect to the first four on Fig 8.15, i. e. the area 
of steeply rising activity compared with increasing USFAR, a 
correlation can be found (correlation coefficient is 0.83 p<0.05) 
which is significant. It may be, therefore, that the level of 
unsaturation is important in the observed ircrea. cE" ]r, activity. 
The differences between the APTT of tie plasras used, both with 
batch 117 and Owren's buffer, is cf interest. Complete removal of 
platelets from the plasma would have been desirable but may not have 
been achieved entirely. This would account for the differences seen 
at the Owren's buffer end of the range. However, by using the batch 
117 results as 100% and the Owren's buffer results as 0% activity, 
it was possible to compare the activities of the liposome 
preparations on different days and with different plasmas. 
Conclusions - the incorporation of PS into the vehicle liposane 
rendered it active in the APTT test system, with concentrations of 
1.8 mol % and above providing a favourable catalytic surface for the 
coagulation proteins. The level of unsaturation is unlikely to be 
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the key determinant of the rapid increase seen in the activity 
curve. 
It was possible to construct a liposome, made from individual 
pure lipids, which showed the same procoagulant activity as batch 





8.9 TO DETERMINE THE COAGULANT PROPERTIES OF A PS-CONTAINING 
LIPOSOME UPON DILUTION 
Aim - to show the effect of dilution on the performance of a 
PS-containing liposomal suspension in the APTT test. 
Procedure -a liposome was prepared of the following 
composition - dipalmitoyl phosphatidyl choline, phophatidyl 
ethanolamine, phosphatidyl serine and cholesterol at 16,16,3 and 
65 mol % respectively. It was tested in the APTT system over the 
range 100 mg to 10-5mg dm-3 of total lipid. 
Result - Fig 8.16 shows the dilution curve of the PS-containing 
liposome. No anticoagulant activity was demonstrated at any 
concentration tested. 
Discussion - the PS-containing U pc: c ,e showed procoagulant 
activity over the entire range of concentraticn tested. Since the 
liposome under study was made up of four lipid classes, each 
individually checked for purity (see Chapter 6.7), it is reasonable 
to wonder whether some early work which reported PS to have 
anticoagulant activity, may have employed lipids that were not pure, 
in systems where liposomes were not formed, i. e., where "membranes" 
were not provided for the interaction of the clotting sequence 
(Marcus et al 1962, Troup and Reed 1958, Turner and Silver 1963, 
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3) 
Fig 8.16 Dilution curve of PS-containing liposome. 
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The "dilution curve" approach employed in this experiment 
proved useful as a device for characterising the coagulant activity 
of a liposome suspension. 
2S7 
8.10 TO DETERMINE WHETHER THE PROCOAGULANT ACTIVITY OF PS MAY BE 
REPLACED BY LYSO-PS, PG OR PI 
Aim - to test whether lyso-PS, PG or PI, phospholipids which, 
like PS, possess negative charge, will substitute for PS in the test 
mixture. 
Procedure -a liposome identical to that described in 
experiment 8.7 was prepared. This was arbitrarily designated the 
"standard" preparation. Four other liposomes were prepared 
according to the following table 
TABLE 8.22 COMPOSITION OF TEST LIPOSOMES 
1. DPPC PE lyso-PS CHOL 
15.42 16.52 5.07 62.99 
2. DPPC PE PG CHOL 
15.7 16.8 3.36 64.13 
3. DPPC PE PI CHOL 
15.77 16.89 2.93 64.41 
4. DPPC PE PS PI CHOL 
15.75 16.87 1.57 1.46 64.34 
Each liposome mixture was tested by preparing a dilution curve, 
as in experiment 8.7. The same range of concentration was used i. e. 
100 mg to 10-5 mg dm-3. 
The USFAR was determined by gas liquid chromatography of the 
methyl esters of the liposome fatty acids (see Ch 6.4). 
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Results - the coagulant activity test results are given in Fig 
8.17. Lyso-PS showed maximum procoagulant activity in the liposome 
suspension containing 100 mg dm -3 of total lipid. This activity, 
about 20% of batch 117, fell as total lipid reduced. 
PG showed no activity whatsoever in this test system - neither 
procoagulant nor anticoagulant. PI - containing liposornes at high 
total lipid concentration showed about 14510C cf the activity of batch 
117. Upon dilution, procoagulant activity was icst, to be replaced 
by a slight anticoagulant effect at concentrations of total lipid 
below 100 yg dm-3. When PS was replaced by a mixture of PS and 
PI, procoagulant activity was evident at high total lipid 
concentration (equivalent to 96% of the activity of batch 117). A 
quite dramatic anticoagulant effect was seen at lower total lipid 
concentrations, however. This effect was much more marked than in 
the 11posomes that contained PI alone. USFAF values are shown in 
Table 8.23. 
TABLE 8.23 UNSATURATED TO SATURATED FATTY ACID RATIOS OF THE FOUR 
TEST LIPOSOMES 





These values were close to that of the standard lipsome i. e. 
0.54 (see Ch 8.11) and there was no correlation between USFAR and 
activity in the APTT system. 
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Fig 8.17 Clotting performance of lipososes containing PI (x--x) 
PI+PS (e-=), lyeo_PS (t-+), and PG 1--I) ccmpared with a 
standard ligosome containing PS 
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Discussion - PS was unique in conferring procoagulant character 
in this test system. Lyso-PS with the identical head group and 
therefore the same net charge, could not replace its activity. PG 
was inert, which was a useful observation since it proved possible 
to use PG as a make-weight" in subsequent studies. 
The role of PI proved to be somewhat perplexing. Fig 8.17 
showed that PI in the vehicle liposome does exhibit some 
procoagulant activity, although at best less than half that shown by 
PS. The combination of PS and PI together showed good procoagulant 
activity at high concentration (sore 96% of that shown by PS alone) 
but a marked anticoagulant effect at low total lipid concentration. 
This anticoagulant effect was more marked than for PI alone. 
Revers and Zwaal (1988) reported that SPH and PE have a 
modulating effect on the prothrombirase and tenase activities at the 
activated platelet surface. In this present experiment it is clear 
that PI has some regulatory effect a'-so. 
Billah and Lapetina (1983) observed that PI concentration 
reduced upon platelet activation and subsequently rose to higher 
levels than in the resting platelet. This implies that PI has some 
inhibitory function. On the other hand it has been reported that PI 
is almost exclusively found on the cytoplasmic side of the platelet 
membrane (Chap et al 1977, Zwaal et al 1977, Zwaal 1978, Perret et 
al 1979, Schick 1979). This implies that it is procoagulant and is 
located away from the plasma clotting protein in the same way as 
PS. In vivo, PI metabolism is under control of a series of 
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reactions known as the PI cycle. Splitting of 
phosphatidyl-4,5-bisphosphate, (PIP2) by an endogenous phospholipase 
C (PLC) (Lapetina and Cuatrecases 1979, Bell and Majerus 1970) gives 
rise to inositol-1,4,5-triphosphate and diacylglycerol (DG). The 
former loses phosphate groups, one at a time, until myo-inositol 
remains. Meanwhile, DG is phosphorylated to form PA and PI is 
formed following an intermediate step involving cytidine 
diphosphate. Several important features occur in this cycle, e. g., 
DG activates protein kinase C, leading to phosphorylation of a 
protein, of 47,000 daltons molecular weight, that is essential in 
the secretion response (Siess et al 1983). Arachidonic acid is 
freed from DG by a PLC that is less Ca 
2+-dependent than the 
phospholipase A2 (PLA2) that splits arachidonic acid from PC and FE 
(Simon et al 1984). This reaction may free small amounts of 
arachidonic acid while cytoplasmic Ca2+ is at low concentration, 
until adequate Ca 
2+ 
concentration is achieved for stimulation of 
PLA2, which generates the major part of the free arachidonic acid. 
Cyclooxygenase and thromboxane synthetase enzymes, contained in 
platelet dense tubular system membranes are able to oxidise 
arachidonate to form endoperoxides and thromboxanes. Thromboxane A2 
is a potent platelet activator. PA, meanwhile, can act as a 
Cat+-ionophore and aid the influx of extracellular Cat+, which 
stimulates the release of arachidonate by PLA2 and activates 
contractile activity by an effect on myosin light chain kinase 
(Feinstein et al 1981, Hallam et al 1984). These are some of the in 
vivo events of the PI cycle. In the present experiment, the plasma 
used was essentially platelet-free so none of these can have taken 
place. Instead, PI will have been at a relative high, possibly 
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inhibitory concentration. This was clear at the highest 
concentration of total lipid, when the procoagulant activity was 96% 
that of batch 117 and even more marked at low total lipid levels 
when strong anticoagulant character was seen. 
It may be that there was sufficient PS available in the 
procoagulant liposome to override any inhibitory effect of PI. On 
dilution this effect became more marked. PI will have interfered 
with the packing density of PS in the liposome any may therefore 
alter the surface arrangement so that protein binding is 
inefficient. It is tempting to speculate that the "conformation 
model" of binding described by Forman and Nemerson (1986) and van 
Rijn et al (1986) may apply in this system and that the binding to 
the PI containing liposome induces a conformational change in the 
clotting enzyme that results in a molecule less able to bind soluble 
substrate. 
It has been suggested that negative charge is crucial in 
conferring procoagulant activity on a lipid mixture (Bangham 1961, 
Papahadjopoulos 1962, Daemen et al 1965, Marcus 1966, Bull et al 
1972). If this was all that was essential for expression of 
procoagulant activity then it should have been possible to replace 
PS by other phospholipids of negative charge. 
Conclusions - PS was unique in its ability to confer 
procoagulant activity on a liposome mixture. Lyso-PS, PG and PI 
could not substitute for PS in this test system. PG was completely 
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inert. This meant that it could safely be used as a "make-weight" 
in further studies. 
In certain circumstances, PI expressed procoagulant or 
anticoagulant character. In concert with PS, both these effects 
were greatly amplified. 
Finally, the difference in USFAR between the four test 
liposomes was not sufficient to explain the wide disparity in 
procoagulant properties observed. Differences in polar head group, 
charge, or in packing density due to fatty acyl composition may be 
more likely. This is considered in greater detail in Chapter 8.14. 
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8.11 TO DETERMINE THE EFFECT OF VARYING THE USFAR OF TEST LIPOSOMES 
Aims - to observe whether there are any changes to the dilution 
curves of liposomes prepared with widely differing levels of 
unsaturation. 
Procedure - the standard liposome was prepared as described 
above. Two more saturated liposome mixtures were prepared by 
substituting a synthetic dipalmitoyl PE for the natural PE of the 
standard mixture. A more unsaturated mixture was prepared by 
substituting dioleyl-PC for the dipalmitoyl PC of the standard 
mixture. Four types of liposomes were prepared in all with 
compositions as shown in table 8.24. 
TABLE 8.24 COMPOSITION OF TEST LIPOSOMES 
1. DPPC DPPE PS CHOL 
39 39 8 14 
2. DPPC DPPE PS CHOL 
15 15 7.5 62.5 
3. DPPC PE : PS : CHOL 
16 16 3 65 
4. DOPC PE PS CHOL 
14 5 17.3 65.5 
USFARs for these preparations were determined by GLC as 
described (Ch 6). Each liposome mixture was tested as described 
above and a dilution curve constructed. 




TABLE 8.25 USFAR OF LIPOSOME MIXTURE 





Figure 8.18 shows the result of testing the coagulant 
properties of the four liposome mixtures. At high total lipid 
concentration there is little difference between preparations 2,3 
and ü. Preparation no. 1, the most saturated, had less procoagulant 
activity than the others at each concentration tested. It was not 
until total lipid concentrations of 100 ug dm -3 or less were 
tested that further differences became apparent. The most striking 
observation was the strong anticogulant character of liposome 1, the 
most saturated mixture. Liposome 2 also showed some anticoagulant 
activity. Liposomes 3 and 4, which behaved in closely similar 
fashion at high total lipid concentration, had markedly different 
coagulant character at low lipid concentration, with liposome 4, the 
most unsaturated preparation, showing higher procoagulant activity 
in this area. 
Discussion - the degree of unsaturation of membrane fatty acids 
has been shown to influence their clotting activity e. g. Ploplis and 
Castellino (1980), Tans et al (1979). In this experiment 
four-component liposomes were made and unsaturation adjusted by 
substituting more or less saturated phospholipids into the 
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total lipid (mg dmý3) 
Fig 8.18 Coagulant activity of liposomes of 
varying USFAR. 1=0.04,2=0.10,3=0.54,4=3.67 
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as shown in table 8.24 with resultant change in the USFAR, shown in 
table 8.25. The overall trend, even though there was some change in 
the relative concentration of PS, was that the most saturated 
mixture was the least procoagulant at high lipid concentration. 
The relative concentrations of PS were within the range that 
gave optimal activity in the experiments described in Chapter 8.8 
(see Fig 8.14) i. e. 1.8 mol % to 20.4 mol %. PS should therefore be 
present in sufficient quantity. 
The most unsaturated mixture contained the highest procoagulant 
activity at every concentration tested. Changes in PS concentration 
were unlikely to account for this trend. The density of packing of 
the PS molecule in the liposome is more likely to be the determining 
factor - dense packing, as would be possible in a relatively 
saturated liposome where the fatty acyl cress-sectioned area is 
smaller than that in an unsaturated fatty acid environment (Lee 
1975, Mean 1986) would present an unfavourable surface for 
reaction. In the more unsaturated liposomes, the packing density 
will be reduced, with the result that PS is available in optimal 
configuration for interaction with the clotting proteins (Zwaal and 
Hemker 1982). There is really very little difference, in practice, 
between liposomes 3 and 4 at total lipid concentrations between 100 
mg and 0.1 mg dm -3 despite the substantial difference in USFAR. 
As seer, in Chapter 8.4, the major APTT reagents have total lipid 
concentrations of 0.33 to 75.31 fag per test. In the present 
experiment 100 mg dm-3 was the highest concentration tested. This 
is equivalent to 10 pg per test. This preparaticr. was then diluted 
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ten-fold at each stage of testing so that by the time the 10-1 mg 
dm-3 concentration was reached there was already less lipid 
present than in any of the commonly used APTT reagents. 
Conclusions - at high total lipid concentration there is little 
difference between the four test liposome preparations. Upon 
dilution, differences become apparent and the more unsaturated 
preparations retain procoagulant activity to lipid concentrations of 
10-5 mg dm-3 9 while the saturated preparations show some 
anticoagulant character at this low concentration. 
The work described in sections 8.7 to 8.11 formed the basis for 
a paper entitled "The procoagulant activity of partial 
thromboplastin extracts: the role of phosphatidyl serine" 
published in Thrombosis Research Vol 26 pp 341-350 (1982). A 
reprint of which is appended. 
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8.12 TO EVALUATE THE ROLE OF PHOSPHATIDYL SERINE IN CONFERRING 
SENSITIVITY TO HEPARIN ON THE APTT TEST 
Aim - to evaluate the effect of alterations in liposome 
mixtures used in the measurement of heparin by the APTT. 
Procedure - liposomes were prepared comprising di-palmitoyl PC, 
PE and Cholesterol. PS was incorporated in a range from 3 to 18 mol 
%. In order to maintain a constant total lipid concentration, 
phosphatidyl glycerol was added to bring the total lipid 
concentration to 100 mg dm 
3. PG was observed to have no activity 
in an earlier experiment (Expt 8.10). In a further series of 
liposome mixtures, PI was substituted for PS, to test for any 
activity in this system. In order to test the effect of reducing 
the total lipid available in the test system, liposomes were 
prepared at total lipid concentrations of 1000,100,50,30,20 and 
10 mg dm 
3. In each liposome the relative properties of the 
components were kept constant. PS concentration was 10.8 mol %. 
Coagulation testing was by using the liposome preparations instead 
of the Manchester APTT reagent in determining the APTT of fresh 
normal plasma before and after the addition of a range of 
concentrations (i. e. 0.05 u cri 
3 to 0.2 u cm 
?) 
of British 
Standard Heparin. A sensitivity ratio i. e. APTT of plasma with 
heparin/APTT of plasma without heparin was derived for each heparin 
concentration studied. The USFAR for each liposome mixture was 
determined by GLC. 
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Results - as the relative concentration of PS in the test 
system increased the APTT of plasma, with and without heparin, 
decreased as shown in Fig 8.19. The heparin sensitivity ratio was 
decreased as a result with increasing concentrations of PS (see Fig 
8.20). 
When PS was replaced by PI the APTT was markedly increased. 
Increasing the relative concentration of PI, however, did not 
decrease the APTT. The heparin sensitivity ratios showed no marked 
change with increasing concentrations of PI (see Figs 8.21 and 
8.22). Table 8.26 lists the USFAR of the mixtures containing PS and 
PI. The ratio of unsaturated to saturated fatty acids decreased 
with increasing PS and PI concentration. This was because the PG 
incorporated as makeweight had a higher level of unsaturat. cn than 
either the PS or PI. 
Alteration of the total lipid concentration from 1g dm -3 to 
100 mg dm-3 produced no change in either APTT or heparin 
sensitivity ratio, whereas the tests performed with 10 mg dm -3 of 
lipid increased the APTT and the sensitivity ratio, as shown in Figs 
8.23 and 8.24. The observation became more marked as the 
concentration of heparin increased. Figs 8.25 and 8.26 show that by 
testing a further range of total lipid concentration of 100,50,30, 
20 and 10 mg dm-3, the APTT and the heparin sensitivity ratios 
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Fig. 8.19 effect of increasing PS on APTT of heparinised plasma 
plasma with no additions 
ý--1. plasma + 0.05 u cm-3 heparin 
O. -O= plasma + 0.10 u cß-3 heparin 
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Fig 8.20 Effect of increasing PS concentration on the 
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Fig 8.21 Effect of replacing PS with PI on the APTT of 
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Fig 8.22 Effect of replacing PS with PI on the heparin 
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Fig. 8.24 Effect of decreasing total lipid on heparin 
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Fig. 8.25 Effect of decreasing total lipid on APT of 
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Fig 8.26 Effect of decreasing total lipid on heparin 




TABLE 8.26 USFAR WITH INCREASING PS OR PI 
PS 
mol % 3.6 7.2 10.8 14.5 18.1 
ratio 0.84 0.80 0.75 0.71 0.67 
PI 
mol % 3.2 6.5 9.8 13.2 16.6 
ratio 0.87 0.85 0.84 0.82 0.8 
i. 
Discussion - an important function of the APTT is its use in 
the laboratory monitoring of heparin therapy (Basu et al 1972). 
There is a good deal of variation in sensitivity to heparin among 
the commonly used commercial APTT methods (Poller et al 1980, Brandt 
and Triplett 1981). 
The main aim of this experiment was to show whether alterations 
in relative concentrations of PS and PI influence sensitivity to the 
heparin-induced defect. 
It is shown that the relative concentration of PS governs the 
sensitivity of the APTT test system to heparin. As the 
concentration of PS decreases senstivity to heparin increases. At 
the same time the procoagulant activity is reduced. Substitution of 
PS and PI was not beneficial; the procoagulant activity being 
markedly reduced and sensitivity to heparin remained unchanged over 
a wide range of concentration. In the experiment in which PS or PI 
concentrations were altered, the degree of unsaturation of the 
phospholipids was unimportant in promoting procoagulant activity and 
heparin sensitivity of the test system at the 100 mg dm -3 level of 
total lipid. As mentioned previously, Ploplis and Castellino (1980) 
and Tams et al (1979) considered that higher levels of unsaturation 
promote increased clotting activity. In expt 8.11, it was shown 
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that this effect occurred only when the total lipid concentration 
was below 100 pg dm 
3. The observed effects in this experiment 
are likely, therefore, to be due to changing in unsaturation. 
It appears that in the APTT test system, lipid is in excess at 
levels over 30 mg dm 
3. Below this level lipid concentration 
becomes critical, with small reductions in concentration resulting 
in marked loss of procoagulant activity and an increase in heparin 
sensitivity. The loss of procoagulant activity on dilution of total 
lipid has been observed by Zwaal et al (1977). They showed a marked 
loss of procoagulant activity upon dilution of a phospholipid 
liposome which was designed to resemble the cytoplasmic surface of 
the platelet membrane. 
Conclusions - heparin sensitivity may be adjusted by altering 
relative PS concentration. When total lipid concentration is less 
than 30 mg dm-3 it. becomes critical for the clotting time and 
marked increases in sensitivity to heparin are obtained at extreme 
dilution. 
The work described in this section formed the basis of a paper 
entitled "Lipid class composition and heparin sensitivity in the 
activated partial thromboplastin time" published in Thrombosis and 
Haemostasis Vol 50, pp 601-603 (1983), a copy of which is appended. 
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8.13 TO EVALUATE THE ROLE OF PS IN THE DIAGNOSIS OF LUPUS-LIKE 
ANTICOAGULANTS (LLA) BY THE APTT 
Aim - to investigate further the mode of action of LLA and to 
determine which phospholipids are involved, with a view to 
simplification of laboratory diagnosis. 
Procedure - for this experiment it was decided that prepared 
liposomes should be added to the Manchester APTT test system. This 
system already contained an aliquot of the Manchester APTT reagent, 
described in detail in experiments 8.1 to 8.6 above. The idea of 
addition of extra lipid follows from the observations of Triplett et 
al (1983) using lysed platelets. 
Liposomes were prepared as described in Ch 6. The vehicle 
liposome was used in order to test a variety of phospholipids 
incorporated into it. PS, PI, PG, PA and lyso-PS were added in 
increasing concentrations from 10 mg dm -3 to 12C mg dm 
3. 
Liposomes containing PS were prepared with total lipid 
Concentrations ranging from 100 mg dm -3 to 1600 mg dm-3. The 
proportions of components remained constant. Preliminary tests 
showed that optimal effect in inhibiting the action of lupus-like 
anticoagulants was found using liposomes with a total lipid 
concentration of 400 mg dm-3 and this concentration was used in 
subsequent coagulation tests. For one experiment, the Manchester 
APTT was used to measure the clotting time of a plasma containing a 
LLA. The test was repeated using increasing concentrations of the 
reagent. 
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For coagulation studies, plasma samples from six consecutive 
patients with LLA (table 8.27) were compared with those from seven 
haemophiliacs with FVIII inhibitors. Plasma from patients with 
prolonged APTT due to a variety of other causes was also studied. 
The presence of a LLA was confirmed by demonstration of an immediate 
acting inhibitor, tissue thromboplastin inhibition and typical 
results in mixing with normal plasma with the kaolin clotting time. 
The APTT was measured by the routine method described in Ch 6. To 
this test system was added either 0.1 cm3 of test liposome 
suspension or 0.1 cm3 of buffered saline as control. 
One stage assays of factors VIII and IX were performed on 
patients with lupus inhibitors using the Manchester APTT reagent as 
the source of lipid and repeated sequentially with the addition of 
the "standard liposome" suspension to both test and standard 
plasmas. 
TABLE 8.27 CLINICAL DETAILS OF PATIENTS WITH LUPUS ANTICOAGULANT 




(a) 33 F SLE + 
(b) 23 M SLE + + 
(c) 25 F SLE + + 
(d) 26 F Mixed Connective + + 
Tissue Disease 
(e) 78 F *None + 
(f) 25 M *None + 
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Fig. 8.27 Effect of increasing concentration of APTT reagent 
on the APTT of a plasma containing a lupus 
naticoagulant. 
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TABLE 8.28 PLASMA CONTAINING A LUPUS ANTICOAGULANT 
Effect of adding a standard four component 
liposome containing phosphatidyl serine. 
Patient APTT Saline - APTT PS liposome APTT Difference APTT - Seconds Seconds Seconds PS Liposome APTT 
Seconds 
Normal 42 45 39 3 
(a) 80 73 56 24 
(b) 96 101 49 47 
(c) 108 100 55 53 
(d) 65 64 54 11 
(e) 109 99 57 52 
(f)* 130 122 86 44 
(g) 73 73 43 30 
*same patient as (e) tested in different occasions when overdosed 
with oral anticoagulants (INR > 5.0). 
TABLE 8.29 APTT OF PLASMA CONTAINING FVIII AND FIX INHIBITOR 
Inhibitor APTT Saline PS-liposome Difference 
sec. APTT sec. APTT - PS- 
sec. liposome 
APTT 
VIII 1.2 u/ml 265 272 264 1 
VIII 1.48 u/ml 149 167 155 -6 IX 2.32 u/ml 245 239 265 -20 
VIII 8.8 u/ml 174 207 189 -15 
*VIII 10.6 u/ml 296 343 237 59 
*VIII 9.2 u/ml 292 347 239 53 
VIII 62 u/ml 172 212 213 -41 
VIII 136 u/ml 171 213 218 -47 
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Fig. 8.28 effect on the APTT of a plasma containing a lupus 
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Fig 8.29 Effect on the APTT of plasmas containing a lupus 
anticoagulant of replacing PS with other phospholipids. 
Patients b and f as in Table 8.28. 
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TABLE 8.30 EFFECT OF ADDITION OF STANDARD PS-LIPOSOME TO PLASMA 
FROM PATIENTS WITH VARIOUS ABNORMALITIES 
Clinical Situation APTT Saline PS-liposome Difference 
seconds APTT APTT APTT - PS- 
seconds seconds liposome 
seconds 
Heparin 435 375 395 40 
Heparin 84 92 65 19 
Heparin + Coumarin 107 118 92 15 
Counarin 49 55 57 -8 
Heparin + Protamin 47 57 65 -18 (Post Cardiac Bypass) 
Heparin + Protamine 45 53 55 -10 
VIII Deficient(VIIIC-21%) 65 69 69 -4 
VIII Deficient(VIIIC= 1%) 195 240 221 -26 
IX Deficient (IX-30%) 63 74 73 -12 
XI Deficient (XI=30%) 72 83 80 -8 XI Deficient (XI-24%) 52 58 68 -12 
XII Deficient (XII=1%) 180 230 234 -54 
TABLE 8.31 FACTOR IX ASSAY ON PATIENT WITH LUPUS-LIKE ANTICOAGULANT* 
Effects of Addition of Liposome Containing PS 
Test Diluticn Factor IX Factor IX 
without liposome with liposome 
1/20 10% 40% 
1/40 14% 40% 
1/100 20% 40% 
1/200 30% 40% 
*patient on oral anticoagulants conco! r_tantly 
Results - an increase in the concentration of the Manchester 
APTT reagent corrected the prolongation of the test resulting from 
lupus anticoagulants (Fig 8.27). Similarly, the addition of a 
standard liposome containing 400 mg dm' of total lipid caused 
significant shortening of the APTT of all the lupus inhibitor 
plasmas tested (table 8.28). When the quantity of PS in a standard 
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liposome was varied (while maintaining the total lipid content at 
400 mg dm-3) there was progressive shortening of the APTT as PS 
content increased. This acceleration was significant as very small 
increases in PS were made (Fig 8.28). 
When other phospholipids were substituted for PS in the same 
vehicle liposome and in the same proportion there was no shortening 
of the APTT (Fig 8.29). When plasma from patients with specific 
inhibitors to factor VIII and IX respectively were tested using the 
standard liposome, containing PS in the same proportion, there was 
only one patient in whom the APTT showed appreciable shortening. 
Even with this patient's plasma, however, the APTT was still 
excessively prolonged (> 200 sec) (Table 8.29). 
Plasma from patients with a prolonged APTT due to factor 
deficiencies and anticoagulant therapy were tested in a similar 
manner. Significant shortening of the APTT occurred only in those 
patients receiving heparin. In patients with factor deficiencies 
the addition of the standard liposome lead to a prolongation of the 
APTT similar to that seen on addition of saline and which was 
ascribed to a dilution effect (table 8.30). When one stage assays 
of factor VIII and IX were carried out on the plasmas containing 
lupus inhibitors a characteristic pattern was observed in all 
cases. Non-parallel dilution response curves were found, with an 
apparent increase in the measured factor at high test dilution. In 
contrast, when the assay was repeated with the addition of the 
standard vehicle liposome containing PS, the dilution response 
curves became parallel indicating that the inhibitor had been 
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overcome. Table 8.31 shows an example of a factor IX assay on a 
patient with LLA who was receiving concomitant oral anticoagulation 
treatment. This was a typical pattern in all the lupus inhibitor 
plasmas tested. 
Discussion - lupus-like anticoagulant is a spontaneously 
acquired immunoglobulin, usually lgG or 1gM, that occurs in a 
variety of clinical situations and interferes with most 
phospholipid-dependent coagulation tests. Feinstein and Rapaport 
(1972) coined the term lupus anticoagulant twenty years after Conley 
and Hartmann first described two patients with systemic lupus 
erythematosis and a coagulation inhibitor. The disorder is not 
associated with a haemorrhagic diathesis unless some abnormality of 
clotting proteins or of the platelets is also present (Shapiro and 
Thiagarajan 1982). There appears to be an increase in 
thromobembolic events however, in patients with the abnormality, as 
well as a high rate of spontaneous abortion (Bowie et al 1963, Elias 
and Elder 1984, Carreras et al 1981, Ware Branch et al 1985). More 
recently, it has been shown that a high percentage of patients with 
AIDS possess the LLA (Bloom et al 1986, Cohen et al 1986). 
The laboratory diagnosis of LLA is based on the presence of an 
immediate acting inhibitor, evidence of tissue thromboplastin 
inhibition and demonstration of the "lupus cofactor" effect i. e. the 
enhancement of the effect by the addition of normal plasma 
(Schleider et al 1976, Exner et al 1978). Recent work (Triplett et 
al 1983, Coots et al 1981) has shown that the tissue thromboplastin 
inhibition test is not sufficientlly specific and cannot reliably 
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distingish between inhibitors of the lupus type, specific factor 
inhibitors and other causes of prolonged APTT. Triplett et al 
(1983) have suggested using the addition of lysed platelets to the 
APTT system. It is confirmed that in an APTT test system the effect 
of the LA can be overcome simply by increasing the concentration of 
lipid available. Furthermore, PS plays a key role in governing this 
effect. The value of the vehicle liposome has again been 
demonstrated in providing a catalytic surface for coagulation factor 
interaction. 
Antibodies to various phospholipids have been found in 
association with naturally occurring LLA (Thiagarajan and Shapiro 
1983) and have also been demonstrated in monoclonal lupus 
autoantibodies produced by hybridoma techniques (Lafer et al 1981). 
It is widely assumed that the inhibitor acts by interference with 
the binding of vitamin K-dependent clotting factors to lipid 
surfaces and this effect has been demonstrated experimentally 
(Thiagarajan et al 1980). 
In this experiment, firm evidence of the specificity of the 
effect of a PS-containing liposome is provided by the demonstration 
of acceleration of the prolonged APTT due to lupus-like 
anticoagulants and the lack of effect on prolonged APTT results 
caused by other types of inhibitor, factor deficiencies and oral 
anticoagulants. 
Conclusions - it is further demonstrated that PS plays a unique 
role in APTT reagents. Also, support is given to the notion that 
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the LLA acts by competing with coagulation factors for sites on 
procoagulant lipid surfaces. Some evidence is given to explain the 
different sensitivities of various commercial APTT reagents to the 
LLA, (Manucci et al 1971, Brandt et al 1987), which may be due to 
differences in their total lipid content or in relative 
concentration of individual lipid classes. It is worthy of note 
that some commercial houses now produce APTT reagents said to be 
sensitive to the LLA when used in conjunction with their existing 
reagents to provide test systems of contrasting high and low lipid 
concentration e. g. Dade "Actin FSL", Biodata "Platelet Extract". 
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8.14 DISCUSSION 
The activated partial thromboplastin time test is one of the 
most widely used tests in coagulation studies. Its main functions 
are to screen for intrinsic clotting factor defects and to monitor 
heparin therapy. In addition, the test may be used as a screening 
test for the detection of lupus-like anticoagulants. An ideal APTT 
reagent would be one which would show good sensitivity to all of 
these. 
The considerable extent of the differences between the various 
APTT reagents' coagulation responses to a spectrum of disorders has 
been noted on many occasions (e. g. Poller and Thomson 1972, Sibley 
et al 1973, Hathaway et al 1979, Manucci 1982). Attempts have been 
made to improve the APTT test system by employing various 
activators, such as ellagic acid (Ratnoff and Crum 1964) or silica 
(Margolis 1961) and adjusting activation times and buffering of the 
test system. 
The source of the reagent lipids, the relative concentration of 
constituent lipid classes and the physical form of the reagents has 
not been studied. The aim of the experimental series described in 
Chapter 8 was to examine some widely used APTT reagents to elucidate 
their morphology, coagulation responses and lipid composition and to 
determine whether any of these features correlated. There is no 
published evidence of similar approaches to this topic, on such a 
scale as presented in this thesis. It was intended that the 
information derived from these experiments could then be employed in 
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the task of defining the optimal lipid constituents required in test 
systems designed for specific functions, e. g. for the monitoring of 
heparin therapy and for the diagnosis of the lupus-like 
anticoagulant. 
In experiment 8.1 it was shown that the five commonly-used APTT 
reagents examined possessed a common structure i. e. they were made 
up of liposomes. A great variety of size and form was observed. 
The measurement of size and surface charge was the subject of 
experiments 8.2 and 8.3 and again revealed wide variation between 
reagents. 
An early attempt to relate structure to activity was made by 
Rouser et al (1958) and Rouser and Schloredt (1958) who concluded, 
after testing a series of natural and synthetic lipids, that there 
was a requirement for phosphatides to be in a dispersed colloidal 
particle in order to show activity. It was not until 1961 that 
Rouser et al described a technique to separate PE from PS. This 
method allowed Marcus et al (1962) to study PS in more detail in a 
clotting test system. It is unfortunate that Rouser's experiments 
were flawed, because of the contamination of PE with PS, but 
nevertheless he was correct in his conclusion about the 
"particulate" nature of the lipid. Wallach et al (1959) described 
injecting ethereal solutions of phosphatides into aqueous buffers to 
form suspensions with clot promoting activity -a technique now 
routinely employed to manufacture liposomes and known as 
reverse-phase evaporation (Sjoka and Papahadjopoulos 1980). The 
electron micrographs in Chapter 8.1 confirm the suggestion of Rouser 
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et al that a discrete structure is essential for lipids to optimally 
promote clotting. Chapter 8.3 dealt with the charge on the 
liposomes of the various APTT reagents. It was observed that all 
the reagent liposomes tested had a negative charge and that this 
feature showed negative correlation with APTT prolongation in FXI 
deficient plasmas and plasmas heparinised in vitro. In their 
experiments, Bangham (1961) and Papahadjopoulos et al (1962) used 
lipid vesicles in a clotting time test of normal plasma and found 
that activity in such a system correlated with negative charge. 
Table 8.19 shows that, in the present work, the only parameter that 
correlated with normal plasma APTT was the quantity of PS per test. 
The convenience of use of the Malvern Instruments Autosizer and 
Zetasizer devices was a great advantage in Chapter 8.2 and 8.3, 
allowing the speedy determination of size and electrophoretic 
mobility of reagent liposomes. The lipid composition of the five 
APTT reagents was determined in Chapter 8.14. Actin FS, made from 
soya beans, was shown to have a different lipid distribution from 
that of the other four reagents, of animal origin. These had a 
broadly similar distribution of phospholipid classes as shown in Fig 
8.7, although there was a wide range of total lipid concentration 
per test (Table 8.6) with the Mancheser APTT containing 0.25 }ig 
total phospholipid per test while Actin had 9.88, pg, Automated APTT 
had 12.28 dug and Activated Thrombofax 18.6 pg. Actin FS contained 
63.31 pg. The reagents also showed differences in neutral lipid 
composition and in distribution of fatty acids. The ratios of 
unsaturated to saturated fatty acids (shown in table 8.8) ranged 
from 0.78 for Actin to 2.54 for Actin FS. Linoleic acid (18.2) was 
the major component of the unsaturated fatty acids of Actin FS. In 
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the reagents of animal origin the major unsaturated fatty acids were 
oleic (18: 1), arachidonic (20: 4) and docosahexaenoic (22: 6). 
Stearic acid (18: 0) was the major saturated fatty acid in these 
preparations. 
Chapter 8.5 dealt with the performance of the five APTT 
reagents in testing the APTT of plasmas from a variety of normal and 
abnormal sources. Care was taken to test a sufficient number of 
plasmas for the derivation of a normal range for each reagent. It 
proved necessary to transform the normal data in order to achieve a 
Gaussian distribution. When this was done it was possible to 
calculate the ratios of the APTT of abnormal plasmas/higher limit of 
transformed normal range. Then, reagents were ranked according to 
their performance in measuring the APTT of the various abnormal 
plasmas. Fig 8.9 shows this ranking. A number of points of 
interest emerge from this experiment. The reagents showed varied 
sensitivities to a spectrum of coagulation disorders. This has been 
commented on previously, e. g., Sibley et al (1973), Manucci (1982), 
Thomson and Poller (1985). When the upper limit of the transformed 
normal range was used to calculate ratios, the major change observed 
was a lowering of the upper limit of normal in Actin, Automated APTT 
and Activated Thrombofax, with an increase in success rate in the 
detection of mild or border line coagulation defects. The 
implication is that great care must be taken in defining normal 
ranges. In chapter 8.6 an assessment was made of the foregoing 
experiments in order to test for correlation between the clotting 
performance data and the observations on size distribution, 
electrophoretic mobility and lipid composition. To do this, the 
325 
rank in clotting performance achieved by each of the reagents was 
compared with a number of observations of size, mobility and lipid 
composition using Spearman's Rank Correlation test. Table 8.19 
shows those correlations that were significant at the 5% level. 
Features that influence charge i. e. proportion and absolute 
concentration of PS and ratio of negatively charged phospholipid to 
total phospholipid are prominent in the table of significant 
correlations. These emphasize the importance of negative charge on 
the reagent liposomes. 
The concentration of total phospholipid was said to govern the 
sensitivity of the method to the presence of lupus-like inhibitor 
(Manucci et al 1979). This was confirmed in the present study. 
Actin FS, with the highest concentration of phospholipids, ranked 
lowest with lupus-like inhibitor containing plasma while Manchester 
APTT, with the lowest phospholipid concentration, gave the highest 
ranking. 
The next experiments were built on the base provided by those 
already discussed. By constructing liposomes of varying 
composition, it was hoped that the role of PS could be clarified, 
since it was clearly of the greatest importance. Table 8.19 showed 
that PS had influence in promoting potent clotting activity of 
normal plasmas and in sensitivity to FVIII and XI deficient plasmas, 
plasmas with a FVIII inhibitor or lupus-like inhibitor and 
sensitivity to the defect caused by addition of heparin to normal 
plasma in vitro. 
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It was decided that a liposome should be constructed of 
individual pure phospholipids and cholesterol. This liposome should 
be tested to show that there was no deterioration of its components 
and examined by electron microscopy to ensure that it was genuinely 
a liposome i. e. that it showed a lipid membrane enclosing an aqueous 
compartment. The liposome should then be tested in the APTT system 
by using it in place of the Manchester APTT reagent. Activity was 
expressed as % of that shown by batch 117 of the Manchester APTT 
reagent, the internal 'house' standard preparation in use at that 
time in the UK Reference Laboratory. It was hoped that this 
liposome would show no activity whatsoever in the APTT system. 
Chapter 8.7 shows that it was possible to prepare a liposome, whose 
structure was confirmed by electron microscopy, that possessed 
neither procoagulant nor anticoagulant activity in the APTT system. 
This liposome could serve as a vehicle for other phospholipids, 
therefore, while contributing no activity of its own to the test 
system. 
We may conclude that, as Rouser suspected, there must be a 
particulate structure so that there can be activity in a lipid 
mixture, but also, that there can be similar structures without any 
activity whatsoever. The next experiment showed the effect on the 
activity in the APTT system of this vehicle liposome containing 
increasing amounts of PS. Procoagulant activity was conferred on 
the liposome by PS incorporation and was maximal at a molar 
concentration of PS of 1.8% and above. This was a most important 
observation and demonstrated that it was possible to construct a 
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liposome made from individual pure lipids which showed the same 
procoagulant activity as batch 117, extract of human brain lipids. 
In the next experiment (Ch 8.9) a PS-containing liposome was 
tested in the APTT system over the range of concentration 100 mg to 
10-5 mg dm -3 of total lipid. Fig 8.16 shows the loss of 
procoagulant activity upon dilution of the liposome. There is no 
evidence of any anticoagulant activity, contrary to reports by 
Marcus (1962), Troup and Reed (1958), Mustard et al (1962) and 
Turner and Silver (1963). These workers may have employed lipids 
that were not pure, in systems where liposomes were not formed. 
In the next experiment (Ch 8.10), PS was replaced by a range of 
other phospholipids. Lyso-PS, PG and PI were used in place of PS in 
the vehicle liposome. A mixture of PI and PS was also employed 
instead of PS. The results showed that PS was unique in its ability 
to confer procoagulant activity on this liposome mixture. Lyso-PS 
and PI both showed iow activity while PG was completely inert. This 
proved useful since it meant that PG could be used as a make-weight 
in later experiments. The activity shown by PI was of great 
interest since it could be expressed as procoagulant or 
anticoagulant depending on the circumstances. When PI was used in 
equimolar mixtures with PS, both these effects were greatly 
amplified. 
In the next experiment the USFAR of the test liposomes was 
varied (see Ch 8.11). At high total lipid concentration there was 
little difference between the preparations with USFARs of 0.1, C. 54 
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and 0.67. The most saturated preparation, with USFAR of 0.04 had 
less procoagulant activity than the other mixtures at every 
concentration tested. This liposome showed strong anticoagulant 
activity upon dilution while the most unsaturated mixture showed 
procoagulant activity even at concentration of total lipid of 10-5 
mg dm 
3. The degree of unsaturation of membrane fatty acids was 
shown to influence their clotting activity by Ploplis and Castellino 
(1980) and by Tans et al (1979). The experiment provides further 
evidence for this view and demonstrates that at total lipid 
concentrations below approximately 1 mg dm -3 a low USFAR liposome 
shows strong anticoagulant activity while a high USFAR preparation 
is procoagulant. 
In Chapter 8.12 the role of PS in sensitivity to heparin is 
considered and it was shown that the relative concentration of PS in 
the vehicle liposome governed the sensitivity of the APTT test 
system to heparin. As the concentration of PS decreased the 
sensitivty to heparin increased. Substitution of PS by PI was not 
beneficial. It appeared in these experiments that total lipid was 
in excess at concentrations above 30 mg dm 
3. Below this 
concentration, lipid becomes the limiting factor, with small 
reductions in concentration resulting in marked loss of procoagulant 
activity and an increase in heparin sensitivity. Zwaal et al (1977) 
observed the loss of procoagulant activity that followed dilution of 
total lipid in a liposome designed to resemble the cytoplasmic side 
of the platelet membrane. 
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The final experiments in the series are described in Chapter 
8.13 and were designed to evaluate the role of PS in the diagnosis 
of lupus-like anticoagulants by the APTT test. Manucci et al (1979) 
and Brandt et al (1987) have observed the different sensitivities of 
various APTT reagents to the LLA. Further evidence of this 
difference is presented above and a possible explanation is 
presented in the light of the experiments in Chapter 8.13 of the 
role of PS in detection of the presence of a LLA. 
These experiments support the view that the LLA acts by 
competing with coagulation factors for binding sites on procoagulant 
lipid surfaces. A reagent which is insensitive to the presence of 
the LLA is likely to have a high concentration of total lipid and be 
rich in PS while a sensitive reagent will show the reverse i. e. low 
total lipid concentration with relatively low PS. The use of both 
sensitive and insensitive reagents may offer a better diagnostic 
test. This observation has been acted upon by some commercial 
producers and a number of alternative lipid preparations are now 
available for this test e. g. the Platelet Extract Reagent made by 
the BioData Corporation of Hatboro, USA, and Actin FSL made by Dade. 
In Chapters 2 and 4, there was some discussion about the form 
of membranes and of lipids in hydrated systems. In preparing the 
liposomes described above a standard technique was employed i. e. 
lipids were dissolved in solvents, usually chloroform or chloroform: 
methanol mixtures, taken to dryness under oxygen-free nitrogen and 
then hydrated. The aqueous phase used in this step was heated, 
before addition to the dried lipid, to a temperature above the 
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highest transition temperature (To) in the lipid mixture and 
sonicated at this temperature. The fact that these preparations 
formed liposomes, on the one hand, as was demonstrated in Fig 8.11, 
and performed well in the APTT, on the other, shows that a membrane 
was available for the interaction of the clotting proteins that bore 
a reasonable resemblance to a natural membrane. A number of workers 
have reported on the way in which hydrated lipids form liposomes. 
Berden et al (1975) and Barsukov et al (1980), using nuclear 
magnetic resonance, observed that vesicles composed of PC with 
acidic phospholipids formed with the latter predominantly located in 
the inner monolayer. In vesicles of PC and PS the latter was 
located predominantly on the inner side at low pH but preferred the 
outer side at higher pH. At given pH values and sizes of vesicles, 
the final transmembrane distribution depended upon the relative area 
occupied by the polar head groups of each phospholipid and on their 
surface charges. Cullis and de Kruyff (1979) examined lipid 
polymorphism in membranes and were of the opinion that the shape of 
a particular phospholipid molecule was of the greatest importance in 
regulating what sort of phase it would form, e. g., 
lyso-phospholipids and detergents were shown to be in the shape of 
an inverted cone with the polar head at the non-pointed end. These 
molecules spontaneously form micellar or hexagonalII phase. PE, 
and cardiolipin, and phosphatidic acid in the presence of Cat+, 
form a hexagonalll phase, as do PA at pH <3 and PS at pH < 4.0. 
In the case of these molecules, the polar head group is at the 
pointed end of the cone. PC, SPH, PS, PI, PG, PA and cardiolipin 
form cylindrical shapes and, according to these authors, readily 
form lamellar phase. There is great disagreement, however, about 
331 
the way in which membranes form in hydrated systems. Several 
reports in favour of the spontaneous formation idea have been 
published (Israelachvili et al 1975,1976,1977,1980 and Mitchell 
and Ninham 1981). An alternative view was presented by Helfrich 
(1974), Fromherz (1983), and Lasic (1982) who picture the 
phospholipid vesicle as a distortion of a planar membrane which 
requires energy for its formation and which is inherently unstable. 
Cornell et al (1982) showed that the minimum radius obtained for 
liposomes was independent of the hydrocarbon chain length when this 
was in the range from 12 to 18 carbons. The minimum radius of egg 
yolk PC vesicles was 10.7 ± 0.3 nm. This result was opposite to the 
findings of Israelachvili (1977). Cornell et al (1986) concluded 
that the spontaneous vesicle formation model only applies to a 
limited class of molecules where the electrostatic term (a term 
which in PC, for example, describes the interaction energy between 
the phosphorus atom of the phosphate group and the nitrogen atom of 
the choline group) is the dominant free energy contribution which 
drives the bilayer to a more curved geometry. In the case of PC 
they suggest that the flexibility of the zwitterion eliminates this 
term causing the planar geometry to be the preferred state. The 
phase behaviour of complex mixtures of acidic and neutral polar 
lipids tends to be dominated by the charged component. Gounaris et 
al (1983) made detailed studies of polar lipid extracts from 
chloroplast thylakoid membranes dispersed in aqueous systems. They 
observed that small bilayer vesicles were formed in distilled 
water. When the charge on the major acidic lipids was neutralized 
by reducing the pH or by addition of low concentrations (< 5 mmol 
dm- 3) of metal cations, fusion of the vesicles resulted and a 
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phase separation of the non-bilayer forming lipids followed with 
formation of inverted micelles sandwiched within a lipid bilayer. 
De Kruiyff et al (1979) and Verkleij et al (1979) studied the effect 
of polyvalent ions on cardiolipiin in mixed layers of cardiolipin 
and PC. They showed that a complex of Ca 
2+ 
with cardiolipin 
formed hexagonal,, phase very readily. Stabilising the lipid 
phase therefore appears to be an important role for charged lipids. 
Cullis and Verkleij (1979) showed that in the absence of Cat+, PS 
stabilizes the bilayer structure formed by an extract of red blood 
cell and platelet lipids. 
A recent study by Rauch et al (1986) showed that hexagonalII 
phase phospholipids, including natural and synthetic forms of PE 
were able to neutralize the lupus anticoagulant activity of 
hybridoma antibodies. Lamellar phospholipids such as PC and 
synthetic lamellar forms of PE had no effect on these antibodies. 
The experiments described in Chapter 8 on the subject of the lupus 
anticoagulant showed a specific effect of a PS-containing liposome 
on the APTT of plasma containing the lupus-like inhibitor. In these 
experiments it appeared that the shortening of the APTT was not due 
simply to absorption of antibody to excess antigen, but to provision 
of extra phospholipid surfaces in the test system to which both 
clotting factors and the inhibitor may bind competitively. 
In conclusion, the experiments described in this chapter show 
the nature of some commonly used APTT reagents and their lipid 
composition. The clotting performance of the reagents was then 
assessed and correlated with lipid compositional data. The 
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information derived from this work enabled the construction of a 
"vehicle" liposome which possessed neither procoagulant nor 
anticoagulant activity in the APTT test. Electron microscopy 
demonstrated that a liposome was formed. The introduction of PS 
into the vehicle rendered it active in the clotting test. PS was 
unique and shown to be of central importance in regulating 
procoagulant activity, sensitivity to heparin and to the presence of 
the lupus-like anticoagulant. 
It is hoped that this work may provide a base for preparation 
of improved APTT reagents or possibly Reference Preparations, 
constructed, perhaps, from individual pure lipids. 
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CHAPTER 9 EXPERIMENTS ON FREEZE-DRYING 
The six experimental series in this chapter have been designed 
to demonstrate the freeze-drying conditions required for tissue 
thromboplastin reagents. In the first section, residual moisture 
was determined in a series of reagents freeze-dried in a 
standardised manner. This freeze-drying sequence is described. The 
next two sections consider the use of liquid nitrogen cooling in the 
freeze-drying machine and its effect on the process. In the fourth 
section, an examination is made of the freeze-drying machinery to 
uncover possible sources of variation in residual moisture levels 
that may be due to position of vials within the plant or to machine 
design. Section 5 describes the preparation of tissue 
thromboplastin reagents intended to serve as international reference 
preparations for the Bureau Ccmmunautaire de Reference of the 
European Economic Community, the World Health Organisation and the 
International Committee for Standards in Haematology. Finally, the 
stability of thromboplastin reagents in fusion-sealed glass and 
rubber-stoppered vials is compared. 
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9.1 TO DETERMINE THE RESIDUAL MOISTURE IN TISSUE THROMBOPLASTIN 
REAGENTS FREEZE-DRIED UNDER STANDARDISED CONDITIONS 
Aim - To establish a value for residual moisture (RM) in 
freeze-dried tissue thromboplastin reagents. 
Procedure - Nineteen batches of human brain thromboplastin were 
lyophilised over a period of eight years between March 1976 and 
November 1984. These were batches which were free of gross 
bacterial contamination and hepatitis B virus (Microbiological 
testing is described in Chapter 6.18). Thromboplastin was dispensed 
as described in Chapter 6.12. Fourteen batches were aliquoted into 
2 cm3 glass vials, shown in fig 6.17. Two batches were dispensed 
into glass vampoules illustrated in the same figure. A further 
batch was dispensed into polypropylene vials and two others into 10 
cm3 glass vials. In every case the procedure was performed using 
the Comp-u-pet apparatus (fig 6.23). For batches 80/120 and 82/253, 
a special dispensing head was made for vampoules. This is also 
shown in fig 6.23. After dispensing, vials were partially stoppered 
using stopper type A in fig 6.18 and vampoules using stopper type 
B. The material was then cooled to -50°C in a mechanically cooled 
refrigerator (Kelvinator UC 517, Laboratory Impex, Teddington). The 
mean cooling rate was 2.5°C per hour. Freeze-drying was as 
described in Chapter 6.12 and followed the sequence illustrated in 
fig 9.1, with a condenser temperature of -65°C. When drying was 
complete, the vials were stoppered in vacuo and the material 
transferred to a refrigerator operating at -20°C for storage. 
Residual moisture was measured as described in Chapter 6.12. 
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Results - Table 9.1 shows the batch number, the type of 
enclosure used, the preparation date and the residual moisture of 
the test preparations. The mean value for residual moisture was 
1.84% with a standard deviation of 0.18. Fig 9.1 shows the 
freeze-drying sequence employed for the lyophilisation of tissue 
thromboplastin. The entire process took five days; one day for 
cooling of load and machine, approximately three days of 
sublimation, and one day of desorption over P205. Fig 9.1 shows 
the process, beginning with the cooling of the freeze-drier shelves 
(dotted line) and the thromboplastin (solid line). After the 
thromboplastin was loaded and the vacuum pump started there was an 
immediate reduction in pressure, measured at head 1 (i. e. near to 
the vacuum pulp - see Chapter 6). The drop in pressure at head 2 
was not as marked because of the subliming water vapour from the 
load. This vapour was trapped on the condensing surface and caused 
it to rise in temperature. Meanwhile, the load and shelf 
temperatures equilibrated, and it was then necessary to switch on 
the shelf heating to provide the energy to support sublimation. As 
the process continued, head 2 pressure dropped to equal that shown 
by head 1. This indicated that the sublimation stage of the process 
was complete. 
The load temperature at this time was 10°C, confirming that 
there could be no residual ice in the thromboplastin and that 
further prolongation of the sublimation phase was pointless. 
Accordingly, the desorbtion stage was begun. The rate of heating 
was increased and during this stage desorbing vapour was entrapped 
337 
in the P205 trap, while the mechanically cooled condenser was 
defrosted. The process was completed when the load temperature 
reached 200C and no further drop in pressure was noted. 
TABLE 9.1 DETAILS OF LYOPHILISED TISSUE THROMBOPLASTIN 
Batch No. Enclosure Date Residual 




















Mar 1976 1.5 
Jun 1977 2.1 
Sep 1977 2.1 
Dec 1977 1.7 
Mar 1978 1.5 
Aug 1978 1.7 
Mar 1979 1.9 
Mar 1979 2.0 
Jul 1979 1.9 
Oct 1979 2.1 
Mar 1980 1.8 
Dec 1981 2.0 
Jul 1982 1.7 
Jul 1982 1.9 
Feb 1983 1.7 
Mar 1983 1.9 
Jun 1983 1.7 
4 Apr 1984 1.9 
4 Nov 1984 1.8 
* Reference Preparation of the EEC Bureau de Communautaire de 
Reference 
International Reference Preparation of the World Health 
Organists ion 
* Reference Preparation of the International Committee for 
Standards in Haematology 
key to vial type 1=2 cm3 glass vial, 13 mm stopper 
2=1 cm3 glass vampoule, flame sealed 
3=4 cm 3polypropylene vial, 13 mm stopper 4= 10 cm glass vial, 20 mm stopper 
Discussion - The nineteen batches of thromboplastin reagent 
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Fig 9.1 Freeze-drying sequence for tissue thromboplastin. 
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lyophilised between 1976 and 1984 were prepared in the same way and 
freeze-dried according to the sequence described. Batch 82/253 was 
prepared for the World Health Organisation and therefore had to be 
presented in a fusion sealed glass enclosure. For this reason the 
reagent was dispensed into vampoules, rather than the standard 
freeze-drying vial (see Chapter 6.12). Batch 80/120 was treated in 
the same way and acted as a practice run for the WHO material so 
that the dispensing, freeze-drying and flame sealing equipment could 
be tested thoroughly. The other types of vial employed were a4 
cm3 capacity polypropylene vial with 13 mm neck, and an 
approximately 10 cm3 capacity glass vial with a 22 mm neck (see 
fig 6.17). While there are not enough data to compare the effect of 
vial geometry on residual moisture, it may be seen that the 
enclosures labelled 2,3 and 4 gave results that fell within the 
range shown by vial type 1. The standard deviation of the residual 
moisture values is encouragingly low and indicates that the 
treatment of the material was reasonably standardised. The 
freeze-drying sequence produced thrombplastins with an acceptable 
level of residual moisture for long-term storage. For example, BCT 
76/005, prepared in March 1976, was used as a house standard at the 
UK Reference Laboratory until supplies were exhausted in June 1979, 
i. e. more than 3 years of use. BCT 78/074, prepared in August 1978, 
was used until late 1982. BCT 79/099, prepared in July 1979 is 
currently a Reference Preparation of the EEC Bureau Communtaire de 
Reference, more than ten years after its manufacture. The stability 
of this preparation has been the subject of an independent 
investigation by van den Besselaar et al (1988) who found no 
evidence of any change in the material. 
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Conclusion - The mean residual moisture value for a range of 
thromboplastin reagents, freeze-dried in a variety of vials, was 
found to be 1.84%. This value appears to be adequate for long-term 
stability of the reagents. The freeze-drying sequence employed 
produced consistent results over the time of the experiment. 
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9.2 OBSERVATIONS ON THE USE OF A LIQUID NITROGEN-COOLED CONDENSER 
IN THE FREEZE-DRYING MACHINE 
Aim - To observe the effect of employing very low condenser 
temperatures during freeze-drying of tissue thromboplastin. 
Method - For this experiment, the mechanically-cooled condenser 
was removed, and replaced by the device shown in fig 6.14. This 
involved disconnection of the mechanical system and its controls, 
and the installation of the liquid nitrogen-cooled condenser. The 
system required a supply of liquid nitrogen, provided by a 
self-pressurising dewar (BOC Cryospeed EC Series, BOC Cryospeed, 
Worsley). This was connected to the condenser by a nylon pipeline 
of 1/2 inch outside diameter, under the control of a thermocouple 
activated valve and controller. Temperature could be set from 
ambient down to -196°C. For safety, the liquid nitrogen pipelines 
were insulated and fitted with "over-pressure" valves which were 
designed to open if the pipeline was closed at both ends causing 
pressure to build up within it. Exhaust liquid nitrogen was piped 
to the outside of the building. 
A batch of thranboplastin reagent was prepared, dispensed into 
2 cm3 glass vials and frozen as described above. It was then 
divided into three and each third freeze-dried in a separate 
freeze-drying run with condenser temperature set at -80°C, 
-120°C and -160°C respectively. Following drying, the vials 
were sealed in vacuo and residual moisture measured as described in 
Chapter 6.12, on ten groups of five vials from each run. Liquid 
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nitrogen usage was calculated for each run by referring to the 
capacitance liquid nitrogen level gauge fitted to the EC Series 
dewar. Analysis of variance and Tukey test were employed to analyse 
the data. 
Results - Fig 9.2 shows the conditions that obtained in the 
three freeze-drying runs. Reducing the condenser temperature 
resulted in a quicker drop in pressure. The warming effect of 
subliming vapour on the condensing surface temperature was less 
marked as condensing temperature was lowered. The ultimate vacuum 
achieved was not changed by lowering condenser temperature. Table 
9.2 lists the residual moisture values for the three thrcmboplastin 
batches. Table 9.3 shows results of analysis of variance which 
indicated a significant interaction between residual moisture and 
condenser temperature. The Tukey test was used to test for 
difference between the means of the residual moisture values for 
each temperature. There was strong evidence (at the 0.1% level) to 
show that drying with the condenser temperature at -80°C removed 
less moisture than at the other two, lower, temperatures. There was 
evidence, at the 5% level only, to show that drying with the 
condenser temperature at -160°C removed more moisture than at 
-120°C. 
Fig 9.3 reveals that a reduction in residual moisture is 
coincident with reduction in the temperature of the condensing 
surface. The value for residual moisture at a condenser temperature 
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Fig 9.3 Relationship between condenser temperature and residual 
moisture. Usage of liquid nitrogen (LN2) is also shown. 
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-80°C -120°C -160°C 
RM estimate 1 1.4 1.16 1.16 
2 1.38 1.17 1.14 
3 1.38 1.19 1.14 
u 1.37 1.2 1.16 
5 1.38 1.17 1.14 
6 1.4 1.16 1.14 
7 1.4 1.16 1.14 
8 1.38 1.19 1.15 
9 1.39 1.17 1.13 
10 1.39 1.18 1.15 
mean 1.39 1.18 1.15 
standard deviation 0.01 0.01 0.01 
TABLE 9.3 ANOVA OF THE DATA IN TABLE 9.2 
Source df SS MS Fp 
temperature 2 0.3480 0.174 1269.73* <0.0001 
residual moisture 27 0.0037 0.000137 
total 29 0.3517 
Discussion - It is clear that the use of the liquid 
nitrogen-cooled condenser had a marked effect on the freeze-drying 
process. Theoretical discussions on the subject of the sublimation 
of ice have been offered by Carman (1948) and more recently by 
Mellor (1978). They proposed that for effective sublimation, the 
total pressure within the system must be less than the vapour 
pressure of the material at the evaporating surface. Also, the 
vapour pressure at the condensing surface must be lower than the 
vapour pressure of ice at the surface of evaporation. As discussed 
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in Chapter 6, the vapour pressure at a condenser surface will be at 
minimum if the accommodation coefficient is unity. Kramers and 
Stemerding (1951) calculated that the probability of a molecule of 
water sticking to a condensing surface at -60°C or lower was 
unity. Since the condenser temperature in the three freeze-drying 
cycles described here was well below this level, this must be the 
case. The result is that the vapour pressure at the condensing 
surface reached a low level very quickly and that this improved the 
efficiency of the freeze-drying. Lower levels of residual moisture 
coincided with lower condenser temperature. 
The data show, however, that the reduction in residual moisture 
was very small when condenser temperature was lowered from -120°C 
to -160°C and that this reduction required some 95 dm3 of liquid 
nitrogen. This use of liquid nitrogen is difficult to justify, 
given that in Chapter 9.1 it was shown that a residual moisture 
level of 1.84% was perfectly adequate for long-term storage of 
tissue thromboplastin. 
A further point of interest concerns the design of the 
condensing surface. Rowe (1964b) considered that the area of the 
condensing surface should be at least equal to the shelf area in a 
freeze-dryer. The liquid nitrogen-cooled condenser employed in this 
experiment had a surface area of 0.74 m2, or 19.07% of shelf 
area. The mechanically-cooled condenser used in Chapter 9.1 had a 
surface area of 1.11 m2, or 28.6% of shelf area. It is clear that 
both produced acceptable results, indicating that design and 
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operating temperature are more important considerations than surface 
area per se. 
Conclusion - It was possible to dry to lower residual moisture 
levels by employing very low temperature condensing surfaces. The 
cost of liquid nitrogen for cooling, however, (approximately 20p per 
dm3) may be prohibitive, and small reductions in residual moisture 
values may not justify the additional expense. 
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9.3 OBSERVATIONS ON THE USE OF A LIQUID NITROGEN-COOLED TRAP TO 
REPLACE PHOSPHORUS PENTOXIDE DURING THE DESORPTION PHASE OF 
FREEZE-DRYING 
Aim - To observe the effect of replacing the phosphorus 
pentoxide trap with a device cooled by liquid nitrogen. 
Method - The stainless steel trays used to hold P205 were 
removed from the freeze-drying plant and the device shown in figure 
6.16 fitted in their place. This apparatus comprised a tubular 
reservoir, to hold liquid nitrogen, to which was attached a series 
of fins, made of brass, to present the maximum cooled surface. The 
entire device was nickel plated to prevent corrosion and to ensure a 
smooth surface for easy cleaning. Liquid nitrogen was pumped into 
the reservoir, via a thermostatically controlled solenoid valve, 
from a BOC EC 200 self-pressurising dewar. The temperature was set 
to -1200C. Exhaust nitrogen vapour was piped to the outside of 
the building. 
A batch of human brain thromboplastin was prepared and divided 
into two. The first was lyophilised using the liquid nitrogen 
cooled trap during the desorption stage while the second used 
P205 to entrap desorbed vapour. The sequence of freeze-drying 
shown in figure 9.1 was followed. Residual moisture was measured in 
samples from each batch. Data was analysed using Students t test. 
Liquid nitrogen use was measured using the capacitance gauge fitted 
to the EC 200 dewar. 
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Results - Residual moisture values for the two freeze-dried 
batches are given in Table 9.4. The batch dried using the liquid 
nitrogen-cooled trap had a lower residual moisture level, confirmed 
by the t test (p < 0.001). Thirty-one dm3 of liquid nitrogen was 
used. 





1 1.74 1.90 
2 1.77 1.92 
3 1.77 1.90 
4 1.76 1.88 
5 1.78 1.89 
6 1.77 1.88 
7 1.74 1.87 
8 1.76 1.90 
9 1.75 1.91 
10 1.78 1.89 
mean 1.76 1.89 
standard deviation 0.015 0.015 
Discussion - Desorption using the liquid nitrogen cooled 
apparatus gave a preparation with a lower residual moisture. This 
may have been due to the improved entrapment of desorbing vapour by 
the device, leading to a lower vapour pressure within the 
freeze-drying plant. This, in turn, would have favoured a more 
efficient drying. Freeze-drying by this method did not result in 
the very low residual moisture levels seen in Chapter 9.2 when a 
liquid nitrogen-cooled condenser was employed, but the quantity of 
liquid nitrogen used, i. e. some 30 dm3, meant a more economical 
means of achieving lower residual moisture was possible. Defrosting 
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and cleaning of the device was simple, requiring only that it be 
washed with hot water and a major advantage was that the use of 
P205 was obviated. 
Conclusion -A liquid nitrogen trap, used in place of P205, 
had several advantages. Firstly, lower residual moisture was 
obtained by its use; secondly, it proved more economical of liquid 
nitrogen than the condenser used in Chapter 9.2; thirdly, it was 
easy to defrost and clean and; finally, it avoided the use of 
P205 and the dangers associated with this compound. 
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9.4 TO TEST FOR INTRINSIC MACHINE VARIATION IN A BATCH OF 
FREEZE-DRIED TISSUE THROMBOPLASTIN 
Aim - To discover whether there were any measurable variations 
in a batch of tissue thromboplastin freeze-dried in the plant 
described above. 
Method - In order to discover whether there were any 
significant variations within materials lyophilised in the plant 
described it was necessary to test four possible areas of potential 
variation. 1. variation from front to back on a shelf, 2. 
variation from edge to middle of a shelf, 3. variation from top to 
bottom of the shelf array within one chamber, 4. variation from 
chamber to chamber. 
Accordingly, a batch of human brain thrombopla5tin was prepared 
as described above. The material was dispensed in 1.5 ml aliquots 
into the polypropylene vial shown in fig 6.17. In all, some 3200 
aliquots were dispensed. This number provided sufficient for the 
immediate study and enough for a reasonable batch to present for 
external monitoring for routine use. 
The vials were arranged as follows. Six freeze-drying trays, 
each holding 25 rows of 20 vials were placed in chamber no. 1 of the 
freeze-drying plant. Chambers 2,3 and 4 were filled with 
freeze-drying trays packed with vials of water and 5 vials per tray 
of thromboplastin. This represented the maxims, load that the 
machine was designed to accommodate, i. e. 18 dm3. 
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The freeze-dryer was then run as shown in fig 9.1 above, and 
the vials stoppered in vacuo at the completion of the process. 
To test for variation from front to back, the six trays of 
dried thromboplastin were removed from chamber 1 and 10 vials were 
removed from rows 1,7,13,19 and 25 from tray 1. These groups of 
10 vials were further divided into two lots of 5 so that two 
residual moisture determinations could be made per row (i. e. 10 per 
tray). This sampling was repeated on each tray from chamber 1. 
To test for variation from edge to middle, a batch of 12 vials 
was removed from the middle of each tray from chamber 1. These were 
the 9th, 10th, 11th and 12th vials from rows 12,13 and 14. 
"Middle" vials were compared with material sampled from the 
outermost columns of vials on each tray i. e. 4 groups of 5 vials 
from each edge column, to provide eight values per tray. 
To test for variation from top to bottom of the shelf array in 
chamber 1 the data already generated was used and front of shelf 
values compared with edge of shelf and middle of shelf values. The 
mean value of all the data per shelf was calculated for comparison. 
To test for chamber to chamber variation, the mean values from 
chamber 1 were compared wtih those from chambers 2,3, and 4. 
Results - The results of residual moisture testing of samples 
from chamber 1 are given in table 9.5. 
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TABLE 9.5 RESIDUAL MOISTURE IN SAMPLES FROM CHAMBER 1 
Row No 17 13 19 25 
Shelf 
no 6 1.81 1.81 1.81 1.8 1.8 1.81 1.81 1.81 1.82 1.82 
5 1.81 1.81 1.81 1.81 1.8 1.81 1.82 1.8 1.8 1.8 
4 1.81 1.8 1.82 1.81 1.81 1.8 1.82 1.81 1.8 1.79 
3 1.82 1.82 1.82 1.8 1.82 1.81 1.78 1.8 1.81 1.79 
2 1.81 1.82 1.81 1.81 1.79 1.8 1.8 1.8 1.79 1.8 
1 1.81 1.8 1.82 1.82 1.81 1.81 1.82 1.8 1.8 1.81 
Analysis of variance applied to these data give the result.. -, shown in 
table 9.6. 
TABLE 9.6 ANOVA OF DATA IN TABLE 9.5 
Source df SS MS Fp 
shelf 5 0.0003333 6.666 x 10-5 4 1.22 0.34 
row 4 0.0007067 1.75575 x 1R- 3.23* 0.03 
column 1 0.0001067 1.067 x 10- 4 1.95 0.18 
shelf x row 20 0.002433 1.2165 x 105 2.22* 0.04 
shelf x column 5 0.0003733 7.466 x 10- 5 1.36 0.28 
row x column 4 0.0001267 3.1675 x 10- 0.58 0.68 
residual 20 0.0010933 5.4665 
5 
x 10-5 
total 59 0.0051733 
The analysis of variance show that there is no evidence to 
indicate difference between shelves, columns or any column 
interactions with rows or shelves. There is evidence at the 5p 
level to show a difference in rows and a shelf x row interacticn - 
i. e. the rows do not return the same result in exactly the same way 
on each shelf. A plot of the row mean values is given in fig 9.4 
and is very confusing because of the large number of shelves and 
rows. Interaction between shelves and rows is indicated by lack of 
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shelf no. 
Fig 9.4 Lack of parallelism in lines joining row means 
for each shelf. 
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showed that the critical distance parameter for the data was 0.009. 
This meant that if a difference between rows was to be significant, 
at the 5% level, it must be greater than 0.009. This was the case 
for the difference between rows 2 and 7 (0.01, p<0.05) but was not 
the case for the next largest difference i. e. rows one and 25 
(0.009, p=0.05). The only significant finding, therefore, was 
that row 7 had a higher residual moisture than the others. 
The residual moisture values of materials sampled from front 
row, back row and left and right edge columns i. e. 12 samples per 
tray are shown in table 9.7. The middle vial residual moisture 
results are also given in this table. 
Analysis of variance failed to show any difference between 
positions, or between shelves, as shown in table 9.8. To achieve 
significance, the F value would have to have been 2.71 or more for 
shelves and 2.87 or more for positions. 
All the data generated so far were used, in an analysis of 
variance to show if any differences could be found. 
There was no evidence to show a difference in residual moisture 
for different rows or colurins or any interactions. There was 
evidence (at 1% level) that there was a difference between shelves 
(F = 4.83 in table 9.9). Tukey's test was employed to show whether 
the difference between shelf residual moisture means was 
significant. The means of the shelves in chamber 1 are shown in 
table 9.10. 
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TABLE 9.7 RESIDUAL MOISTURE FROM EDGES AND MIDDLE OF FREEZE-DRYING SHELVES 
shelf Front row Left column Back row Right column Middle 
6 1.81 1.81 1.80 1.80 1.79 1.80 1.82 1.82 1.81 1.80 1.80 1.83 1.81 
5 1.81 1.81 1.80 1.79 1.81 1.80 1.80 1.80 1.80 1.79 1.80 1.81 1.81 
4 1.81 1.80 1.79 1.79 1.80 1.81 1.80 1.79 1.80 1.81 1.79 1.80 1.81 
3 1.82 1.82 1.83 1.82 1.81 1.79 1.81 1.79 1.80 1.82 1.80 1.81 1.81 
2 1.81 1.82 1.81 1.82 1.81 1.81 1.79 1.80 1.81 1.82 1.80 1.80 1.80 
1 1.81 1.80 1.82 1.82 1.81 1.81 1.80 1.81 1.82 1.83 1.81 1.81 1.81 
TABLE 9.8 ANOVA OF DATA FROM TABLE 9.7 
source df ss 
shelf 5 0.0004635 
position 4 0.0002133 
residual 20 0.00084167 
total 29 0.0015185 
MS 
9.27 x 10-5 2.20 0.09 
5.3325 x 10 1.27 0.31 
4.20835 x 10-5 
Fp 
TABLE 9.9 ANOVA (ALL DATA) 
source df SS MS F p 
shelf 5 0.001835 3.67 x 10-4 4.83* 0.0081 
row 3 0.0002896 9.653 x 10-5 1.27 0.32 
column 1 0.00001875 1.875 x 10-5 0.25 0.63 
shelf x row 15 0.001723 1.149 x 10-4 1.51 0.22 
shelf x column 5 0.0004188 8.376 x 10-5 1.10 0.40 
row x column 3 0.0002729 9.097 x 10-5 1.20 0.34 
residual 15 0.0011396 7.5973 x 10-5 
total 47 0.0056979 
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TABLE 9.10 SHELF MEAN RESIDUAL MOISTURE VALUES 







The Tukey test showed that there was no significant difference 
between shelves. Tukey's range test was also applied to the shelf 
mean data. In this test the "critical distance" statistic was found 
to be 0.022. Since the largest difference between shelves was 0.017 
this means that there was not a significant difference between 
shelves (p > 0.05). 
Table 9.11 shows an analysis of variance applied to mean 
residual moisture data from shelves and from chambers. 
TABLE 9.11 ANOVA (MEAN RESIDUAL MOISTURE, SHELVES AND CHAMBERS 
Source df SS MS Fp 
chamber 3 0.00085 
8 
2.833 x 10-4 9.17** 0.0014 
6 0 8 * shelf 5 0.000587 x1 3. 0.02 1.75 0 
-5 residual 15 0.0004635 3.09 x 1Ö 
total 23 0.0019013 
The ANOVA shows that there is evidence at the 1% level to show 
a difference between chambers and, at the 5% level, between 
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shelves. Shelf means (over all chambers) and chamber means (overall 
shelves) may be seen in table 9.12. 
TABLE 9.12 SHELF AND CHAMBER MEANS 
Shelf Chamber 
1 1.82 1.81 
2 1.81 1.82 
3 1.81 1.82 
4 1.81 1.80 
5 1.81 
6 1.82 
Application of the Tukey test to the data shows that there was 
no significant difference between chamber 1 and chambers 2 and 3 
(which were identical) or between chamber 1 and chamber 4. The 
difference between chamber 4 and chambers 2 and 3 was significant, 
at the 5% level. Chambers 1,2, and 3 did not differ significantly. 
Shelves 4 and 5 were the same and gave the lowest values. The 
largest difference was between 6 and ü and 5 and was significant (at 
5% level). The next largest difference was between 2 and 6 but was 
not significant. Differences between shelves 1,2,3 and 6 were not 
significant. 
The overall mean residual moisture value was 1.81% with a 
standard deviation of 0.01. The highest recorded value was 1.83% 
and the lowest was 1.78%. The coefficient of variation of the 
residual moisture measurements was 0.51%. 
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Discussion - The mean value for residual moisture was found to 
be 1.81% with a standard deviation of 0.01 and CV of 0.51%. This 
shows a much narrower range and CV than might have been expected. 
The method of choice - the "heat and weigh" method, described in 
Chapter 6.12 gave a standard deviation of 0.06 and a CV of 3.04% for 
a sample of twenty determinations with a mean residual moisture of 
2.1%. The 114 determinations used in the current experiment have 
given rise to an improvement in standard deviation and CV. The 
statistical methods employed may have been over sensitive in showing 
the significant differences reported, but nevertheless, the overall 
performance of the freeze-drying machine and thromboplastin 
lyophilisation sequence were encouraging. 
The "heat and weigh" method has been advocated by a number of 
authors e. g. Seligmann and Farber (1971), Pemberton (1977) and May 
et al (1982), and their comments and suggestions were borne in mind 
when the apparatus described in chapter 6.12 was designed. May et 
al (1989) reported wide variations in the CV calculated for a range 
of lyophilised biological materials, from 46% for a batch of immune 
globulin down to 1.9% for measles vaccine. They found that CVs were 
smaller for samples having a residual moisture over 1%. Large CVs 
were found in samples with residual moisture less than 1p. 
When the freeze-drying plant was designed, a decision was made 
to utilise four chambers, each containing six shelves with an area 
of 0.16 m2. Commercial scale freeze-drying machines are built 
with only one or two shelves in a chamber, each of relatively 
enormous surface area. The evidence from this experiment is that 
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the small shelves offer good conditions for freeze-drying to low 
residual moisture and consistent inter-vial variation. 
Conclusion - The data show a narrow range overall and all are 
within the coefficient of variation of the method. Some differences 
were statistically significant but do not upset the general picture 
of a system free of gross variation. 
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9.5 PREPARATION OF TISSUE THROMBOPLASTIN REAGENTS TO SERVE AS 
REFERENCE PREPARATIONS FOR THE EEC, WHO AND ICSH 
Aim - To prepare extracts of tissue thromboplastin from human 
brains, to freeze-dry these reagents and present them in a form 
acceptable to the EEC, WHO and ICSH for use as international 
reference preparations. 
Methods - Thromboplastin was extracted from human brains as 
described by Stevenson (1978). For the EEC batch, designated 
79/099, aliquots of 1.5 cm3 were dispensed into the vial type 1 in 
fig 6.17. For the WHO batch (82/253) aliquots of 0.75 cm3 were 
dispensed into the vampoule shown in the same figure. This was used 
so that the reagent could be sealed in glass following drying. The 
ICSH reagent, labelled 84/441, was dispensed in 1.5 cm3 aliquots 
into the vial type 4 in fig 6.17. 
The Comp-u-pet apparatus described in Chapter 6.12 and pictured 
in fig 6.23 was used for dispensing the reagents. In the case of 
82/253, the Comp-u-pet was fitted with a special dispensing head, 
shown in fig 6.23, designed for filling vampoules. The weight of 
material dispensed was tested for inter-vial variation by dispensing 
every hundredth aliquot into a pre-weighed vial and calculating the 
dispensed weight by difference. The coefficient of variation was 
calculated from this data. The reagents were lyophilised according 
to the sequence shown in fig 9.1. Following drying the vampoules, 
containing batch 82/253 for WHO, were flame sealed as described in 
Chapter 6.12. Residual moisture determinations were carried out, as 
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in this same section, and inter-vial variation in prothrombin time 
testing was assessed by using the reconstituted reagent in the 
measurement of the prothrombin time of a single plasma. The minimum 
acceptable number of vials included was 28 (Stevenson 1978). To 
determine the optimal concentration of phenol in their 
reconstitution fluids, sample vials from each reagent were 
reconstituted with a graded series of phenol solutions and tested 
for procoagulant activity and sensitivity to the coumarin-induced 
clotting defect. Each reagent was calibrated in an international 
multicentre exercise to ensure its suitability as a reference 
preparation, and a series of degradation, studies was set up to 
monitor stability of the materials. Calibration exercises have been 
described elsewhere (Thomson et al 19EL, 1986, Hermans 1984, 
Kirkwood 1984, Tomenson 1984) as have the proposed degradation 
studies on the WHO preparation 82/253 (Thomson et al 1984). 
Long-term degradation studies on the other two international 
reference preparations, 79/099 and 84/441, have been on-going since 
their manufacture. On each occasion of testing, at approximately 
three month intervals, the reagent was used to measure the 
prothrombin time of three test plasmas. The test plasmas were pools 
of donations from coumarin-treated patients or normal volunteers. 
The pooled plasmas were aliquoted into screw-topped plastic 
containers (Starstedt Ltd, Leicester) and stored in liquid 
nitrogen. The plasma pools have been replaced at approximately 3 
year intervals. 
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Vacuum testing of vials was performed as described in Chapter 
6.12 and microbiological tests were carried out as described in 
Chapter 6.18. 
Results - Table 9.13 shows the test results for the three 
reagents described. 
TABLE 9.13 CHARACTERISTICS OF THREE INTERNATIONAL REFERENCE 
THROMBOPLASTIN REAGENTS 
79/099 82/253 84/441 






CV of prothrom- 1.6% (16.1 secs) 1.5% (16.9 secs) 
bin time of a 
single plasma 
tested using 28 
vials of reagent 
(mean PT in 
brackets) 
Phenol concen- 5.3 2.7 
tration in re- 
constitutijon fluid 
mmole dm- 
1.6ý (13.5 secs) 
18.6 
International 1.048 1.085 1.04 
Sensitivity Index 
Vacuum tested by high-frequency spark tester 
Hepatitis B negative negative negative 
surface antigen 
HIV competi- negative negative negative 
tive ELISA 
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The results of the long term degradation studies on batches 
79/099 and 84/441 are given in fig 9.5. 
Discussion - All three thromboplastin reference preparations 
described are still in use at the present time. The oldest, 79/099, 
was prepared in July 1979 and shows no evidence of instability after 
more than 10 years of use as a reference preparation of the EEC. 
Van den Besselaar et al (1988) confirmed this observation. The 
stability of this reagent may have surprised those proponents of the 
idea that sealing in glass is essential for long term storage of 
biological standards. (In the next section, butyl rubber stoppered 
vials are compared with fusion-sealed glass). The WHO stipulates 
that their reference preparations must be sealed in glass. Batch 
82/253 was prepared in this way in order to comply with this 
regulation. It, too, is unchanged since its preparation (Thomson 
1990 unpublished observations) and stability studies are still 
ongoing. Some results of degradation studies of batch 82/253 at 
elevated temperature are given in Chapter 9.6. The most recent 
reagent described, batch 84/441, was freeze-dried in rubber 
-stoppered vials also. It has proven to be stable to date. 
As noted above, drying to a residual moisture level of less 
than 2% may be important for long term stability. Taking care over 
filling weight of reagents and inter-vial variation also contributed 
to the final character of the reagents and enabled them to fulfil 
the role of international reference preparations. Multicentre 
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Conclusion - The most desirable quality of a reference 
preparation is that 
also be sensitive 




it should be stable over many years. It should 
to the coumarin induced defect (i. e. have an ISI 
show minimal inter-vial variation. Freedom from 
to users is a further desirable feature. All 
have been met by the reagents described in this 
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9.6 TO EXAMINE THE STABILITY OF HUMAN BRAIN THROMBOPLASTIN 
FREEZE-DRIED IN VIALS WITH BUTYL RUBBER STOPPERS AND IN 
FUSION-SEALED VAMPOULES 
Aim - To show whether material stored in fusion-sealed 
vampoules has a longer shelf-life than that stored in butyl 
rubber-stoppered vials. 
Methods - Two batches of human brain thromboplastin were 
employed for this experiment, 80/120 and 82/253. Batch 80/120 was 
prepared to test the vampoule filling apparatus and the vampoule 
sealing device described in Chapter 6.12 and to act as a trial run 
for freeze-drying thromboplastin in vampoules, before proceeding to 
batch 82/253, the WHO reference preparation described in Chapter 
9.5. The major part of 80/120 was dispensed into vampoules and 
approximately 200 cm3 into vials. 82/253, on the other hand, was 
dispensed entirely into vampoules. Both batches were frozen and 
lyophilised according to the cycle shover in fig 9.1. When the 
process was complete all the vampoules containing 80/120 were fusion 
sealed. The majority of vampoules of 82/253 were also fusion 
sealed, as described in Chapter 6.12, but approximately 200 were 
stored with their butyl rubber stoppers still in place. Therefore, 
both batches included fusion-sealed vampoules and rubber stoppered 
vials or vampoules. These were vacuum tested before storage at 
-20°C or at 37°C for heat-accelerated degradation studies. 
Batch 80/120 was tested for stability by using the reconstituted 
reagent to test the prothrombin time of two plasmas, N1, a normal 
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control, and P2, from an anticoagulated patient. The plasmas were 
stored in liquid nitrogen. Batch 80/120, in vampoules, was tested 
at monthly intervals for six months, then three monthly. Batch 
80/120 in rubber stoppered vials, was tested weekly. Batch 82/253 
was tested by using the reconstituted reagent to measure the 
prothrombin time of two plasmas, N2, a lyophilised normal plasma, 
and P4, a plasma obtained from an anticoagulated patient. 82/253, 
in fusion-sealed vampoules, was tested at weekly intervals for 4 
weeks, 3 months followed by 3-monthly intervals while the material 
in rubber-stoppered vampoules was tested weekly. At each time of 
testing, samples were also removed from the -20°C store and tested 
in the same way. 
Vacuum testing was performed on rubber-stoppered vials and 
vampoules at weekly intervals and six monthly on fusion-sealed 
vampoules using the spark tester as described in Chapter 6.12. A 
disadvantage of this device was its inability to show a discharge 
glow when testing vials with a pressure of >100 mb. It was decided, 
therefore, to employ the method according to Barbaree and Smith 
(1981), also described in Chapter 6.12, to demonstrate whether there 
was still "negative" pressure in the rubber stoppered vials and 
vampoules which had failed the vacuum test by the spark tester 
method. 
Residual moisture was determined also as described in Chapter 
6.12, at baseline, two weeks and four weeks in the case of 
rubber-stoppered vials and vampoules, and 6 monthly in the case of 
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fusion-sealed vampoules. Malondialdehyde was determined, at the 
same intervals, by the method described in Chapter 6.20. 
Results - The accelerated degradation study on 80/120 is shown 
in fig 9.6. The line drawn at 36.3 sec gives the baseline 
prothrombin time value + 10% for the anticoagulated plasma. This 
value was chosen to represent the maximum limit below which the 
thromboplastin could be regarded as maintaining stability. The line 
at 21.2 sec is the equivalent baseline + 10% limit for plasma N1. 
The stability of 80/120 in fusion-sealed vampoules at 37°C 
was some 25 months with the coumarin plasma, P2, and 32 months with 
the normal plasma, N1. The material in rubber-stoppered vials, 
however, showed poor stability, exceeding the acceptable limit with 
both test plasmas by two weeks. Results obtained from material 
stored at -200C are shown by the dotted line. These are seen to 
be stable over the period of the experiment. 
The study of 82/253 shcwed a similar pattern (see table 9.1u) 
with the rubber-stoppered material going outside the set limit by 
three weeks whle the fusion-sealed preparation took some 27 months 
for plasma N2 and 30 months for P4. Results obtained using material 
stored at -20°C are also given and indicate stability after five 
years. 
The fusion-sealed vampoules in every case retained vacuum and 
the materials lyophilised in these containers showed no change in 
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Fig. 9.6 Degradation study of 80 1 
1120 in vampoules and vials. Solid line 
shows material stored at 37°C while the broken line shows that stored 
at -20°C. The horizontal solid line is the baseline +10% value for each 
test plasma. Below this line the thromboplastin is regarded as having 
maintained stability. 
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TABLE 9.14 HEAT ACCELERATED DEGRADATION STUDY OF 82/253, PT(sec) OF NORMAL 
(N2) AND COUMARIN (P4) CONTROL PLASMA 
rubber-stoppered fusion-sealed fusion-sealed 
vampoules at 37°C. vampoules at 37°C. vampoules at -20°C. 
N2 P4 N2 P4 N2 P4 
baseline 17.7 36.2 17.7 36.2 17.7 36.2 
week 1 17.5 38.5 17.5 37 17.5 37.5 
week 2 17.5 39.5 17 36.5 17.5 37 
week 3 20.5 41.5 17 37 17.5 37.5 
week 4 23 42 17.5 37 17.5 37 
3 months 17 36 17.5 37 
6 months 17.75 37 18 36.5 
9 months 17.5 37.5 18 36 
12 months 18 37 18.5 36.5 
15 months 18 37.5 18.5 36 
18 months 19 38 18 37 
21 months 18.75 38.5 17.5 36.5 
24 months 19 39.5 17.5 37 
27 months 19.5 39.5 18 37.5 
30 months 19.75 40.5 17.5 37 
36 months 17.5 37 
42 months 18 37.5 
48 months 17.5 37 
54 months 17.5 37.5 
60 months 18 37.5 
N2 baseline + 10% = 19.47 secs. P4 baseline +10% = 39.82 secs. 
TABLE 9.15 RESIDUAL MOISTURE AND MALONDIALDEHYDE IN 80/120 AND 82/253 IN 
FUSION SEALED VAMPOULES, AT 370 C 
residual moisture % mda (nmole/ml) 
80/120 82/253 80/120 82/253 
baseline 1.83 1.90 11 17.5 
12 months 1.86 1.90 12 18.5 
24 months 1.88 1.88 10.5 18.5 
30 months 1.85 1.91 11.5 18.0 
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There were no spark test failures in the vials of 80/120 
stoppered with the type A stopper in fig 6.18. The combination of 
stopper type B and vampoules was less successful, however, and a 
failure rate of 6% was noted by 4 weeks. Testing by the method of 
Barbaree and Smith showed that there was still negative pressure in 
the vampoules, i. e., pressure between atmospheric and approximately 
100 mb. The observation that there was sufficient vacuum to cause 
the syringe piston to close partially in this test implies that the 
pressure must have been well below atmospheric. 
Residual moisture and mda values for the rubber-stoppered 
materials are given in table 9.16. 
These data show that in both preparations, 80/120 and 82/253, 
there was an increase in residual moisture and in mda over the four 
weeks of storage at 370C. The degradation of the material may 
have been due to an oxidation similar to that seen in the stored BCT 
preparations in Chapter 7.3, and may have been facilitated by 
ingress of atmospheric moisture and oxygen. In contrast, the data 
shown in table 9.15 indicate that the materials in the fusion-sealed 
vampoules was unchanged in residual moisture or mda content 
throughout. The mechanism of the degradation of these preparations 
is unlikely, therefore, to have been dependent upon an oxidative 
process. 
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TABLE 9.16 RESIDUAL MOISTURE AND MALONDIA6DEHYDE IN 80/120 AND 
82/253 IN RUBBER STOPPERED ENCLOSURES, AT 37 C. 
residual moisture % mda (creole/dm-3) 
80/120 82/253 80/120 82/253 
baseline 1.83 1.90 11 17.5 
2 weeks 1.89 1.99 15 27 
4 weeks 1.97 2.11 19 39.5 
Discussion - Lyophilised thromboplastins stored in 
fusion-sealed vampoules showed significantly better stability than 
either rubber-stoppered vials or vampoules in an accelerated 
degradation study at 37°C. Since the thromboplastin was 
sequestered away from atmospheric water vapour and oxygen, it may be 
assumed that neither of these contributed to the degradation of the 
material. There will have been a small quantity of residual 
moisture from the outset, 1.83% for batch 80/120 and 1.9% for 
82/253. These values, as seen in Chapter 9.1, were similar to 
seventeen other thromboplastins which were stable throughout 
long-term storage at -200C. 
Certain questions arise from these observations - firstly, what 
made the rubber-stoppered preparations degrade so quickly? The 
answer to this may be that the stoppered vials and, to a larger 
extent, the stoppered vampoules could not prevent the ingress of 
water vapour and oxygen which may have aided the degradative 
process. From the data on mda levels, this process seems to have 
been an oxidative one. Hopkins (1976) described the difficulties 
faced by manufacturers of rubber stoppers for freeze-dried 
preparations. A rubber stopper formula may comprise a polymer, a 
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reinforcing agent, an activator, a curing agent, pigments and 
processing aids such as plasticizers and softeners. The rubber 
stoppers used in the freeze-drying experiments reported here are 
made of butyl rubber, i. e. the polymeric ingredient is a copolymer 
of 97% isobutylene and 3% isoprene (natural rubber). Aluminium 
chloride is the catalyst employed in the polymerisation process. 
Plasticizers such as phthalate esters or ethylene glycol may be 
added to increase flexibility of the final product. To reduce 
friction in mixing these materials, softeners such as vegetable oils 
may be added. These do not enter into chemical combination with the 
polymer. Butyl rubber has a useful low temperature tolerance with a 
glass transition point around -75°C. Other polymers, such as 
neoprene (polychloroprene) have a glass transition around -40°C 
while silicone (a large group of siloxane polymers) has a slightly 
lower glass transition of about -50°C, but is more permeable to 
gases. Steinherz (1963) gives values for permeability of 100 x 
10-8 cm3 sec-1 inch-1 of gasket, for silicone and 0.25 x 
10-8 cm3 sec-1 inch-1 for butyl rubber. The selection of 
butyl rubber as the material of choice for freeze-drying stoppers 
was made with these considerations in mind. 
It may be that the permeability of the stopper is increased at 
higher storage temperature. This is implied by the observations in 
Chapter 9.1 of long shelf life at -20oC of the same 
thromboplastins which last for only a few weeks at 370C. 
A further concern is that there may be an interaction of the 
thromboplastin and some volatile component of the rubber stopper 
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formulation. It is possible that such leaching from the stopper 
might occur at 370C, but be so slow as to go unnoticed at 
-20°C. This is less likely to be the case, however, since higher 
residual mosture and mda levels in the degraded material lend weight 
to the idea of an oxidative process aided by permeating water 
vapours and oxygen. 
It was noticed that the stopper/vampoule combination was less 
successful than the stopper/vial equivalent. It should be pointed 
out that vampoules are manufactured with their necks rather less 
rigourously finished than those of freeze-drying vials. 
Manufacturers apparently believe that since stoppering of vampcules 
will be a temporary measure only, it is not necessary to finish 
their necks to a very high standard. The consequence of this is 
that many vampoules will not seal in vacuo and it is possible that 
there will be admission of atmospheric vapour through ill fitting 
stoppers. 
Greiff et al (1975) reported on the use of several synthetic 
elastomers such as neoprene, methacrylate and polyvinyl alcohol 
applied as an extra sealing layer to already sealed vials. Their 
best result was obtained with neoprene although the technique had 
many technical difficulties which rendered the process impractical 
for large batches of vials. Greiff et al (1975) and MacKenzie et all. 
(1976) have commented on the adequacy of various methods of sealing 
of glass ampoules and Roth (1966) has described the advantages of 
the "draw-seal" method employed in the present experiments. 
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A second question, related to the thromboplastin in 
fusion-sealed vampoules, is what process is responsible for the 
degradation of the material? As already discussed, the components 
of this degradative process, or their precursors, are within the 
material from the outset. A sealed glass container allows no 
atmospheric gases to reach the dry thrombplastin. The low level of 
residual moisture favours the long term stability of freeze-dried 
thromboplastins at -20°C and degradation of the lipid moiety is 
ruled out by the low mda level in the degraded material. A 
mechanism involving proteins or interactions of proteins with 
sugars, e. g. the mechanism known as non-enzymatic browning may be 
involved. 
This reaction, known as the Maillard reaction, is complex and 
incompletely understood. Its importance to the food industry and 
its physiological significance have been described and discussed, 
e. g. Labuza and Sa: tmarch (1981), Means and Min (1982). The first 
step in the process involves a condensation reaction between an 
amino group, contributed by a free amino acid or a protein, and the 
carbonyl group of a reducing sugar, resulting in the production of a 
Schiffs base and a molecule of water. The reaction is affected by 
factors such as the type and quantity of initial reactant species, 
pH, water content, and storage temperature. The total protein in 
freeze-dried thromboplastin reagents is in the range 3-4.5 g 
dm-3 whle glucose is present below C. 2 mmol dm -3 (Stevenson 
1978). Means and Min (1982) have pointed out that only a very small 
fraction of most common sugars is normally present in aldehydic form 
e. g. 0.25% of fructose and <0.1% of glucose. These observations 
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reduce the likelihood of the Maillard reaction taking place on 
anything but a very limited scale. A further difficulty is that the 
pH of thromboplastin reagents is in the range 6-6.5 (Stevenson 
1978) while the Maillard reaction is favoured by much higher pH 
values (due to increased reactivity of free amino groups). 
Saltmarch and Labuza (1982) reported that water can retard the rate 
of the initial glycosylamine reaction in which water is a product. 
These authors also point out the dilution of reactant species that 
would occur when water content is increased. This must be balanced, 
however, by the increased mobility of reactive species that would 
follow from decreased viscosity of the aqueous phase on dilution. 
Increased rates of reaction would result. Labuza and Saltmarch 
(1981) also reported increased rates of reaction when temperature 
was increased in a variety of test systems. It is possible 
therefore that the Maillard reaction has a role in the degradation 
of freeze-dried thromboplastin reagents. It is the case that aged 
thromboplastin reagents darken in colour and show increased 
absorbance at 420 nm (Stevenson 1980 - unpublished observation). 
This is consistent with the reported data on non-enzymatic 
browning. The values for residual moisture given in table 9.15 show 
no increase with time of storage but may simply indicate that the 
heat and weigh method may not be sensitive enough to detect any 
small increase in moisture due to the Maillard reaction. 
Conclusions - Thromboplastin in rubber-stoppered vials and 
vampoules stored at 37°C degrades in a few weeks, in a manner 
similar to that shown by liquid BCT stored at 4 °C (see Chapter 
7.3). An oxidative process is responsible. These observations 
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suggest that permeability of rubber-stoppers may be an important 
feature in the degradation process. Thromboplastins stored at 
37°C in fusion-sealed vampoules were stable for many months and 
finally degraded in a manner not consistent with oxidation of the 
lipid moiety. The WHO Secretariat (1965) declared that "In all 
cases, the sealing of ampoules should be by fusion of the glass. 
Sealing by rubber or plastic closures is unsatisfactory for long 
term preservation of international standards, reference preparations 
and reference reagents. " The above experiments confirm this 
statement but only during high temperature storage. At -20°C 




In the first experimental series it was shown that a series of 
batches of thromboplastin reagent, freeze-dried in a standardized 
manner, dried to a residual moisture value of 1.84% with a standard 
deviation of 0.18. This drying regime produced reagents with 
excellent long-term stability, which were calibrated in 
international multicentre exercises and adopted as International 
Reference Preparations of the EEC, WHO and ICSH. 
Some modifications to the freeze-drying machinery were 
undertaken to examine the effect of liquid nitrogen cooling both in 
the sublimation stage and in the desorption stage of the process. A 
reduction in residual moisture was obtained when condenser 
temperature was lowered. As considerable quantities of liquid 
nitrogen were required for this cooling the method was not 
considered practical. A finding that was of great interest was that 
the surface area of the condenser could be as little as 19% of shelf 
area and show no evidence of decreased efficiency. In fact, the 
opposite was the case, since the reagent dried to significantly 
lower residual moisture when the liquid nitrogen trap was used. A 
more economical use of liquid nitrogen was possible, however, as 
shown in Chapter 9.3 when the P205 trap was replaced by a device 
cooled by liquid nitrogen. This device proved successful in 
providing an efficient trap for desorbing vapour. It was easier to 
clean and also avoided the use of P205, an unpleasant reagent to 
handle both in its dry state and when quenched. 
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Chapter 9.4 was designed to test the freeze-drying machine for 
differences from front to back of a shelf, from middle to edge of a 
shelf, from top to bottom in an array of shelves and from clamber to 
chamber in the machine. Testing of residual moisture from some 114 
different sites within the system provided the data. While some 
statistically significant differences were noted, it was clear that 
the data were distributed in a very narrow range (mean value 1.81%, 
standard deviation 0.01) and within the calculated coefficient of 
variation for the method. 
In the next section a description was given of the preparation 
of some thromboplastin reagents to serve as reference preparations. 
The dispensing of these materials, in one case requiring a specially 
designed dispensing device, is described together with fusion 
sealing of the WHO batch 82/253. The findings for CV of dispersed 
weight of reagent and for prothrombin time testing are given for 
each reagent. These results are encouraging and lend weight to the 
idea that intrinsic variation in the dispersing and freeze-drying 
machinery is very small. Long term studies of stability are 
presented which show that 79/099 and 84/441 remain stable to date. 
Residual moisture values for all three reagents were lower than 2% 
which may have been a contributing factor to their long term 
stability and the ISI values indicate that their sensitivity to the 
coumarin-induced defect is good. In the final section a comparison 
is made of the stability of thromboplastin reagents stored in 
rubber-stoppered vials and fusion-sealed glass. Data are presented 
that indicate that different degradative mechanisms must operate in 
the two types of enclosure stored at elevated temperature. The 
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rubber-stoppered vial is not a suitable enclosure for long-term 
storage of thromboplastin at high temperature. Stevenson (1978) 
found that the change in thromboplastin that occurred during storage 
in the freeze-dried state at 56°C was not the same as the changes 
that occured in liquid reagent stored at 4°C. The current 
experiment reveals that more than one mechanism of degradation also 
operates at 37°C. For practical purposes, however, it is clear 
that thromboplastin reagents stored in rubber-stoppered vials at 
-20°C have a long shelf life. High temperature storage must be 
avoided. Reagents stored in fusion-sealed glass can tolerate higher 
temperature storage but eventually degrade in a fashion that does 
not involve the oxidative processes reported for the reagent at 
lower temperatures. 
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CHAPTER 10 CONCLUSION 
Original work presented includes a study, by electron 
microscopy of the tissue thromboplastin reagent (British Comparative 
Thromboplastin). Its changing morphology over a period of 102 
months was revealed. 
A concomitant alteration in lipid class composition and fatty 
acid distribution was shown and an increase in malondialdehyde with 
time of storage was noted also, observations strongly indicative of 
an oxidative process. 
An electron microscopic study on some widely used partial 
thromboplastin reagents demonstrated for the first time that these 
are composed of liposomes. These were sized and their 
electrophoretic mobility determined. Their lipid composition was 
elucidated and a search for correlations between performance in the 
clotting test and their physical and chemical properties was carried 
out. A number of significant correlations were noted e. g. the APTT 
of normal plasma shortened with increasing relative concentration of 
PS. 
In consequence, liposomes were manufactured from individual 
pure lipids to determine whether the brain and soya bean extracts 
that comprised the APTT reagents could be mimicked in their activity 
by simple mixtures of pure components. First a vehicle liposome was 
constructed. This showed neither pro- nor anticoagulant properties 
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in the APTT test system and was used as a vehicle for testing other 
phospholipids. 
Of those phospholipids tested, PS was unique in its ability to 
shorten the APTT, i. e. to increase the procoagulant activity of the 
test liposome. Other phospholipids showed little or no capacity to 
confer procoagulant activity. PI was of interest since it possessed 
some anticoagulant properties. Sensitivity to heparin could also be 
adjusted by controlling the relative concentration of PS. Liposomes 
containing PS accelerated the APTT of plasmas containing a 
lupus-like anticoagulant while having no effect on APTT prolonged by 
other types of inhibitor, factor deficiencies, or by oral 
anticoagulants. Support is offered for the idea that the lupus 
anticoagulant acts by competing with coagulation factors for sites 
on procoagulant lipid surfaces. 
Finally, some investigations were made in the freeze-drying of 
tissue thromboplastin reagents. The mean value for residual 
moisture of 19 batches of the lyophilised thromboplastin was found 
to be 1.84%. When the freeze-drying machine was modified by fitting 
a liquid nitrogen-cooled condenser, operating at very low 
temperatures, drying efficiency was improved with reduction of 
residual moisture coinciding with reduction of condenser 
temperature. Condenser surface area in these experiments was 
approximately 19% of shelf area, a much lower proportion than was 
previously thought practicable. The P205 trap was replaced in 
later experiments by a liquid nitrogen-cooled apparatus. This also 
reduced residual moisture and proved more economical of liquid 
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nitrogen. The freeze-drying machinery was found to be free of any 
intrinsic variation. Vial positioning from front-to-back or 
edge-to-middle on a shelf, or between shelves in one chamber, or 
between chambers, did not give rise to any variation outside the 
error of the residual moisture method. 
Steps taken in the freeze-drying of three International 
Reference Preparations of thromboplastin of the World Health 
Organisation, the Bureau Communautaire de Reference of the EEC, and 
the International Committee for Standards in Haematology are 
described. Consideration was given to their long-term stability. A 
comparison of rubber-stoppered vials with fusion-sealed vampoules 
revealed a marked improvement in stability of tissue thromboplastin 
reagents sealed in glass. This improvement was seen at 37°C but 
not at -20°C, when rubber-stoppered vials appeared to be equally 
suitable enclosures. 
It is hoped that these contributions to the knowledge of 
thromboplastins may be of some value in the still active quest for 
universally acceptable standards for thromboplastin reagents. 
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